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Abstract 
The M 13 bacteriophage is -1 J..lm long, with a capsid comprised of five coat proteins. 
Small peptides can be displayed upon the coat proteins. The aim of this work was to use 
the phage display of small peptides for the purpose of fabricating a self-assembling 
molecular transistor with the M 13 bacteriophage acting as the scaffold. Each aspect of 
this fabrication was considered. 
Firstly, a 50 nm long microphage particle was re-created and used to produce a 
215 nm long phage particle. These smaller phage particles could be used to make the 
transistor 100 nm in size. To create the scaffold, selenocysteine was displayed on the 
coat protein pIlI and used to self-assemble two to four phage particles around 10 nm 
gold nanoparticles or quantum dots. These higher order structures were then purified 
using a linear sucrose gradient. So that the transistor could be directed to a specific area 
of an existing electronic circuit, the coiled-coil pair ACID:BASE was used. ACID was 
displayed on the coat protein pIX whilst a BASE peptide containing a C-terminal 
cysteine was immobilised onto a gold surface. It was shown that ACID and BASE form 
a coiled-coil when the BASE is immobilised on a surface and that the M 13 
bacteriophage, displaying ACID, can be anchored to the surface via coiled-coil 
formation. Finally, tyrosine was displayed on the major coat protein pVIII so that gold 
could be specifically reduced onto the M13 phage particle scaffold to create the gold 
electrodes of the transistor. Although within solution, and on a carbon surface, gold was 
reduced onto the phage particles, when the particles were adsorbed onto an Si02 surface 
there was no gold deposition. 
Therefore, although much progress was made towards the goal of a self 
assembling transistor, the aspects devised within this study need to be combined. 
Page iii 
Contents 
Chapter 1: Introduction .......................................................................................... 1 
1.0 Introduction ..................................................................................................... 2 
1.1 Bionanotechnology ......................................................................................... 2 
1.2 Viruses and Nanotechnology .......................................................................... 7 
1.3 The M 13 bacteriophage ................................................................................ 11 
1.3.1 The life-cycle of the M13 bacteriophage ....................................... 14 
1.3.2 Infection ......................................................................................... 15 
1.3.3 Replication ..................................................................................... 16 
1.3.4 The M 13 bacteriophage viral pore ................................................. 17 
1.4 Phage Display ............................................................................................... 18 
1.4.1 Phagemid phage display ................................................................ 21 
1.4.2 Bio-panning ................................................................................... 22 
1.4.3 Bio-panning and peptides specific to inorganic materials ............. 25 
1.5 The M 13 phage coat proteins and their uses in bionanotechnology ............. 26 
1.5.1 The minor coat proteins pilI, pIX. p VI and p VII .......................... 26 
1.5.2 The major coat protein pVIII ......................................................... 30 
1.5.2.1 Virion structure ............................................................... 31 
1.5.2.2 pVIII phage display and bionanotechnology .................. 32 
1.5.2.3 Liquid crystal properties of the M 13 bacteriophage ....... 35 
1.6 Summary of the M 13 bacteriophage and bionanotechnology ...................... 38 
1.7 Aims of the thesis and the molecular transistor ............................................ 38 
1.8 Scope of the work ......................................................................................... 41 
Pageiv 
Chapter 2: Materials and Methods ................................................................... 43 
2.0 Materials ....................................................................................................... 44 
2.0.1 General Reagents ........................................................................... 44 
2.0.2 Bacterial Strains ............................................................................. 44 
2.0.3 Antibiotic stock and working concentrations ................................ 45 
2.0.4 Media recipes ................................................................................. 46 
2.0.4.1 2x YT medium ................................................................. 46 
2.0.4.2 Super broth (SB) medium ............................................... 46 
2.0.4.3 Agarose top ..................................................................... 47 
2.0.4.4 Agar ................................................................................. 47 
2.0.5 Buffers and other reagents ............................................................. 48 
2.0.5.1 Phosphate buffered saline (PBS) pH 7.4 ......................... 48 
2.0.5.2 20% Polyethylene glycol (PEG) and 2.5 M NaCl solution 
(PEGlNaCI) ................................................................................ 48 
2.0.5.3 2x Protein loading buffer (Laemmli buffer) .................. 49 
2.0.5.4 lOx A buffer for linear sucrose gradients ........................ 49 
2.0.5.5 lOx Glycine running buffer. ............................................ 50 
2.0.5.6 Coomassie blue staining solution .................................... 50 
2.0.5.7 De-stain solution ............................................................. 51 
2.0.5.8 Tris-HCI buffer ............................................................... 51 
2.1 General methods ........................................................................................... 52 
2.1.1 Growth of overnight E. coli culture ................................................ 52 
2.1.2 Preparation of chemically competent E.coli cells .......................... 52 
2.1.3 Transformation using chemically competent E.coli cells .............. 52 
2.1.4 Preparation of bacterial stocks for freezing ................................... 54 
2.1.5 Preparation of phage stock ............................................................. 54 
Page v 
2.1.5.1 Growth of phage and PEG precipitation ................ 54 
2.1.5.2 Caesium chloride purification ......................................... 55 
2.1.5.3 Linear sucrose gradients ................................................. 56 
2.1.5.4 Fractionation ................................................................... 58 
2.1.6 Measurement of phage concentration ............................................ 60 
2.1.6.1 Phage titering (measured in pfu/mL) ............................. 60 
2.1.6.2 Spectrophotometry of phage particles ........................... 61 
2.1.6.3 Definition of virions/mL and plaque forming units 
(pfu )/mL ...................................................................................... 61 
2.1.7 Colony PCR ................................................................................... 62 
2.1.8 Transmission Electron Microscopy (TEM) .................................. 64 
2.1.9 DNA Gel Electrophoresis .............................................................. 64 
2.1.9.1 10% Polyacrylamide Gel ................................................ 64 
2.1.9.21% and 3% Agarose Gel ................................................. 65 
2.1.10 Protein Gel Electrophoresis Under Denaturing Conditions ......... 65 
2.1.10.1 Tris-glycine SDS GeL .................................................. 65 
2.1.11 Molecular biology techniques ...................................................... 67 
2.1.11.1 Polymerase Chain Reaction (PCR) .............................. 67 
2.1.11.2 Phenol Chloroform extraction of DNA and ethanol 
precipitation ................................................................................ 69 
2.1.11.3 Insertional PCR ............................................................. 70 
2.1.11.4 Ligation of DNA fragments .......................................... 72 
2.2 Specific Methods for Chapter 3 .................................................................... 73 
2.2.1 Creation of the microphage plasmid (pMicro) .............................. 73 
2.2.2 Creation of longer microphage cassette (pMicroKan) .................. 75 
2.2.3 Creation of the helper plasmid pM13CP ....................................... 75 
2.2.4 Production of shorter length phage particles using M13K07 ....... 77 
2.2.5 Production of shorter length phage particles using M13CP .......... 78 
Page vi 
2.2.6 Purification of shorter phage particles ........................................... 78 
2.2.7 Caesium chloride purification of shorter length phage particles ... 79 
2.2.8 Linear sucrose density ultracentrifugation of shorter length phage 
particles ................................................................................................... 79 
2.2.9 Size exclusion chromatography of shorter length phage particles. 79 
2.2.10 Titering of shorter length phage particles .................................... 80 
2.2.11 Measurement of shorter length phage particle length by TEM ... 80 
2.3 Specific Methods for Chapter 4 .................................................................... 82 
2.3.1 Insertion of selenocysteine into gill .............................................. 82 
2.3.2 Production of selenocysteine containing phage ............................. 84 
2.3.3 Production of microphage containing selenocysteine .................... 84 
2.3.4 Creation and production of pIlI cysteine mutant ........................... 85 
2.3.5 Binding of M13pIIISel and wild-type M13 to gold nanoparticles 85 
2.3.6 Binding of M 13pIlISei and wild-type M 13 to quantum dots ........ 86 
2.3.7 Purification of phage:nanoparticle complexes on a linear sucrose 
gradient ................................................................................................... 89 
2.3.8 Purification of higher order structures using size exclusion 
chromatography ...................................................................................... 89 
2.3.9 Fabrication of microphage higher order structures ........................ 90 
2.4 Specific Methods for Chapter 5 .................................................................... 91 
2.4.1 Creation of pCGMTpIXHisACIDap and pCGMTpIXHisFOS ..... 91 
2.4.2 Production of M13pIXHisACIDap and M13pIXHisFOS phage ... 92 
2.4.3 Purification of M 13pIXHisACIDap and M 13pIXHisFOS phage. 92 
2.4.4 Creation and production of M 13pIlIACIDap phage ...................... 93 
2.4.5 HPLC of ACIDap and BASEap peptides ...................................... 94 
2.4.6 Circular dichroism (CD) spectroscopy of ACIDap and BASEap 
peptides ................................................................................................... 95 
2.4.7 Surface Plasmon Resonance (SPR) analysis .................................. 95 
2.4.8 Dual Polarisation Inferometry (DPI) analysis ................................ 96 
Page vii 
2.S Specific Methods for Chapter 6 .................................................................... 98 
2.S.1 Display of tyrosine on pVIII.. ........................................................ 98 
2.S.2 Fabrication of gold coated phage in solution ................................. 99 
2.S.3 Deposition ofM13Y onto carbon and incubation with gold salt... 99 
2.S.4 Attempts to deposit gold on M13 adsorbed to Si02 surface ....... 100 
2.S.4.1 Piranha cleaning of Si02 surface .................................. 100 
2.S.4.2 Adsorption ofM13 particles to Si02 surface and 
incubation with gold salt ........................................................... 101 
2.S.S AFM (Atomic Force Microscopy) .............................................. 101 
2.S.6 Scanning Electron Microscopy of gold nanowires ...................... 102 
2.S.7 Conductivity measurements ......................................................... 102 
Chapter 3: The Microphage ............................................................................... 103 
3.1 Introduction ................................................................................................. 104 
3.1.1 The Microphage ........................................................................... 104 
3.1.2 The Helper phage M13K07 ......................................................... 110 
3.1.3 The Helper Plasmid ..................................................................... 113 
3.1.4 Aims of the work described within this Chapter ......................... 114 
3.2 Results and Discussion ............................................................................... lIS 
3.2.1 Creation of microphage ............................................................... lIS 
3.2.2 Creation of pMicroKan ................................................................ 119 
3.2.3 Creation of the pM 13CP helper plasmid ..................................... 120 
3.2.4 Production of shorter phage using the helper plasmid pMI3CP. 121 
3.2.S Production of shorter phage usin~ the helper phage M13K07 .... 12S 
3.2.6 Production of different length phage and purification ................. 126 
3.2.7 Examination of shorter phage particles ........................................ 130 
Page viii 
3.3 Conclusions and Future Work ................................................................... 135 
Chapter 4: Fabrication of Higher Order Structures ................................ 139 
4.1 Introduction ................................................................................................. 140 
4.1.1 The importance of new fabrication techniques ............................ 140 
4.1.2 Self-assembly of molecular transistors ........................................ 142 
4.1.3 Viral self-assembly into higher order structures .......................... 143 
4.1.4 Selenocysteine .............................................................................. 147 
4.1.5 Aims of the work described within this Chapter ......................... 150 
4.2 Results and Discussion ............................................................................... 151 
4.2.1 Display of selenocysteine on pIlI ................................................ 151 
4.2.2 Incorporation of selenocysteine into M13pIlISel ........................ 153 
4.2.3 Titer of M13plIISel.. .................................................................... 153 
4.2.4 Fabrication of higher order structures with gold nanoparticles ... 155 
4.2.5 Investigation into the concentration relationship between 
M 13pIlISei and gold nanoparticles ....................................................... 161 
4.2.6 Fabrication of higher order structures with M 13plIISei and 
quantum dots ......................................................................................... 165 
4.2.6.1 Fabrication using 14 nm quantum dots ......................... 165 
4.2.6.2 Fabrication using 22 nm quantum dots ......................... 168 
4.2.7 Purification of higher order structures using size exclusion 
chromatography .................................................................................... 170 
4.2.8 Fabrication of higher order structures using microphage ............ 173 
4.3 Conclusions and Future Work .................................................................... 175 
Page ix 
Chapter 5: Phage Particle Attachment to a Gold Surface ...................... 179 
5.1 Introduction ................................................................................................. 180 
5.1.1 Coiled-coils .................................................................................. 180 
5.1.2 Attachment of M13 phage particles to a surface ......................... 185 
5.1.3 Aims of the work described within this Chapter ......................... 187 
5.2 Results and Discussion ............................................................................... 188 
5.2.1 Production and purification of ACIDap and BASEap peptides ... 188 
5.2.2 Analysis of ACIDapIBASEap coiled-coil formation ................... 190 
5.2.3 Display of leucine zippers on the M13 bacteriophage ................. 191 
5.2.3.1 Display of ACIDap on pIX ........................................... 191 
5.2.3.2 Production and purification of M13pIXHisACID ........ 192 
5.2.3.3 Display of the leucine zipper FOS on pIX .................... 196 
5.2.3.4 Display of ACIDap on pilI ........................................... 197 
5.2.4 Surface Plasmon Resonance (SPR) and Dual Polarisation 
Interferometry (DPI) analysis of ACIDap:BASEap interaction ........... 198 
5.2.4.1 SPR analysis of BASEap:ACIDap coiled-coil 
formation ................................................................................... 199 
5.2.4.2 DPI analysis of BASEap:ACIDap coiled-coil 
formation ................................................................................... 202 
5.2.5 SPR analysis of M 13pIXHisACIDap phage interaction with surface 
immobilised BASEap ........................................................................... 205 
5.3 Conclusions and Future Work .................................................................... 208 
Chapter 6: Fabrication of Gold-Coated M13 Bacteriophage ................ 211 
6.1 Introduction ........................... ;; .................................................................... 212 
6.1.1 Bio-mineralisation of nanoparticles ............................................. 212 
Page x 
6.1.2 Amino acid reduction of metal salts ............................................ 215 
6.1.3 Aims of the work described within this Chapter ......................... 218 
6.2 Results and Discussion ............................................................................... 219 
6.2.1 Display of tyrosine on p VIII ........................................................ 219 
6.2.2 Fabrication of gold coated phage in solution ............................... 220 
6.2.3 Deposition of M13Y onto carbon and patterning with gold ........ 226 
6.2.4 Attempts to deposit gold on M 13 adsorbed to Si02 surface ....... 228 
6.3 Conclusions and Future Work .................................................................... 238 
Chapter 7: General Conclusions ...................................................................... 241 
7.1 Conclusions from Chapter 3 ....................................................................... 242 
7.2 Conclusions from Chapter 4 ....................................................................... 243 
7.3 Conclusions from Chapter 5 ....................................................................... 244 
7.4 Conclusions from Chapter 6 ....................................................................... 245 
7.5 Closing remarks .......................................................................................... 246 
References ................................................................................................................. 247 
Appendix A ............................................................................................................... 281 
1.0 DNA sequence of pM 1 ............................................................................... 282 
2.0 DNA sequence of pMicro plasmid ............................................................. 282 
3.0 DNA sequence of pMicrokan ..................................................................... 283 
4.0 DNA sequence of pM 13CP ........................................................................ 284 
4.1 DNA and protein sequence of M 13CP ........................................... 289 
Page xi 
Appendix B ............................................................................................................... 293 
1.0 DNA sequence of M 13plIISel phage .......................................................... 294 
1.1 DNA and protein sequence of M 13plIISel phage .......................... 294 
2.0 DNA sequence of M 13pIIIC phage ............................................................ 295 
2.1 DNA and protein sequence of M 13plIIC phage ............................. 295 
3.0 DNA and protein sequence of wild-type pIlI ............................................. 295 
Appendix C .............................................................................................................. 297 
1.0 Mass spectrometry data of ACIDap and BASEap peptides ....................... 298 
1.1 Fraction 1 of HPLC purified BASEap peptide ............................... 298 
1.2 Fraction 2 of HPLC purified BASEap peptide ............................... 298 
1.3 HPLC purified ACIDap peptide ..................................................... 299 
2.0 DNA sequence of pCGMTpIXHisACIDap ................................................ 299 
2.1 DNA and protein sequence of pCGMTpIXHisACIDap ................. 300 
3.0 DNA sequence of pCGMTpIXHisFOS ...................................................... 300 
3.1 DNA and protein sequence of pCGMTpIXHisFOS ....................... 301 
4.0 DNA sequence of M13pIIIACIDap ............................................................ 301 
4.1 DNA and protein sequence of M 13pIIIACIDap ............................. 302 
5.0 SPR kinetic fits for ACIDap and M13pIXHisACID interacting with 
immobilised BASEap peptide ........................................................................... 303 
5.1 SPR kinetic fit for ACIDap interacting with immobilised BASEap 
(Chapter 5, Figure 5.10 B) .................................................................... 303 
5.2 SPR kinetic fit for M 13pIXHisACIDap interacting with immobilised 
BASEap (Chapter 5, Figure 5.13 B) ..................................................... 304 
Page xii 
Appendix D ............................................................................................................... 305 
1.0 DNA sequence ofM13Y ............................................................................ 306 
1.1 DNA and protein sequence ofM13Y ............................................. 306 
2.0 DNA and protein sequence of wild-type M13 pVIII.. ................................ 306 
List of Figures 
Chapter 1: Introduction .......................................................................................... 1 
Figure 1.1. Examples of nano-scale materials fabricated by Nature ................................ 3 
Figure 1.2. The Tobacco Mosaic Virus ............................................................................ 8 
Figure 1.3. The structure of M 13 bacteriophage ............................................................. 13 
Figure 1.4. The life-cycle of the M 13 bacteriophage ...................................................... 14 
Figure 1.5. pIlI interaction with F-pilus .......................................................................... 16 
Figure 1.6. Methods of phage display ............................................................................. 20 
Figure 1.7. Bio-panning .................................................................................................. 24 
Figure 1.8. The minor coat protein pIlI .......................................................................... 28 
Figure 1.9. A nano-ring created by the M13 bacteriophage ........................................... 29 
Figure 1.10. Amino acid sequence of the p VIII coat protein ......................................... 31 
Figure 1.11. Model of M 13 filamentous bacteriophage capsid determined by NMR 
spectroscopy ................................................................................................................... 32 
Figure 1.12. M 13 binding to gold nanoparticles ............................................................. 34 
Figure 1.13. The liquid crystal structures ....................................................................... 35 
Figure 1.14. Self-assembling liquid crystal M 13 bacteriophage layer ........................... 37 
Figure 1.15. The Molecular transistor.. ........................................................................... 39 
Page xiii 
Figure 1.16. Schematic of a possible fabrication protocol of a self-assembling molecular 
transistor .......................................................................................................................... 40 
Chapter 2: Materials and Methods ................................................................... 43 
Figure 2.1. Materials supplied with Biocomp gradient station ....................................... 58 
Figure 2.2. The Biocomp gradient station and fractionator ............................................ 59 
Figure 2.3. The gradient fractionator trumpet.. ............................................................... 60 
Figure 2.4. Typical absorption spectrum of a purified (PEGlNaCl) M13 particle ......... 62 
Figure 2.5. Position of pilI and pVIIl sequencing primers ............................................. 63 
Figure 2.6. Gel ladders for DNA and proteins ................................................................ 66 
Figure 2.7. Vector Map ofpJET1.2 ................................................................................ 75 
Figure 2.8. The Qdot quantum dot from Invitrogen ....................................................... 87 
Figure 2.9. The structure of sulfo-SMCC ....................................................................... 87 
Chapter 3: The Microphage ............................................................................... 103 
Figure 3.1. An electron micrograph of microphage particles ....................................... 107 
Figure 3.2. The structure of the microphage cassette ................................................... 109 
Figure 3.3. The intergenic region of the M13 bacteriophage ....................................... 112 
Figure 3.4. Schematic of method used to create pM13CP ............................................ 114 
Figure 3.5. Maps of the pJet1.2 and pMicro vectors .................................................... 115 
Figure 3.6. Insertion of packaging signal (PS) into th~ pET26-b vector ...................... 117 
Figure 3.7. Insertion of defective origin, (+) Ori~29, into the pM 1 vector. ................. 118 
Figure 3.8. Controlling the length of phage particles ................................................... 120 
Page xiv 
Figure 3.9. Creation of pM13CP helper plasmid .......................................................... 122 
Figure 3.10. Phage produced using pM13CP and pMicro and pLitmus 28i ................. 123 
Figure 3.11. Titer of pLitmus28i and pM 13CP ............................................................ 124 
Figure 3.12. Production of microphage ........................................................................ 125 
Figure 3.13. Linear sucrose gradient fractionation of different length phage particles 126 
Figure 3.14. Transmission electron micrographs of gradient fractionated phage particles; 
pMicro, pMicroKan, pLitmus, and M13K07 helper phage ......................................... 127 
Figure 3.15. Size exclusion purification of microphage particles ................................ 128 
Figure 3.16. Denaturing PAGE analysis of GroEL ...................................................... 130 
Figure 3.17. Homogeneity of shorter phage particle populations ................................. 131 
Figure 3.18. The length of different phage particles ..................................................... 132 
Figure 3.19. CsCI gradient of different length phage particles ..................................... 133 
Figure 3.20. Titer of different length phage .................................................................. 134 
Chapter 4: Fabrication of Higher Order Structures ................................ 139 
Figure 4.1. Photolithography ........................................................................................ 141 
Figure 4.2. AFM images of M13 bacteriophage higher order structures ...................... 144 
Figure 4.3. Gold coated M13 bacteriophage higher order structures ........................... 146 
Figure 4.4. Incorporation of selenocysteine into the opal stop codon in prokaryotes .. 149 
Figure 4.5. Amplification of DNA fragment encoding for selenocysteine containing 
peptide ........................................................................................................................... 152 
Figure 4.6. Linear sucrose gradient purification of MI3pIIISei phage particles bound to 
gold nanoparticles ......................................................................................................... 157 
Page xv 
Figure 4.7. Linear sucrose gradient purification of M 13pIIISel and wild-type M 13 
phage particles bound to gold nanoparticles ................................................................. 159 
Figure 4.8. Linear sucrose gradient purification of M 13pIIISel and phosphine stabilised 
gold nanoparticles ......................................................................................................... 160 
Figure 4.9. Concentration dependence of M13pIIISei and GNPlOnmlcit in fabricating 
higher order structures .................................................................................................. 162 
Figure 4.10. Quantitation of sucrose purified higher order structures .......................... 163 
Figure 4.11. Fabrication of higher order structures using M 13pIIISel phage and 525 nm 
emission QDs ................................................................................................................ 167 
Figure 4.12. Fabrication of higher order structures using M 13pIIISei phage and 800 nm 
emission QDs ................................................................................................................ 169 
Figure 4.13. Purification of higher order structures using size exclusion chromatography 
...................................................................................................................................... 172 
Figure 4.14. Higher order structures using microphagepIIISel .................................... 174 
Chapter 5: Phage Particle Attachment to a Gold Surface ...................... 179 
Figure 5.1. Structure of a coiled-coil ............................................................................ 180 
Figure 5.2. Schematic showing coiled-coil interactions ............................................... 182 
Figure 5.3. The ACID:BASE leucine zipper pair ......................................................... 184 
Figure 5.4. Schematic of M13 phage particle attachment to a gold surface ................. 186 
Figure 5.5. HPLC purification of ACIDap and BASEap peptides ............................... 189 
Figure 5.6. Circular dichroism of the ACIDaplBASEap leucine zipper pair ............... 191 
Figure 5.7. Display of the ACIDap peptide on pIX ...................................................... 193 
Figure 5.8. HisTrapTM column purification of M13pIXHisACIDap and 
Page xvi 
M 13pIXHisFOS ............................................................................................................ 195 
Figure 5.9. Schematic of DPI and SPR sensor chips .................................................... 199 
Figure 5.10. SPR analysis of ACIDap:BASEap interactions ....................................... 201 
Figure 5.11. Dual Polarisation Interferometry (DPI) ................................................... 203 
Figure 5.12. DPI analysis of ACIDap:BASEap interactions ........................................ 204 
Figure 5.13. SPR analysis of M 13 phage and immobilised BASEap ........................... 206 
Chapter 6: Fabrication of Gold-Coated M13 Bacteriophage ................ 211 
Figure 6.1. The magnetotactic bacteria ......................................................................... 214 
Figure 6.2. Cartoon showing a proposed mechanism of metal reduction by tyrosine .. 216 
Figure 6.3. A TEM image of M13 phage mixed with gold salt overnight in solution. 221 
Figure 6.4. Time course of M 13Y and wild-type phage mixed with gold salt ............. 223 
Figure 6.5. Phage particles on a carbon surface exposed to gold salt ........................... 227 
Figure 6.6. M 13 bacteriophage particles adsorbed to Si02 surface ............................. 228 
Figure 6.7. M13 phage particles adsorbed to Si02 and incubated with gold salt for 
different times ............................................................................................................... 229 
Figure 6.8. M 13 bacteriophage particles adsorbed to Si02 surface and incubated with 
varying amounts of gold salt ......................................................................................... 231 
Figure 6.9. Height and width measurement of M 13Y particles .................................... 232 
Figure 6.10. M 13Y phage on Si02 surface exposed to dilute hydrochloric acid .......... 234 
Figure 6.11. Scanning electron microscopy of M13Y phage exposed to 6 mM gold salt 
on a Si02 surface ........................................................................................................... 235 
Figure 6.12. Electronic characterisation of M13Y phage particles .............................. 236 
Page xvii 
List of Tables 
Chapter 1: Introduction .......................................................................................... 1 
Table 1.1. The M13 proteins ........................................................................................... 11 
Table 1.2. Peptides that show high affinity to inorganic materials ................................. 25 
Chapter 2: Materials and Methods ................................................................... 43 
Table 2.1 A list of the primers used in creating the microphage plasmid pMicro .......... 73 
Table 2.2 A list of the primers used in creating the helper plasmid M 13CP .................. 76 
Table 2.3. Dimensions and composition of Qdot® nanocrystals ................................... 86 
Chapter 5: Phage Particle Attachment to a Gold Surface ...................... 179 
Table 5.1. Rate and equilibrium constants obtained from sensograms shown in Figures 
5.10 Band 5.13 ............................................................................................................ 207 
Page xviii 
Abbreviations 
AFM: Atomic Force Microscopy 
CCD: Charge-coupled device 
CD: Circular dichroism 
CT: C-terminal 
DMF: Dimethylformamide 
DPI: Dual Plasmon Interferometry 
dUMP: Deoxyuridine monophosphate 
GNP: Gold Nanoparticles 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC: High-performance liquid chromatography 
IPA: Isopropyl alcohol 
IPTG: Isopropyl ~-D-l-thiogalactopyranoside 
LPEI: Linear-polyethylenimine 
NEB: New England Biolabs 
Ni-NT A: Nickel(II)-nitrilotriacetic acid 
O-mRNA: Orthogonal messenger ribonucleic acid 
O-ribosome: Orthogonal ribosome 
P AA: Polyacrylic acid 
PCR: Polymerase Chain Reaction 
PEG: Polyethylene glycol 
PMMA: Poly(methyl methacrylate) 
PS: Packaging signal 
QD: Quantum dot 
RBS: Ribosome binding sequence 
Page xix 
RF DNA: Replicative Form Deoxyribonucleic acid 
PS: Packaging Signal 
SB: Super broth 
SPR: Surface Plasmon Resonance 
TFA: Trifluoroacetic acid 
TMV: Tobacco Mosaic Virus 
TNT: Trinitrotoluene 
UPRT: Uracyl phosphoribosyltransferase 
Page xx 
Chapter 1 
Introduction 
Chapter 1 
1.0 Introduction 
In the winter of 1959, the physicist Richard Feynman gave a presentation to the West 
Coast division of the American Physical Society entitled 'There 's plenty of room at the 
bottom' (Feynman, 1960). Within the talk he laid out the concepts for a new area of 
science which, in time, became known as nanotechnology. What he discussed, as the 
title suggests, was "the manipulation and control of atoms and molecules on the small 
scale". Why, he pondered, was it not possible to "write the entire 24 volumes of the 
Encyclopaedia Britannica on the head of a pin?" or to manoeuvre "things atom by 
atom" when it was well within the realms of physics to carry out such tasks. 
Although not widely cited at the time, just seven times until 1980 (Tourney, 2009), it is 
now widely accepted as a prescient presentation that foresaw the coming together of a 
diverse range of disciplines to focus on answering the questions that Feynman pondered 
upon in his presentation; and therefore producing the nanoscale materials and devices 
we see today. 
1.1 Bionanotechnology 
One aspect the talk focused on was biology, where cells act as entire factories producing 
a plethora of complex nanoscale machines and materials (Figure 1.1 highlights some 
weJl known nanoscale materials). Feynman had the imagination to 'Consider the 
possibility that we too can make a thing very small [the cell] which does what we want-
--that we can manufacture an object that manoeuvres at that level!' (Feynman, 1960). 
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Figure 1.1. Examples of nano-scale materials fabricated by Nature. All images are 
from a scanning electron micrograph (taken from Sarikaya, 2003). 
A shows the growth edge of an abalone, a sea mollusc known for its brightly coloured mother of 
pearl (nacre) shell. It shows platelets (blue) separated by an organic film (orange) that form the 
mother of pearl. The layers provide a very strong and tough bi-composite. The inset picture 
shows a transmission electron micrograph of the same structure. 
B shows an ordered array of magnetite nanoparticJes created by a magnetotactic bacterium 
which allow the bacterium to migrate using the Earth's magnetic field; the inset shows a 
transmission electron micrograph of these ordered nanoparticJes. 
C shows hydroxyapatite crystallites woven together to form an ordered, tough structure which 
makes up mouse teeth enamel (inset). 
D shows a sponge (Rosella) spicule (inset) which IS created from layered silica and has 
properties similar to fibre optic cables. 
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Bionanotechnology is exactly that: a field of study to use what has evolved in Nature 
and manipulate it to produce desirable materials and devices at the nanoscale. 
The ribosome is perhaps the best example of a biological nanoscale machine and as 
George Whitesides (a Harvard chemist) points out; it provides an "existence proof' 
(editorial in Nature Materials, 2009) that nanotechnology can work. The ribosome is a 
protein and RNA complex, 20 nm in diameter, which shows specific recognition of 
reactants, i.e. messenger and transfer RNA, and reliable production of products, i.e. 
proteins (Ramakrishnan, 2002). All this is done reproducibly in ambient conditions, 
with the added benefit that the ribosome self-assembles from discrete particles produced 
from DNA within the cell. It is these aspects; self-assembly, reproducibility at ambient 
conditions, and the ability to "programme" the nanomachine using DNA, that make 
nature such an exciting target for technological applications. 
Comparing the ribosome with the synthetic production of a small peptide provides an 
example to show the potential benefits of harnessing Nature's nanoscale machines. 
Synthetic production is normally a slow process with a current upper limit of 100 amino 
acid long chains. The fabrication of these chains requires the step-wise deprotection of 
the N-terminus of the chain and the formation of a peptide bond with the next amino 
acid. The reaction is carried out in a non-aqueous solvent; typically TFA (trifluoroacetic 
acid) and DMF (dimethylformamide), both of which are toxic. Assuming a high yield of 
99% with each step, after only 26 amino acids the yield would already be down to 
-75%. Contrast this with the ribosome which can produce proteins hundreds of amino 
acids long, in an aqueous solution, with a high yield and with no toxic chemicals 
involved. 
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However, the ribosome has evolved to use the 64 DNA codons and the 20 genetically 
encoded amino acids, 22 if you include pyrrolysine (Srinivasan, 2002) and 
selenocysteine (Bock, 1991). It is therefore difficult to incorporate un-natural amino 
acids into a protein sequence using the ribosome, e.g. fluorescent amino acids which 
can be used to study peptide folding. Aside from allowing the investigation of proteins, 
it is thought that the incorporation of un-natural amino acids could allow for the 
evolution of proteins with novel functions (Xie, 2006). 
Currently, the favoured system to incorporate un-natural amino acids into a protein 
sequence using the ribosome is to use the amber stop codon (Xie, 2006). A unique 
tRNA molecule was derived from the archaeal species Methanococcus jannaschii which 
recognises the amber stop codon, leading to incorporation of an un-natural amino acid at 
that site (Wang, 2000). The amber codon (VAG) is the least used stop codon (Benzer, 
1962) and so incorporation of un-natural amino acids in response to this codon means 
that there is minimal interference with normal cellular translation. However, the 
efficiency of un-natural amino acid incorporation in this way can be as low as 20% 
(Barrett, 2010). Likewise, incorporating multiple different un-natural amino acids using 
this approach is not possible as there is no way to specify which un-natural amino acid 
is translated at each amber stop codon. In contrast, the step-wise construction of 
proteins using synthetic methods allows far easier incorporation of multiple un-natural 
amino acids. 
Therefore many scientists have been attempting to combine the advantages of both 
synthetic production and the ribosome. The aim is to have a self-assembling synthetic 
ribosome, with all the associated benefits, which is able to incorporate mUltiple un-
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natural amino acids efficiently. Recently, the group of Dr Jason Chin has focused on 
creating an orthogonal ribosome (O-ribosome), i.e. a ribosome that recognises mRNA 
molecules which cannot be recognised by wild-type ribosomes (Rackham, 2005; 
Barrett, 2010; Neumann, 2010). They have evolved the ribosome and mRNA, within 
E.coii, and focused on the ribosome binding sequence (RBS) within the mRNA and its 
complementary partner in the 16S RNA sequence of the ribosome (Rackham, 2005). 
The RBS has been shown to be main determinant in translational efficiency, i.e. it is the 
main recognition site of the mRNA by the ribosome. The RBS within the mRNA and 
16S RNA were randomly mutated to create libraries of ribosomes and mRNA, each 
with a different RBS sequences. The mRNA used within the library encoded for the 
enzyme uracyl phosphoribosyltransferase (UPRT) and for chloramphenicol resistance. 
To select for orthogonal mRNA (O-mRNA), i.e. mRNA that could not be recognised by 
wild-type ribosomes, the mRNA library was transformed into E.coli and grown in the 
presence of 5-fluorouracil; this is converted by UPRT to 5-fluoro-dUMP, which in turn 
strongly inhibits thymidylate synthase and so causes cell death. Therefore E.coli cells 
which survived growth in the presence of 5-fluorouracil contained mRNA mutants 
which were not recognised by wild-type ribosomes. 
These cells were then transformed with the ribosome library and grown in the presence 
of chloramphenicol. Only ribosomes that recognised the O-mRNA, encoding 
chloramphenicol resistance, could translate it and so provide the cell with 
chloramphenicol resistance. By selecting for specific RBSs within the ribosome and 
mRNA, it was possible to create orthogonal ribosomes and mRNA which when present 
within an E.coli cell acted independently of the endogenous ribosomes and mRNA 
(Rackham, 2005). Therefore these O-ribosome and O-mRNA can create proteins with 
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minimal interference of endogenous cellular functions. The O-ribosome was then used 
to select O-ribosomes that could efficiently decode quadruplet codons, e.g. AGGA 
(Neumann, 2010). The selection was again carried out by using mRNA that encoded for 
chloramphenicol resistance. However, the mRNA contained the quadruplet sequence 
AGGA. A quadruplet anti-codon tRNASer was produced by a plasmid within the cell 
which recognised the AGGA sequence. Only O-ribosomes which could accommodate 
the quadruplet tRNASer would provide the E.coU cell with chloramphenicol resistance. 
The use of quadruplet co dons means that there are blank codons, i.e. there are no natural 
tRNAs that will recognise them, into which un-natural amino acids can be incorporated 
via the quadruplet t-RNA (Neumann, 2010). What they have therefore created is a 
ribosome that can read the genetic sequence in a novel way and incorporate multiple un-
natural amino acids into a protein sequence. This example highlights how the 
understanding of cellular nanoscale mechanisms can be used to manipulate them and 
change their function whilst retaining the benefits of working in aqueous solutions and 
ambient conditions. 
1.2 Viruses and Nanotechnology 
The field of bionanotechnology is rapidly growing with scientists exploiting DNA 
(Dietz, 2009), proteins (Naik, 2002), and even whole cells (such as the magnetotactic 
bacteria in Figure 1.1). There is, however, one area of research which exploits all three; 
that involving viruses and bacteriophages (the subtle distinction between the two is that 
phage infect only bacteria). These are miniscule replicating units, on the scale of 
nanometres: between 10-100 nm, containing a simple genome, either DNA or RNA, 
coated in a protective protein shell, that utilise a host cell's machinery to replicate. 
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Typically the protein coat is made up of a small repertoire of proteins encoded by the 
viral genome, which self-assemble into ordered, symmetrical structures. 
It is the properties of self assembly; simple manipulation of the coat proteins using 
genetic modification of the genome and the ease of large-scale production (Shenton, 
1999; Lee, 2006) which make viruses such inviting targets for nanotechnology 
applications. Some of the earliest work in this field focused on the plant virus TMV 
(Tobacco Mosaic Virus); which is a rod-shaped virus in which the coat is made up of 
2130 copies of an identical coat protein (Dujardin, 2003; Figure 1.2 A) encoded for 
within the viral genome. 
A 
Figure 1.2. The Tobacco Mosaic Virus. TEM image showing a wild-type TMV capsid 
stained with 2% uranyl acetate (A). TMV mutant coat proteins displaying a solution 
exposed hexahistidine tag at position 1 were re-assembled into a capsid-like particle, but 
lacking any genomic RNA, at pH 8. The hexahistidine tag was used to spontaneously 
order citrate-stabilised 2 nm gold nanoparticles via electrostatic binding along the 
capsid-like particle (B). Images kindly provided by Dr Gosia Wnek. Scale bar equals 
100 nm. 
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A large proportion of bionanotech research with TMV focuses on using the viral capsid 
as a scaffold for the deposition of materials, e.g. gold (Figure 1.2 B) to create 
"nanowires". By altering the genome of TMV, Lee, et ai. (2005), inserted two cysteine 
residues at positions 2 and 3 of the TMV coat protein which were solvent exposed on 
the surface of the TMV capsid (Lee, 2005). Transfection of tobacco plants with the 
genome led to the production of TMV virus particles, 300 nm in length, displaying 2 
cysteines on every coat protein for the entire length of the virus. Cysteine contains a 
single sulphur atom which forms a strong covalent bond with gold atoms (Grandbois, 
1999; Jadzinsky, 2007). The displayed cysteines were used to bind to the gold 
nanoclusters, irregularly shaped nanoparticles -10 nm in size, which had been created 
from the chemical reduction of a gold salt solution. Using this method the TMV particle 
was entirely coated in gold nanoclusters. The majority of work involving TMV, and 
other viruses, has followed this approach, i.e. the alteration of key amino acid residues 
of the coat protein by DNA manipulation so that specific chemical groups are exposed 
in the viral capsid and then using these groups to bind metal ions to the outside of the 
virus. 
One of the challenges of bionanotechnology is that of interfacing self-assembled 
macromolecular structures within an electronic circuit. Thus many groups have focused 
on manipulating TMV into creating a device that self-assembles into a specific location 
that is connected to the surrounding circuit. Yi, et al. (2005), achieved this by 
incubating TMV virus particles at pH 8, which dissociated some of the coat proteins 
from the 5' end of the RNA genome and exposed this portion of the nucleic acid to 
solution. By hybridising the protein-free 5' end of RNA genome to a complementary 
strand of DNA covalently bound to a gold electrode, it was possible to attach the TMV 
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Via nucleic acid hybridisation (Yi, 2005). Numerous small peptides have been 
discovered by phage display (section 1.4) that recognise specific targets, e.g. cocaine 
(Carrera, 2004), cancer markers (Brissette, 2006) and the explosive TNT (Goldman, 
2002). These could be displayed on the surface of the TMV virus; thus creating a self-
assembling biosensor. 
Another group utilised the TMV virus displaying two cysteine residues created by Lee, 
et al. (2005), to bind the viral particles to a specified area of a gold surface and then 
used the same particles as sites for metal deposition. The displayed cysteines were used 
to create a layer of TMV particles on a gold surface via thiol-gold bonds (Gerasopoulos, 
2010). The immobilised TMV particles were then coated with nickel via electro less 
plating, i.e. chemical reduction of a nickel salt to randomly coat the TMV particles. A 
pre-fabricated zinc layer was then placed above the nickel coated TMV layer. The two 
layers acted as the anode and cathode, respectively, of a battery (Gerasopoulos, 2008). 
AIM KOH solution was then used as the battery electrolyte so that electrons could 
migrate between the anode and the cathode. The increased surface area that the nickel 
coated TMV provided increased the initial capacity of the battery by a factor of six 
compared to batteries without the virus. Working with TMV therefore shows us that 
viruses can be used as scaffolds that can bind spontaneously to a pre-determined area 
and at the same time act as nucleation sites for inorganic materials, creating a self-
assembling nanodevice. 
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1.3 The M13 bacteriophage 
A parallel branch of bionanotechnology research has involved the M 13 bacteriophage. 
This is a filamentous phage of the Inovirus family (Clackson, 2004), so named because 
of its discovery in Munich waste water (hence the M) in 1963 (Hofschneider, 1963). 
Specifically, it is part of the Ff (F-pilus specific) class of phage, of which fl and fd are 
also members (Marvin, 1963). The Ff nomenclature relates to the observation that the 
phage infect Escherichia coli (E.coli) via the F-pilus, a membrane appendage used by 
bacteria for transferring DNA plasmids between one another (Marvin, 1998). The three 
phage of the Ff group share 98% DNA sequence homology and their gene products are 
interchangeable (Clackson, 2004). This fact is important since it means that protein II, 
involved in the recognition and initiation of Ff reproduction, will recognise any Ff viral 
origin of replication, e.g. protein II of M 13 will recognise the commonly used fl origin 
of replication. 
Table 1.1. The M13 prQ~. This lists the M13 gene names, 
the size of proteins encOdedt: and functions of those proteins. 
Gene I encodes both protein I ,and XL (Makowski, 1984; 
Russel, 1991) . .' . 
Gene Pro .... S_.(aa) Funcdon 
I I 348 Assembly/export 
XI 108 Asserhbly/export 
IT IT 410 Replication 
m ·m 427 Capsid 
N N 426 Assembly/export 
V V 87 Replication 
VI 
-
VI 112 Capsid 
vn vn 33 Capsid 
vm vm 73 Capsid 
Ix IX 32 Capsid 
X X 110 Replication 
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The wild-type M13 virion is a flexible rod (Figure 1.3 A and B), persistence length - 1 
micron (Kbalili, 2007), with a 7,222 nucleotide single-stranded DNA genome (Figure 
1.3 C) contained within a-I !-lm long capsid (Clackson, 2004; Marvin, 1966). 
Although the genome encodes 11 proteins (denoted by Roman numerals I - XI, Table 
1.1), only five are incorporated into the viral capsid. The others are involved in the 
replication and assembly of the virion (Clackson, 2004). The five coat proteins (pIlI, 
pVI, pVII, pVIII and pIX) function to encapsulate the ssDNA genome of the M13 
bacteriophage. They are split into two families; the major, and minor coat proteins. 
pVIII comprises the only major coat protein and -2800 copies of pVIII form the phage 
coat. It is thought that this is the smallest number of p VIII coat proteins that can be used 
to encapsulate the 7,222 base DNA genome (Greenwood, 1991). However the number 
of p VIII molecules changes with the length of the ssDNA (Clackson, 2004). 
The minor coat proteins, pIlI, p VI, P VII and pIX, are located at either end of the virion, 
and in theory these may be distinguished by electron microscopy, one end appearing 
blunt, whilst the opposite end looks pointed (Dogic, 2006). However it is often difficult 
to differentiate between each end (Figure 1.3 B). By using shorter phage particles it is 
possible to detect the larger pIlI proteins (Figure 1.3 B inset). This "pointed" end 
contains 3-5 copies of both pIlI and p VI, whilst the "blunt" end is once again composed 
of 3-5 copies each of pVII and pIX (Figure 1.3 A - Dogic, 2006). However, it is 
common practice in schematics of the M 13 bacteriophage to show 5 copies of each coat 
protein. 
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Figure 1.3. The structure of M13 bacteriophage. A shows a schematic of the M 13 
bacteriophage. B shows a transmission electron micrograph of a single M13 phage negatively 
stained with uranyl acetate. Inset shows a 50 nm long microphage particle. C shows the genetic 
map of wi Id-type M 13 bacteriophage. Scale bar equals 200 nm. 
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1.3.1 The life-cycle of the M13 bacteriophage 
The M13 bacteriophage is non-lytic, i.e. unlike many other bacteriophage it does not 
kill the host cell in order to release phage progeny (Marvin, 1969). Instead its life-cycle 
(Figure 1.4) involves the infection of an E.coli cell via an F-pilus and the production of 
new phage particles through a membrane pore created from viral proteins. 
Production of 
new phage 
particles 
Infection 
~ 
PS 0 / ___ .... .-- ssDNA 
oc:::--=-:--= ... :. t I / .. ' 
•• •• ~ . 
I 0dSDNA 
Vi ra l pore 
TalA recep tor 
pV 
pVI 
pili 
I pV11 
, p V1I1 
piX 
Figure 1.4. The life-cycle of the M13 bacteriophage. Adapted from Clackson, 2004. 
Page 14 
Chapter 1 
This method of replication results in a persistent infection, as a result of which the host 
cell replicates at roughly half the rate of an un-infected host (Marvin, 1969, Russel, 
1991). New phage progeny are continually released from the infected cells, resulting in 
a large number of phage being produced in a relatively short time. Phage are produced 
within 10 minutes of infection and the production increases exponentially for the next 
30 minutes where after the increase becomes linear (Clackson, 2004). 
The fact that the infected E.coli continually produce phage particles is highly desirable 
for possible commercial applications given that industrial fermenters could be set up 
relatively cheaply and used to grow vast quantities of phage. Recent work has shown 
that using a computer controlled fermenter results in phage yields 10 times higher than 
using standard flasks with yields of 2 x 1015 virions/L (Grieco, 2009). 
1.3.2 Infection 
Infection of the E.coli host occurs via the interaction of the pIlI proteins with the F pilus 
(Figure. 1.5, stage 1) by the Nl and N2 domains of pIlI which undergo a conformational 
change (Figure 1.5, stage 2 - Deng, 1999). Further interaction with the TolA protein 
(Figure 1.5, stage 3) results in the depolymerisation of the virus capsid and the insertion 
of the ssDNA genome into the cell. After the ssDNA genome is inserted into the cell, a 
complementary strand is then synthesised from the ssDNA to create a double stranded 
circular piece of QNA (Geider, 1974) termed the replicative form (RF). It is from the 
RF DNA that all the viral proteins are transcribed and progeny ssDNA copied. 
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Figure 1.5. pIlI interaction with F -pilus. A diagram showing the binding sites and 
conformational changes of pIlI. 
1.3.3 Replication 
It has been shown that p V forms a dimer which then binds to the ssDNA (Salstrom, 
1971). In the early stages of infection when pV levels are low, unbound ssDNA is 
rapidly converted to RF DNA (Figure 1.4). Only when pV is at a high enough 
concentration are phage particles produced (Salstrom, 1971). The p V dimers bind along 
the viral + strand ssDNA strand, collapsing it into a rod like shape (Gray, 1989) with 
the packaging signal (PS), a DNA hairpin structure, exposed at one end: p V binds 
preferentially to ssDNA (Bauer, 1988; Mou, 1999; Alberts, 1972). 
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1.3.4 The M13 bacteriophage viral pore 
The viral pore is a complex of pI, plV and pXI. plV is known to assemble into 
approximately 12 to 14 600 kDa subunits that form a 24 nm long cylindrical structure 
within the outer membrane (Russel, 1991) with a gated channel (Marciano, 2001) 
running through the centre with a diameter of 8 nm (Linderoth, 1997). It is through this 
channel that the M13 particle is thought to pass (Marciano, 2001). 
pI and pXI are essentially the same protein but pXI lacks a 240 amino acid long 
sequence starting from the N-terminal domain of pI. It is the result of an internal 
translation re-initiation event (Rapoza, 1995). pXI is known to be essential to phage 
production but its specific function(s) is still unknown (Rapoza, 1995). The C-terminal 
domain of pI and pXI contains a conserved nucleotide binding motif which extrudes 
into the cytoplasm whilst the N-terminal domain of pI contains a plY binding domain 
(Rapoza, 1995). pI and pXI form a complex containing 5-6 copies of each protein that 
spans the inner membrane. It is thought they may form a pore as well although it is still 
not known (Clackson, 2004). 
Little is known about how the phage passes through the viral pore. It is thought that the 
coat proteins pIX and p VII, which cap one end of the bacteriophage, interact with the 
PS along with the C-termini of the pI/pXI complex (Feng, 1999). The ssDNA then 
passes through the pore with p vm coat proteins replacing the p V dimers along the 
ssDNA backbone; this process is known to be powered by ATP hydrolysis and the 
membrane potential (Feng, 1997). 
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Once the ssDNA has passed through the pore the end is "capped" by binding of pIlI and 
pVI to complete the phage (Rakjonac, 1999). It has been shown that when pIlI or pVI is 
absent the phage stays tethered to the pore and that more ssDNA can be packaged 
behind it, resulting in phage particles 10 times longer than wild-type (Rakjonac, 1998). 
Within typical phage populations it has been found that 5% of the phage particles are 
double in length (Salivar, 1967), suggesting that "capping" errors do occur frequently, 
perhaps because the levels of pIlI and pVI are not high enough within the E.coli cell at 
the time. 
1.4 Phage Display 
Phage display is the term used to describe the display of short, non-phage, peptide 
sequences on the phage coat proteins (which is reviewed in Clackson, 2004) and is one 
of the primary reasons for the use of the M13 bacteriophage in bionanotechnology. It 
was developed in 1985 when George Smith discovered that the pIlI protein could 
tolerate insertions of small peptides, creating fusion proteins that were incorporated into 
the viral capsid without stopping infection of the E. coli host (Smith, 1985). A 171 bp 
DNA fragment of the gene that encodes for the endonuclease EcoRI was inserted into 
the BamHI site at position 2220 of the f1 bacteriophage. Therefore a 57 amino acid 
fragment of EcoRI was displayed at position 198 of the mature pIlI coat protein, i.e. in 
the middle of the pilI coat protein. When the phage was purified and incubated with an 
anti-EcoRI antibody the phage became non-infective: the anti-body was binding to the 
EcoRI fragment and inhibiting pilI interaction with the E.coli. Wild-type phage were 
unaffected by the antibody and the effect could be reversed in a low pH buffer, after 
which the peptide-displaying phage become infective again, although at levels 100 
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times lower than wild-type. After this proof of principle experiment, other groups 
showed that small peptides could be displayed at position 1 of pIlI (Parmley, 1988), 
position 2 of pVIII (llyichev, 1989) and on the three remaining coat proteins, pVI, pVII 
and pIX (Jespers, 1995; Kwasnikowski; 2005, Gao, 1997; Gao, 1999). 
The following section will describe how phage display is carried out. It focuses 
primarily on pIli display at position 1; however, the principle is the same for the display 
of peptides on any of the other coat proteins. 
To display a peptide on a specific coat protein, a DNA sequence that encodes for the 
desired peptide is inserted between the start of gene III (which corresponds to position I 
of the mature protein) and the signal sequence (Figure 1.6 B). The signal sequence 
ensures that the protein is transported to the E.coli membrane for incorporation into the 
virion before being cleaved off by the endogenous leader peptidase (Clackson, 2004). 
The insertion of the displayed peptide's DNA into gIll is carried out using the RF form 
of the phage genome. Once the modified phage genome is inserted into a suitable E.coU 
host, the RF DNA produces phage particles containing the pIli coat protein displaying 
the peptide. This is the simplest method of phage display and results in every copy of 
pIlI displaying a peptide: termed, polyvalent display. 
However, it is not always possible to have polyvalent display due to physical 
constraints. For example, p VIII cannot express peptides longer than 8 amino acids on 
every copy of pVIII (Petrenko, 1996; Malik, 1996), or a peptide expressed on pIli may 
interfere with infection (Smith, 1988). However, it is possible to overcome this 
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limitation by using a phagemid system (section 1.4.1), which allows peptides longer 
than 8 amino acids to be displayed (Clackson, 2004). 
A B 
Displayed Displayed 
pIlI signal __ 11IiII1::===:;J 
sequence 
pIlI signal __ 1.1:::::::=:::::;;1 
sequence 
M 13 origin of replication 
Plasmid origin of replication 
Transformation 
E.coli E.coli 
Growth 
Super-infection 
Displayed peptide 
\ 
~===I==. ~~\~PIIl II Encapsulated phagemid JJII~'" 
Displayed peptide 
Monovalent display of peptide Polyvalent display of peptide 
Figure 1.6. Methods of phage display. Two commonly used methods of phage 
display; insertion into the phagemid vector (A) or insertion into the phage itself (B). 
Adapted from Clackson et al. (2004). 
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1.4.1 Phagemid phage display 
A phagemid vector (Figure 1.6 A) is a bacterial plasmid that contains an altered phage 
coat protein gene, e.g. gene III with inserted DNA corresponding to a displayed peptide, 
a bacterial origin of replication and an M 13 origin of replication. When inserted into 
E.coli, the phagemid behaves as a bacterial plasmid and is replicated and transferred to 
all daughter cells of the original E.coli. This means that the entire culture contains a 
copy of the phagemid. However, no phage particles are produced since only the altered 
gIll is present. A helper phage is needed in order to produce phage particles displaying 
the desired peptide. The helper phage is an M 13 phage with a defective viral origin of 
replication so that the ssDNA of the phagemid is preferentially encapsulated (discussed 
further in Chapter 3). 
The viral coat protein within the phagemid is typically under the control of the lacZ 
operon and therefore along with the helper phage, isopropyl ~-D-1-
thiogalactopyranoside (lPTG) is added to induce the production of the altered coat 
protein. Within the E.coli, thereafter, there is production of all the phage proteins (I-XI) 
from the helper phage along with the altered pIlI coat protein from the phagemid, i.e. 
there are two populations of pIlI coat protein: the wild-type pIlI and the pIlI displaying 
the peptide produced from the phagemid. The two populations "compete" to be 
encapsulated into phage capsids. Typically 10% or less of the phage particles in a 
phagemid preparation will contain a pilI protein displaying the peptide: termed 
monovalent display (Clackson, 2004). 
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1.4.2 Bio-panning 
Peptides that have an affinity for a specific material are identified using the method of 
"bio-panning" and this is the same whether the genome or phagemid system is used 
(Clackson, 2004). By inserting sequences of degenerate codons, typically encoding 7 -
15 amino acids, into gene III it is possible to create random sequences of peptides that 
are displayed at position 1 of pilI. A single culture of E.coli is able to produce upwards 
of 1011 phage particles (Noren, 2001) and therefore it is possible to create billions of 
phage particles, each with a different peptide sequence displayed on the surface (Figure 
1.7); this is termed a "phage library" (Petrenko, 1996). 
In order to identify a peptide that has a high affinity for an inorganic material, or in fact 
any material, the phage library is exposed in vitro to the immobilised target (Figure 1.7, 
1). Any phage that display a peptide with an affinity for the target will then become 
attached. Washing with a pH neutral buffer containing a small amount of the non-ionic 
detergent Tween to stop phage-phage interactions removes all the other phage, leaving 
only the phage with an affinity for the target (Figure 1.7,2). These phage are then eluted 
(Figure 1.7, 3), typically with an acidic wash, e.g. glycine-HCI pH 2.2, to break the 
phage interaction with the immobilised target. The eluted phage are then amplified by 
infecting host bacteria before being extracted and purified (Figure 1.7, 4 and 5). 
Subsequent rounds of bio-panning, normally 3 - 5 rounds, lead to the enrichment of a 
few bacteriophage displaying peptides with a high affinity for the target substrate. The 
DNA of these bacteriophage is then extracted and sequenced to identify the binding 
peptide (Figure 1.7, 6), which can then be used in other applications. 
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Although phage display and bio-panning are excellent techniques there are issues that 
make them non-ideal. As has been pointed out by Bassindale et al. (2007), there is the 
possibility of inherent bias in the selection of certain sequences. These biases manifest 
themselves as sequences that may be the "best" binders to the target, yet they inhibit the 
infection or production of that phage particle and so are selected against in the 
amplification step (Figure 1.7). Likewise during the elution step (Figure 1.7), the acidic 
buffer glycine-HCI, used to disrupt the peptide-target interactions, may have a greater 
effect on highly basic peptides meaning these are released more readily compared to 
acidic peptides. Naik et al. (2004) have devised a modification of the phage display 
method to remove the glycine-HCI step bias. Their method follows the standard bio-
panning protocol (Steps 1 - 3 of Figure 1.7). However, they made the assumption that 
glycine-HCI would not remove all the bound phage from the target and that the tightest 
binders would still be associated. Therefore they treated the target with glycine-HCI and 
then washed away any unbound phage. They then heated the target, and any remaining 
bound phage, to 95°C for 10 minutes to break down the phage particles and release their 
ssDNA genome. They then used the released ssDNA as the template for PCR using 
primers specific to gene III to amplify the displayed peptide DNA sequence. They used 
this method to obtain unique peptide sequences specific to 10 nm cobalt nanoparticles 
that were not found using the traditional bio-panning procedure. However, they did not 
report whether these sequences had a higher affinity than those found with traditional 
bio-panning (Naik, 2004). 
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Figure 1.7. Bio-panning. Cartoon showing the principal aspects of M13 bacteriophage 
" 
bio-panning using a pIlI expressed library. Adapted from Willats, 2002. 
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1.4.3 Bio-panning and peptides specific to inorganic materials 
The use of bio-panning has identified numerous inorganic binding peptides that may 
have a practical use in bionanotechnology (Table 1.2). 
Table 1.2. Peptides that show high affinity to inorganic materials. A list highlighting 
some examples of materials where phage display has been used to find peptide 
sequences specific to that material. 
Pepti:le Sequence Material it binds to Size Library Reference 
VSGSSPDS Gold (Au) 8 
...E.Lll Huang, 2005 
Nobk: Metals CDRTSlWRC 
Platinwn (Pt). 9 
...Em Sarikll}'ll, 2003 
CA YSSGAPPMPPFC Silver (Ag) 14 plll Naik,2002 
CSVTQNKYC Pallad ium (Pd) 9 pm Sarikaya, 2003 
AQNPSDNNTHTH Galliwn arsenide (GaAs) 12 pm Whaley, 2000 
Semiconductors CTYSRLHLC 
Cadmiwn sulphide (CdS) 9 pili Flynn, 2003 
CNNPMHQNC Zinc sulphide (ZnS) 9 pm Flynn, 2003 
HGHPYQHLLRVL Carbon Nanotubes 12 pLll Lee,2009 
AlWVSPY Titanium oxide (Ti02) 7 pLll Liu, 2009 
Oxides EAHVM HK V APRPGGGSC Zinc oxide (ZnO) 17 pm UJreLSU, 2005 
TVVQTYSMVTRA Silicon oxide (Si02) 12 pm Eteshola, 2005 
CHAALTMQC Mica 9 pllJ Donatan, 2009 
Minerals CMLPHHGAC 
Hydroxyapatite 9 p11J Gungormus, 2008 
DVFSSFNLKHMRG Calcite (Calciwn carbonate) 12 ~1JJ Gaskin, 2000 
HTQNMRMYEPWFG Argt>nite (Calciwn carbonate) 12 ~lll Gaskin, 2000 
MSPHPHPRHHHT Silica (Si02) 12 pLll Naik,2002 
Bbc0ll1'utibile substrates YPSAPPQWLTNT Titania (Ti02) 12 plll Fang, 2008 
THRTSTLDYFV1 Chlorine-doped po~ole (PPyCl) 12 plll Sa~vi, 2005 
However, peptides have been identified that show not just specificity to a pruticular 
material but also specificity to the structure of that material. Whaley et al. (2000) 
panned for sequences that were specific to the different crystal faces of GaAs (gallium 
arsenide). A pill library, displaying random 12-mer peptides, was used to select for 
sequences that were specific for GaAs(100). When the GaAs(lOO) specific phage were 
then incubated with GaAs(111), i.e. gallium arsenide with a different crystal lattice 
structure, the phage failed to interact with the surface. 
Page 25 
Chapter 1 
A similar experiment was carried out using a pilI 7 -mer library to find peptide 
sequences specific to surface defects within a sheet of germanium (Sinensky, 2006), e.g. 
the boundary between two germanium crystals, or large changes in surface morphology. 
Two rounds of bio-panning were carried out using a germanium film on a silicon 
surface (Ge-on-Si) as the target. Ge-on-Si is created from a vapour of germanium, in a 
vacuum, which forms a single crystal of germanium on the silicon substrate. However, 
this process leads to numerous defects in the germanium layer (Colace, 2000). The 
phage selected were therefore specific to defects and germanium alike. In order to select 
specificity for the defects, a round of negative selection was carried out, i.e. by bio-
panning the selected phage against a germanium wafer. The wafer was created by 
cleaving a single germanium crystal, which produces far fewer defects. They identified 
two sequences (CSYHRMATC and CTSPHTRAC) which showed a 10: 1 preference for 
Ge-on-Si over germanium wafers compared to wild-type M 13 phage, i.e. the sequences 
were more specific to the defects of the germanium than to the germanium crystal itself. 
The two experiments described above highlight the versatility of phage display and bio-
panning, and that specific peptide sequences can be identified that are specific to almost 
any material and the different forms that the material may have. 
1.5 The M13 phage coat proteins and their uses in bionanotechnology 
1.5.1 The minor coat proteins pIlI, pIX. P VI and p VII 
The viral gene gIll encodes a 406 amino acid long peptide (Hill, 1982), pilI. It is by far 
the largest viral coat protein. In contrast, pIX and pVII are 32 and 33 amino acids long, 
respectively, and are two of the smallest ribosomally translated proteins known 
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(Clackson, 2004). The remaining minor coat protein pVI is 112 amino acids long 
(Rakonjac, 1999). pIli differs from the other coat proteins since it has a large 
hydrophilic domain, whilst the other proteins are mostly hydrophobic (Beck, 1978). It is 
perhaps the most important coat protein since it is responsible for the recognition of the 
bacterial F-pilus and TolA receptor, both of which must be bound to by pIlI for 
successful infection (Deng, 1999). 
Work by the Strengele and Kremser laboratories using mutagenesis and protein analysis 
of pIlI (Kremser, 1994; Strengele, 1990) have indicated that it is divided into three 
domains: Nl, N2 and C-terminal (Figure 1.8 A), which are separated by glycine rich 
linker sequences. The N 1 and N2 domains consist primarily of ~ strands with a single 
alpha helix in each domain (Lubowski, 1998). It is thought, from crystallographic 
studies of the first 217 residues (Figure 1.8 A), that Nl and N2 interact extensively 
(Lubkowski, 1998), thus creating a 'horseshoe shape' (Figure 1.8 B). This conformation 
exposes the polar residues, Lys22, Asp24, Lys25 and Asp28, in the Nl domain, and 
threonine residues in the N2 domain. These exposed residues on the N 1 and N2 
domains interact, forming a central channel between the two domains (Figure 1.8 B) 
with the hydrophobic residues stabilising the structure (Lubkowski, 1998). It has been 
suggested that this channel acts as the binding site for the F-pilus (Lubowski, 1998; 
Chatellier, 1999). 
Whilst the N 1 and N2 domains are required for infection, pIlI deletion mutants 
containing only the C-terminal (CT) domain show that it plays an important structural 
role and is required for both pVI interaction and phage release from the cell (Rakonjac, 
Page 27 
Chapter 1 
1999). Whereas the two N-terrninal domains are exposed to solution, it is thought that 
the C-terrninal is buried within the phage capsid (Rakonjac, 1999). 
F -pilus binding 
channel 
Red = Nl domain 
Blue = N2 domain 
Linker ::. 
1 (Parmley, 1988) 
Figure 1.8. The minor coat protein pIli. A shows the crystal structure, at 1.46 A, of 
the first 217 amino acids of the M13 coat protein pIlI. PDB code: Ig3p (Lubowski, 
1998). B shows a schematic of the three main domains of pilI (Nl, N2 and C-terrninal), 
linked by glycine rich sequences, and their position within the protein sequence, e.g. 
N 1: 1-68. The commonly used areas for peptide display, and sites of peptide insertion 
within the protein sequence, are highlighted by arrows, together with the reference of 
the first report to successfully phage display at these sites. 
Little is known about the remaining minor coat proteins. The lack of structural and 
functional data about these coat proteins reflects their lack of biotechnology 
applications with 99% of phage display studies utilising pIli and p VID. However, pIX is 
increasingly used to express small peptides (Gao, 1997) and has been used in M13 
bionanotechnology (Nam, 2004; Khalil, 2907). 
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Two examples highlight how using minor coat protein phage display can result in 
potentially useful structures. Both used pIlI and pIX peptide display within the same 
phage particle. Nam, et al. in 2004 used M13 to create a nano-ring, i.e. they engineered 
the M 13 phage particle so that it joined end to end, creating a loop or ring-like structure 
(Figure 1.9). 
Figure 1.9. A nano-ring created by the M13 bacteriophage. An Atomic Force 
Microscopy (AFM) image of M13 bacteriophage joined end to end to create a loop 
structure called a nano-ring. Taken from Nam, 2004. 
They created an M13 phage mutant that displayed an anti-streptavidin peptide on pIlI 
and a hexahis tag (HHHHHH) on pIX: both at position 1 within the two coat proteins. 
By mixing this phage with a linker molecule consisting of streptavidin conjugated to a 
Ni(I1)-nitrilotriacetic acid complex (Ni-NTA) it formed a nano-ring. The pm peptide 
bound to the streptavidin whilst the hexahis tag on pIX bound tightly to the Ni-NTA 
complex (Figure 1.9). As expected, the formation of nano-rings was very inefficient 
unless the amounts of phage and linker molecule were at equal concentrations. At 
higher or lower concentrations of phage: linker molecule, then very few nano-rings 
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were observed. By adding imidazole (which competed with the hexahis tag binding to 
the Ni-NTA complex) it was possible to reverse this reaction and break up the rings. 
Therefore they essentially created a biological nano-switch where the nano-ring could 
be open or closed by adding or removing imidazole. 
Sweeney, et al. created another hetero bi-functional phage that displayed pairs of 
leucine zippers. These are short, helical polypeptides which associate with their specific 
partner, e.g. the leucine zipper ACID has a high affinity to its leucine zipper partner 
BASE (O'Shea, 1993). They created a mutant M13 phage that displayed ACID at 
position 1 on pIlI and BASE at position 1 on pIX. When these phage were mixed 
together they formed long filaments of phage joined end-to-end via the leucine zipper 
pairs, with some filaments up to 15 Ilm long. However, there was no mechanism to 
control the length of these filaments. 
Although the structures described above are relatively simple, they provide a proof of 
principle that the M 13 bacteriophage minor coat proteins can be programmed using 
simple genetic manipulation to self-assemble into higher order structures. 
1.5.2 The major coat protein p VIII 
The pVIII coat protein is 50 amino acids long (Clackson, 2004). Currently it is thought 
that p VIII exists as a continuous alpha helix between residues 10-46 (Vos, 2009) and 
can be split into four domains (Figure 1.10): an acidic domain located at the N-terminal 
end followed by regions that are largely amphipathic and hydrophobic and finally a 
basic region located at the C-terminal end (Papavoine, 1998). Some groups have argued 
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that the amphipathic domain and hydrophobic domains are connected by a flexible 
hinge-region (Papavoine, 1998); more recently this has been refined into a theory that 
pVIII has the ability to undergo helical deformations between residues 38-50, which 
allow the protein to a) have a simple tilt mechanism in order to fit into the membrane, 
and b) undergo efficient incorporation into the phage particle (Vos, 2009). The basic 
domain located at the C-terminus is known to interact with the ssDNA genome (Hunter, 
1987; Rowitch, 1988). Substitutions of the positively charged lysines within the basic 
C-terminal region with negatively charged glutamate residues have shown that the 
positive charge of the lysines are needed to negate the negative charges of the DNA 
phosphate backbone (Hunter, 1987; Rowitch, 1988). 
Amphipathic Basic 
NH,.AEGDDPAKAAFNSLQASATEYIGY A WAMVVVIVGA TIGIKLFKKFTSKAS.cooH 
Acid Hydrophobic 
Figure 1.10. Amino acid sequence of the pVIII coat protein. 
1.5.2.1 Virion structure 
Within the assembled virion, the pVIII protein has a linear 'I' shape (Vos, 2009). The 
- 2800 copies of p VIII assemble into a helix around the circular ssDNA genome with 
2.4 nucleotides per pVIII subunit (Clackson, 2004). The pVIII proteins have been found 
by Raman microspectroscopy to tilt away from the DNA by approximately 16° 
(Overman, 1996) and overlap one another, giving a so-called fish scale or roof tile 
appearance to the viral capsid. The overlapping structure of the p VIII coat proteins 
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results in the negatively charged N-terminal acid domain being exposed to the solvent 
and giving the phage particle an overall negative charge (Clackson, 2004). The coat 
proteins show a 5-fold (pentamer) rotation axis around the ssDNA with a 2-fold screw 
axis of 32 A pitch; i.e. each pentamer is rotated 1800 and translated by 16 A (Figure 
1.11) from the previous pentamer (Marvin, 1966). This creates a helical structure where 
each turn of the helix contains five pVIII proteins (Wen, 1997). It has, however, been 
suggested that M13, and related filamentous phage, show structural polymorphism 
(Wang, 2006) and that this is averaged out by the various techniques that have been 
utilised to study its structure. 
A B 
View of an M13 phage 
particle along the helical axis 
View of a section of the M13 phage 
particle from the side 
.... pVIII coat 
t)i~.~ protein 
.... pVIII coat 
protein 
Figure 1.11. Model of M13 filamentous bacteriophage capsid determined by NMR 
spectroscopy. A and B show the arrangement of the pVIII coat proteins in the capsid 
along the helical axis of the M13 phage particle (A) and from the side (B). The various 
colours show different pVIII pentamer sets. Taken from Zeri, 2003. 
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1.5.2.2 p VIII phage display and bionanotechnology 
Peptides are typically displayed on pVIII by replacing the EGD ammo acids at 
positions, 2 to 4, with the desired sequence. However, it has been found that only 
relatively short peptides can be displayed on pVill, typically 6 - 8 amino acids 
(Clackson, 2004). The exact reason for this is unknown but it is thought it may be that 
the displayed peptides may interfere with the passage of the phage particle through the 
viral pore as it passes out of the E.coii membrane (Clackson, 2004). Another reason 
may be that the displayed peptide may obstruct p VIII interactions with the minor coat 
proteins at the ends of the phage particle (V. Petrenko, personal communication). 
Whatever the mechanism, it limits the flexibility of display on p Vill. However this does 
not stop the display of peptides on p VIII from being used to produce nanoscale devices. 
Using pVIII phage display has lead to the fabrication of some of the simplest nanoscale 
devices: a conducting nanowire. The M13 bacteriophage is an excellent shape to act as a 
scaffold for deposition of materials to create nanowires, i.e. the phage particle is long 
and thin. By displaying small peptides on p VIII that nucleate a specific material Angela 
Belcher and her group have created gold (Huang 2005), cobalt: platinum (Lee 2009), 
cobalt oxide (Nam 2006), cadmium sulphide, and zinc sulphide nanowires (Flynn 
2003). Huang, et ai. in 2005 used a p V ill 8-mer phage display library to isolate a 
peptide sequence that had an affinity for a gold surface. It was found that the gold 
binding peptide (VSGSSPDS), which was displayed on all the copies of p VIII, also had 
an affinity for 5 nm gold nanoparticles. Mixing the mutant M13 phage with 5 nm gold 
nanoparticles resulted in the nanoparticles spontaneously ordering themselves along the 
length of the phage (Figure 1.12 A). Chloroauric acid (HAuCl4), as a source of gold 
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ions (Au3+), was then reduced with sodium borohydride in the presence of the decorated 
phage particles. The 5 nm gold nanoparticles acted as a nucleating site for the reduced 
gold and the nanoparticles increased in size until they merged to create a continuous 
nanowire (Figure 1.12 B). Importantly, the nucleation of these materials was done under 
ambient conditions. This is in contrast to more traditional techniques for the fabrication 
of nanowires which require harsh conditions, such as high temperature and organic 
solvents (Huang, 2005). The continuous gold coating on the mutant M13 phage 
particles was found to be conducting and showed a linear relationship between current 
and voltage, i.e. the gold coated mutant phage behaved like a gold nanowire. However, 
the gold coated mutant phage had an average resistance of - 600 n, which is -100 times 
greater than that of bulk gold. 
Figure 1.12. M13 binding to gold nanoparticles. M13 phage particles displaying a 
gold binding peptide bound to 5 nm gold nanoparticies (A) and after gold deposition 
(B). Taken from Huang, 2005. 
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1.5.2.3 Liquid crystal properties of the M13 bacteriophage 
Perhaps the most interesting property of the M 13 bacteriophage is that at high 
concentrations it shows liquid crystal properties (Welsh, 1996; Clackson, 2004). The 
liquid crystal phase is a stable phase between the solid crystal and isotopic liquid phases 
(Kumar, 2001); i.e. the M13 particles spontaneously self-assemble into ordered lattices. 
Liquid crystals can be broadly divided into two distinct groups; the first is thermotropic 
where the liquid crystalline properties vary with temperature; and lyotrophic where the 
liquid crystalline properties vary with concentration. The M13 bacteriophage behaves as 
a lyotrophic liquid crystal because of its rod-like structure (Welsh, 1996). 
Disordered Nematic 
Directional order 
Cholesteric 
Smectic 
Layer 1 
Layer 2 
Directional and 
positional order 
Increasing M 13 phage particle concentration 
Figure 1.13. The liquid crystal structures. A schematic showing the different types of 
liquid crystal categories using the M13 bacteriophage. 
The structure of the liquid crystal phase can be subdivided into three categories: 
nematic, smectic and cholesteric (Figure 1.13; Kumar, 2001). These refer to the level of 
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order found within the phase. Therefore with regard to M13, the more concentrated a 
solution gets, the phase order will shift first from nematic to smectic, and then at higher 
concentrations the order will shift to cholesteric. M 13 particles found in the nematic 
phase will all point in the same direction; whereas those found in the smectic phase will 
point the same direction but will also be organised into layers, i.e. they have directional 
and positional ordering. Thus by controlling the concentration of M 13 it is possible to 
control the level of order that the particles will self-assemble into and so create a higher 
ordered structure. 
Various studies have used the liquid crystal properties of the M13 bacteriophage to 
create ordered M13 bacteriophage liquid crystals that act as a scaffold for the deposition 
of inorganic materials such as gold (Yoo, 2006), gallium nitride (GaN) (Yoo, 2006), 
cobalt oxide (Yoo, 2006) and iron phosphate (FeP04) (Lee, 2009). All the studies used 
the same method to create the M13 phage liquid crystals. 1 mL of 1010 virions/mL of 
the M13 phage, displaying one of the inorganic material binding peptides on pVIII, was 
placed on top of multiple, 10 nm thick, polyelectrolyte layers (Figure 1.14 A) consisting 
of linear-polyethylenimine (LPEI) and polyacrylic acid (PAA). The polyelectrolyte 
layer was positively charged and therefore attracted the negatively charged phage 
particles to the surface. At the surface the phage were at a high enough concentration to 
self-assembly from a random order (Figure 1.14 B) into a liquid crystal (Figure 1.14 C). 
The packing density of the phage, i.e. the number of phage particles per mm2, could be 
controlled by the pH of the phage solution, with very dense packing of the phage at pH 
4.8 and very sparse packing when the pH was increased to pH 5.5. The displayed 
peptides on p VIII were still solvent accessible and were used to bind the specific 
inorganic materials and so coating the phage. 
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Polyelectrolyte layer forces 
M 13 phage particles to 
surface Ordered M13 phage layer 
Randomly ordered M13 phage Ordered M13 phage layer 
Figure 1.14. Self-assembling liquid crystal M13 bacteriophage layer. M13 
bacteriophage were mixed with a positively charged polyelectrolyte layer (A). The 
positive polyelectrolyte multilayer attracts the M13 bacteriophage to the surface and the 
M13 bacteriophage self-assembles into an ordered layer. B shows a phase-mode AFM 
image of the initially randomly aligned M13 bacteriophage and C shows M13 at high 
concentration after forming the ordered layer. Taken from Yoo, 2006: 
The M13 phage liquid crystals have been used to create a simple lithium ion battery 
(Lee, 2009). Two different M13 phage layers were created; one coated with cobalt 
oxide and the other coated with iron phosphate. These two layers were used as the 
anode and cathode of the battery, respectively. When used as part of a lithium ion 
battery they were shown to perform almost as well as existing macroscopic lithium ion 
batteries (Cahoon, 2009). 
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1.6 Summary of the M13 bacteriophage and bionanotechnology 
The work described above highlights the reasons why the M13 bacteriophage was 
chosen for the work described in this thesis : 
1. The phage particle has excellent dimensions for the fabrication of conducting 
nanowires. 
2. Peptides can be displayed on the phage coat proteins in order to specifically bind 
inorganic materials. 
3. The display of peptides is controlled by the phage genome which can easily be 
altered using simple molecular biology techniques. 
4. The M13 bacteriophage can be programmed, via phage display, to self-assemble 
into high order structures which can be used as simple nano-scale devices. 
1. 7 Aims of the thesis and the molecular transistor 
The aim of the work described within this thesis has been to use the properties of the 
M13 bacteriophage described above to create a self-assembling molecular transistoL 
The transistor is a ubiquitous device within all electronics. At its most basic the 
transistor is a switch with two states: On and off. The on and off states equate to the 1 
and 0 of the binary language which is used for the various calculations that computer 
chips carry out (Kastner, 2000). 
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Figure 1.15. The Molecular transistor. A schematic showing the two basic layouts of 
a transistor. A shows the gate associated with the source and drain electrodes on the 
same plane. B shows the gate underneath the source and drain electrodes separated by a 
silicon dioxide layer. 
A transistor consists of four main components (Figure 1.15); three metallic electrodes 
(source, drain and gate) surrounding a metallic or semi-conducting island. Electrons 
flow from the source electrode to the drain electrode via the island. A voltage applied 
across the gate electrode is used to control this flow of electrons. Altering the voltage 
applied across the gate changes the energy state of the island. Applying enough voltage 
changes the energy state to allow electrons to "hop" from the source to the island and 
then "hop" again from the island to the drain. The work described within this thesis 
focuses on genetically programming the M13 bacteriophage to self-assemble around a 
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nanoparticle island and then to act as a scaffold for the deposition of gold to create the 
electrodes (Figure 1.16). 
Leucine 
zIpper 
50 nm long M13 
phage particle 
.~Island 
• 
;::;:S\ 
:;;:<$ I 
1M 13 phage particles self-assemble around island via displayed pIlI peptide 
Higher order structure f iii## w:: =<~ :a.: *. 
Leucine zipper pair 
Gold surface r-'--......., 
Transistor 
1 Higher order structure directed to pre-fabricated circuit via leucine zipper interactions 
1 M13 phage particles act as a scaffold for deposition of gold to create transistor 
Figure 1.16. Schematic of a possible fabrication protocol of a self-assembling 
molecular transistor. A schematic showing the proposed steps involved in the creation 
of a self-assembling molecular transistor using M 13 phage. 
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1.8 Scope of the work 
As mentioned above, the aIm of this work has been to create a self-assembling 
molecular transistor. Each of the following chapters investigates a different aspect of 
this aim: The work described within Chapter 3 looks at the creation of bespoke length 
M13 bacteriophage from 50 nm to 500 nm which would allow the transistor to be far 
smaller than if wild-type M13 phage (1 !-lm) were used in its construction; i.e. a 20 fold 
miniaturisation in its size if the 50 nm long phage were used. The work described within 
Chapter 4 looks at the fabrication and purification of higher order structures which 
would act as the scaffold for the creation of the transistor. Chapter 5 looks at how the 
transistor could self-assemble into an existing electronic circuit by using leucine zipper 
pairs to direct the higher order structures to specific locations on a surface. Finally work 
described within Chapter 6 looks at using the M13 bacteriophage as a scaffold to 
deposit gold onto the phage particles to create the electrodes of the transistor. 
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Materials and Methods 
Chapter 2 
2.0 Materials 
2.0.1 General Reagents 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.) unless 
otherwise stated. All primers were purchased from MWG-Biotech (Ebersberg, 
Germany) with High Purity Salt Free (HPSF) purification. DNA sequencing was carried 
out by The Sequencing Service at Dundee University, U. K. or GATC Biotech Ltd 
(Cambridge, U.K.). Restriction enzymes were purchased from New England Biolabs 
(Hitchin, U.K.). 
2.0.2 Bacterial Strains 
E.coli KI2 ER2738 ([F'proA +B+ lacl' L1(lacZ)M15 z~r.-:TnlO(TetR)] fhuA2 gin V L1(lac-
proAB) thi-l L1(hsdS-mcrB)5) was obtained from New England Biolabs, Cat. No. 
E4104S. 
NEB 5-alpha F'l' Competent E. coli (High Efficiency) ([F' proA + B+ lacfl ~(lacZ)M 15 
zzf::TnlO (TetR)]fhuA2~(argF-lacZ)U169 phoA glnV44 <P80L1(lacZ)MI5 gyrA96 recAl 
endAl thi-l hsdRl7) was obtained from New England Biolabs, Cat. No. C2992H. 
XLI-Blue supercompetent cells (recAl endAl gyrA96 thi-l hsdR17 supE44 relAl lac 
[F' proAB lacIqZ~15 TnlO (Tetr)]) was obtained from Stratagene (La Jolla, 
Calafornia, U.S.A.) as part of the QuikChange® II mutagenesis kit (Cat. No. 200523). 
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XLI-Blue Competent cells (recAl endAl gyrA96 thi-l hsdR17 supE44 reLAl lac [F' 
proAB Lac/qZ~15 TnlD (Tetr)]) were obtained from Stratagene (La Jolla, Calafornia, 
U.S.A.), Cat. No. 200249. 
All of the above bacterial strains contain the common characteristic of F-pilus 
expression linked to tetracycline resistance. This results in a high expression of F-pili 
(needed for M13 infection) in the presence of tetracycline. In theory, any bacterial strain 
with this characteristic can be used to grow M13. 
2.0.3 Antibiotic stock and working concentrations 
Carbenicillin disodium salt (Cat. No. CI389): 100 mg/mL in 70% (v/v) ethanol (lOOOx 
stock). Working concentration: 100 [,lg/mL. Mode of action: inhibits bacterial cell-wall 
synthesis (peptidoglycan cross-linking) by inactivating transpeptidases on the inner 
surface of the bacterial cell membrane. Carbenicillin was used instead of ampicillin due 
to its increased resistance to degradation from beta-Iactamase enzymes. 
Chloramphenicol (Cat. No. C0378): 34 mg/mL in 100% (v/v) ethanol (lOOOx stock). 
Working concentration: 34 [,lg/mL. Mode of Action: Inhibits translation on the 50S 
ribosomal subunit at the peptidyltransferase step (elongation inhibition). 
Kanamycin B sulphate salt (Cat. No. B5264): 50 mglmL in ddH20 (I OOOx stock). 
Working concentration: 50 [,lg/mL. Mode of Action: Binds to 70S ribosomal subunit; 
inhibits translocation and elicits miscoding. 
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Tetracycline hydrochloride (Cat. No. T7660): 10 mg/mL in 70% (v/v) ethanol (1000x 
stock). Working concentration: 10 !-tg/mL. Mode of Action: Inhibits protein synthesis 
(elongation) by preventing binding of aminoacyl-tRNA to the 30S subunit. 
All antibiotics were 0.22 !-tm filtered and stored at -20°C. All stocks were made at 1000x 
concentration; therefore 1 !-tL of antibiotic was added per 1 mL of medium. 
2.0.4 Media recipes 
2.0.4.1 2xYT medium 
Per litre. 
To 900 mL of ddH20 added: 
• 16 g tryptone 
• 109 yeast extract 
• 5 g NaCI 
Mixed until powder had dissolved, adjusted to pH 7 with 5 N NaOH and adjusted the 
volume to 1 L with ddH20. The medium was then autoclaved. 
2.0.4.2 Super broth (SB) medium 
Per litre. 
To 900 mL of ddH20 added: 
• 32 g typtone 
• 20 g yeast extract 
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• 5 g NaCl 
Mixed until powder had dissolved, adjusted to pH 7.4 with 5 N NaOH and adjusted the 
volume to 1 L with ddH20. The medium was then autoc1aved. 
2.0.4.3 Agarose top 
Per litre. 
To 900 mL of ddH20 added: 
• 109 tryptone 
• 5 g yeast extract 
• 5 g NaCI 
• 1 g MgCl2eH20 (magnesium chloride hexahydrate) 
• 7 g Agarose 
Mixed until powder had dissolved, adjusted to pH 7.4 with 5 N NaOH and adjusted the 
volume to 1 L with ddH20. The agarose top was then dispensed into 50 mL aliquots in 
80 mL bottles and autoc1aved. 
2.0.4.4 Agar 
Per litre. 
To 900 mL of ddH20 added: 
• 16 g tryptone 
• 10 g yeast extract 
• 5 g NaCI 
• 15 g agar 
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Mixed until powder had dissolved, adjusted to pH 7.4 with 5 N NaOH and adjusted the 
volume to 1 L with ddH20 before autoclaving. Agar was allowed to cool to - 50°C 
before antibiotics were added. 
2.0.5 Buffers and other reagents 
2.0.5.1 Phosphate buffered saline (PBS) pH 7.4 
PBS was made using phosphate buffered saline (Dulbecco A) tablets (Oxoid, part of 
Thermo Fisher Scientific, Cat. No. BR0014G). One tablet was used per 100 mL of dd 
H20; so for 1 L 10 tablets were used. Typical formula in 1 L ddH20: 
• 8 g NaCI 
• 0.2 g Potassium chloride 
• 1.15 g Di-sodium hydrogen phosphate 
• 0.2 g Potasium dihydrogen phosphate 
Tablets produced a PBS solution of pH 7.4. After dissolving the tablets into the ddH20, 
the solution was autoclaved (or when needed, sterilised with a 0.22 /-lm filter) 
2.0.5.2 20% Polyethylene glycol (PEG) and 2.5 M NaCI solution 
(PEGlNaCI) 
Per litre: 
• 200 g PEG (Sigma-Aldrich, Cat. No. P5413) 
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• 146.1 g NaCI 
The solution was autoclaved and then allowed to cool. As PEG cools it splits into two 
layers. Therefore it is important to keep mixing the PEG every 10 minutes or so which 
will create a white cloudy solution. Eventually it cools to a point where the solution 
suddenly becomes clear upon mixing. Occasionally after PEG has been left overnight it 
develops a very slight cloudiness; this does not affect its performance. 
2.0.5.3 2x Protein loading buffer (LaemmLi buffer; LaemmLi, 1970) 
To make 5 mL: 
• 0.625 ilL 1 M Tris-HCI, pH 6.8 (0.125 M) 
• 2 mL 10% SDS (4%) 
• 1 mL Glycerol (20%) 
• 0.5 mL 2-mercaptoethanol (10%) 
• 1 mg (approx.) Bromophenol blue (approx. 0.004%) 
• 0.875 mL ddH20 (to 5 mL) 
Stored at 4 0c. 
2.0.5.4 lOx l buffer for linear sucrose gradients 
Per litre: 
• 24.5 g HEPES (4-(2-hydroxyethyl)-I-piperazineethanesulfonic acid) 
• 58.44 g NaCl 
Mixed until powder had dissolved and adjusted the volume to 1 L with ddH20 before 
filtering with a 0.22 Ilm filter. 
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To use for linear sucrose gradients: 25 mL of lOx A buffer was added to 1 mL of 0.25 M 
EDTA (ethylenediaminetetraacetic acid) and made up to 250 mL with ddH20. Within 
Ix A buffer the final concentrations were as follows: 100 mM HEPES, 1 M NaCl, 1.25 
mMEDTA. 
2.0.5.5 lOx Glycine running buffer 
Per litre: 
• 10 g Sodium lauryl sulfate (SDS) 
• 30.3 g Tris-base 
• 144.1 g glycine 
Adjust volume to 1 L with ddH20 and store at room temperature. Add 100 mL lOx 
glycine buffer to 900 mL ddH20 to create Ix glycine running buffer. 
2.0.5.6 Coomassie blue staining solution 
Per litre: 
• 2.5 g Coomassie brilliant blue R-250 (Cat. No. B8647) 
• 450 mL methanol 
• 100 mL acetic acid 
Adjust volume to 1 L with ddH20 and store at room temperature. 
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2.0.5.7 De-stain solution 
Per litre: 
• 450 mL methanol 
• 100 mL acetic acid 
Adjust volume to 1 L with ddH20 and store at room temperature. 
2.0.5.8 Tris-HCI buffer 
Per litre: 
• 20 mL Trizma-HCI (Cat. No. T3253) 
• 29.22 g NaCl 
Adjust volume to 1 L with ddH20 and 0.22 [.tm filter sterilised. Store at room 
temperature. 
Page 51 
Chapter 2 
2.1 General methods 
2.1.1 Growth of overnight E.coli culture 
A single colony of E.cofi was picked and placed into 50 mL red-topped Falcon tube 
containing 10 mL of 2x YT medium and tetracycline. Culture was grown at 37°C with 
shaking at 220 rpm overnight. 
2.1.2 Preparation of chemically competent E.coli cells 
1 mL of an overnight culture of E.coli was added to 10 mL of 2xYT media containing 
tetracycline and grown for -1 hour at 37°C with shaking at 220 rpm to an optical 
density at 600 nm (OD600) of -0.5. The cells were spun down in a Sorvall RC-5B 
refrigerated super-speed centrifuge at 1500 rpm (200 x g) for 10 minutes at 4°C. The 
supernatant was removed and the cells placed on ice. The cell pellet were re-suspended 
with 1/5th volume (2 mL) of ice cold 50 roM CaCh and left on ice for 20 minutes and 
were spun down again at 1500 rpm for 10 minutes at 4°C. The supernatant was removed 
and the cells re-suspended with 1/1Oth volume (l mL) of ice cold 50 mM CaCh and left 
on ice for 1 hour. The cells were used directly for transformation. 
2.1.3 Transformation using chemically competent E.coli cells 
Competent E.coli cells (prepared in section 2.1.2) were dispensed into aliquots of 200 
flL in 1.5 mL Eppendorf tubes that had been pre-cooled on ice for 10 minutes. Up to 
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100 ng of DNA (either phage RF DNA or plasmid DNA) was added to the cells, mixed 
gently by flicking the tube, and then incubated on ice for 40 minutes. Cells were heat 
shocked in a water bath at 42°C for 90 seconds and returned to ice and incubated for a 
further 2 minutes. 0.8 mL of 2x YT broth was added to each aliquot of cells and 
incubated at 37°C with shaking at 220 rpm for 1 hour in order for the cells to regain 
normal membrane permeability. 10 ilL, 100 ilL and 890 ilL were plated out onto three 
2x YT agar plates containing tetracycline and, if required, other antibiotics (depending 
on plasmid DNA). When using plasmid DNA the solution was pipetted onto the surface 
of the agar plate and spread evenly across the surface with a glass spreader. 
When transforming phage RF DNA, the transformed cells were added to 3 mL of 
molten agarose top (stored in 5 mL tubes in a water bath at a temperature of 47°C) and 
200 III of an overnight E.coli culture (section 2.1.1). The solution was mixed by 
inversion and then quickly poured onto a 2x YT agar plate containing tetracycline and 
swirled to ensure complete and even coverage of the agar by the molten agarose top. 
The agarose top was allowed to set for 10 minutes at room temperature before being 
incubated overnight at 37°C. When transforming phage RF DNA a negative control was 
used that contained no DNA in order to check for phage cross-contamination. If plaques 
were present on negative control then other plates were discarded and the 
transformation repeated. 
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2.1.4 Preparation of bacterial stocks for freezing 
900 ilL of overnight E.eoli culture (section 2.1.1) was mixed with 100 ilL of 80% 0.22 
Ilm filtered glycerol (8% final concentration) in a 1.5 mL Eppendorf tube and stored in 
a -80°C freezer. 
2.1.5 Preparation of phage stock 
2.1.5.1 Growth of phage and PEG precipitation 
A single plaque was picked from an agar plate and used to inoculate 1 mL of 2x YT 
medium (in a 50 mL Falcon tube) containing tetracycline and 10 III of an overnight 
E.eoli ER2738 culture (section 2.1.1); giving a 1 in 100 dilution of the E.eoli. This 
culture was incubated at 37°C, with shaking at 220 rpm, for -4.5 hours. The culture was 
transferred to a 1.5 mL Eppendorf tube and spun at 10000 rpm (9167 x g) at 4°C using a 
table top microcentrifuge (I-15K, Sigma, Osterode am Harz, Germany) for 10 minutes 
to pellet the cells. The supernatant (containing the phage particles) was removed to a 
clean 1.5 mL Eppendorf tube and the pellet discarded. 400 ilL of the supernatant was 
added to 100 mL of 2x YT (in a 500 mL conical flask) containing tetracycline and 1 mL 
of overnight E.eali ER2738 culture. The culture was incubated at 37°C with shaking at 
220 rpm for -4.5 hours. The culture was transferred to a 250 mL centrifugation tube 
(Nalgene, Rochester NY USA, Cat. No. 3120-0250) and spun at 10000 rpm (8000 x g) 
using a JA-14 rotor (Beckman Coulter, Part No. '339247) in a Sorvall RC-5B 
refrigerated super-speed centrifuge (Thermo Fisher Scientific Inc, Waltham MA USA) 
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for 10 minutes to pellet the cells. The supernatant was transferred to a fresh 250 mL 
tube and the pellet discarded. 
1/6th volume of PEGlNaCl (20% PEG/2.5 M NaCl) was added to the supernatant in 
order to precipitate the phage particles and left overnight at 4°C. The supernatant was 
spun down at 10,000 rpm (6500 x g) for 10 minutes at 4°C to pellet the phage. The 
supernatant was removed and discarded and the pellet re-suspended in 1 mL of PBS 
buffer (pH 7.4) and transferred to a 1.5 mL Eppendorf tube. 1I6th volume of PEGlNaCI 
was added and the solution left overnight at 4°C. The solution was spun down at 10,000 
rpm for 10 minutes as before and the supernatant removed. The pellet was re-suspended 
in 1 mL of PBS buffer (pH 7.4) and the solution spun down at 10,000 rpm (9200 x g) 
for 10 minutes at 4°C in a table top microcentrifuge (GenFuge 24D, Progen Scientific 
London UK, Cat. No. C-2400) to remove any in-soluble matter. The supernatant 
(containing the purified phage) was transferred to a clean 1.5 mL Eppendorf tube and 
stored at 4°C. Concentration of the phage stock was found via titering or 
spectrophotometry. 
2.1.5.2 Caesium chloride purification 
This method was developed by Prof. George Smith at the University of Missouri. 4.83 g 
of 98% pure CsCI (Cat. No. C4036-250G) was weighed out into a 50 mL glass beaker 
(zero the balance using the glass beaker). The balance was then zeroed again with the 
glass beaker containing the CsCl. The PEG purified phage was added to the beaker and 
ddH20 added to make the final weight 10.75 g. The mixture was swirled gently until the 
caesium chloride had dissolved and poured into a 12 mL (14 x 95 mm) open-top 
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polyc1ear tubes (Seton scientific, Los Gatos CA USA, Cat. No. 7031). Seton tubes must 
be used since they are the only ones that work with the gradient fractionator (Biocomp 
instruments, Frederiction NB Canada, Cat. No. 152-002). The tube (along with another 
balanced tube) was then loaded onto a SW 32 Ti open bucket rotor (Beckman Coulter, 
Brea CA USA, Part No. 369650) and spun at 30,000 rpm for 48 hours using an Optima 
L-80 XP (Beckman Coulter, Part No. 392051). The phage were fractionated using a 
gradient fractionator as in section 2.1.5.4; the phage appear as a milky band roughly a 
quarter way down the tube. 
2.1.5.3 Linear sucrose gradients 
A stock of 2 M (68.4%) ultrapure sucrose (USB coporation Cleveland OH USA, Cat. 
No. 21938) was prepared in Ix A buffer by weighing out 171 g of sucrose and making 
the solution up to 250 mL with Ix A buffer. The buffer was chosen as it was part of an 
established protocol. The sucrose solution was mixed with a magnetic stirrer overnight 
at 4°C to dissolve the sucrose. 2 M sucrose can be stored for long periods at 4°C; 
however, when diluted, i.e. down to 60%, solutions should be used on the same day. 
Linear sucrose gradients were created using a gradient station (Biocomp, Cat. No. 153-
002), the same machine as used for fractionation in section 2.1.4.4 (Figure 2.2), and 
open-top polyc1ear tubes (Seton scientific). To create a gradient, two solutions were 
made using the 2 M sucrose stock and A buffer; i.e. for a 30 - 60% gradient then 30% 
and 60% solutions were made (for six 12 mL seton tubes then 50 mL of each solution is 
enough). The gradient station comes with a marker block (Figure 2.1 A) which was 
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used to mark the 12 mL seton tubes (the higher mark, which is for rate zonal gradients, 
was used) using a permanent pen. 
The lower concentration of sucrose (i.e. 30%) was then poured into the tubes until the 
meniscus was just above the pen line. A 20 mL disposable syringe was then filled with 
the higher concentration of sucrose (i.e. 60%); this must be refilled for each tube. A 
long metal needle was then attached to the syringe and pushed to the bottom of the tube. 
The higher concentration of sucrose was slowly pushed into the tube so that it displaced 
the lower concentration of sucrose up to the marked line. Therefore within the 12 mL 
tube the higher concentration (i.e. 60%) was below the lower concentration (i.e. 30%) 
sucrose. The tubes were then capped with the rate zonal caps supplied by Biocomp 
(Figure 2.1 B) and left at 4°C for 30 minutes to allow the sucrose to settle. 
The Biocomp gradient station comes pre-programmed with a selection of sequences for 
different tubes and sucrose concentrations to create a linear sucrose gradient. The 
correct sequence was selected and the tubes placed into the supplied Magnabase (Figure 
2.1 C). This was then placed onto the magnetic base on the gradient station (Figure 2.2 
A), which had been levelled. The sequence was then started to create the linear sucrose 
gradient. The tubes were then stored for 1 hour at 4°C to allow the sucrose to settle. 
The caps were carefully removed from the tubes and an equivalent volume of sucrose to 
the PEG purified phage sample taken from the top of gradient. The PEG purified phage 
were loaded onto the top of the gradient with care taken to avoid disturbing the gradient. 
The tubes were balanced with ddH20 and loaded onto a SW 32 Ti open bucket rotor 
(Beckman Coulter, Brea CA USA, Part No. 369650). The phage were spun at 18,500 
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rpm overnight (typically 17 hours) using an Optima L-80 XP (Beckman Coulter, Part 
No. 392051). The phage were fractionated using a gradient fractionator (Biocomp 
instruments, Frederiction NB Canada, Cat. No. 152-002) as in section 2.1.5.4. 
c 
25 mm rate zonaf (left) and 
;sopycnic (right) caps. 
Figure 2.1. Materials supplied with Biocomp gradient station. These were used to 
create linear sucrose gradients. A) Marker block, B) Rate zonal cap, C) Magnabase. 
Taken from Biocomp gradient station manual. 
2.1.5.4 Fractionation 
All phage, after ultracentrifugation using open-top polyclear tubes (Seton scientific), 
were fractionated using a gradient fractionator (Biocomp instruments - Figure 2.2). 
Samples were fractionated continuously at a speed of 0.3 mm1second whilst measuring 
the absorbance at 260 nm. The gradient fractionator utilises a specialized trumpet 
(Figure 2.2 D) that is attached to a piston (Figure 2.2 E). The centrifuge tube is aligned 
under the trumpet using the supplied tube holder (Figure 2.2 C). The piston then pushes 
the trumpet down into the tube. The trumpet forms an air-tight seal within the tube so 
that the liquid in the tube is forced up though the trumpet and into the connected tubing 
(Figure 2.3). Biocomp state that the trumpet provides better sample resolution compared 
to needle fractionation. The liquid then passes through a UV detector (Pharmacia UV-M 
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II, GE Healthcare, Cat. No. 18-1001-10) which measures the absorbance at 260 nm. The 
UV detector was connected to a DI-158U USB data acquisition device (DataQ 
instruments, Akron OH USA) which was in turn connected to a PC which records the 
absorbance using the WinDaq®/Lite waveform browser (DataQ instruments) Finally 
the liquid passes out of the tubing where it can be collected. 
·~---+E 
Figure 2.2. The Biocomp gradient station and fractionator. A) shows the magnetic 
base which is used to form the gradients. B) is the syringe used for washing the system. 
C) is the tube holder. D) shows the trumpet and E) shows the piston. Taken from 
Biocomp gradient station manual. 
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Tubing 
Tube 
Trumpet 
Figure 2.3. The gradient fractionator trumpet. Taken from Biocomp gradient station 
manual. 
2.1.6 Measurement of phage concentration 
2.1.6.1 Phage titering (measured in pfulmL) 
10 !AI of phage stock was 10-fold serially diluted in 90 !AI of sterile H20 and vortexed 
vigorously to ensure sufficient mixing to yield estimated concentrations of 106 - 1010 
phage/mL. 10 !AI of a dilution was added to 3 mL of molten agarose top (stored in 5 mL 
tubes in a water bath at a temperature of 47°C) and 200 !AI of an overnight E.coli culture. 
The solution was mixed by inversion and quickly poured onto 2xYT agar plates 
containing tetracycline and swirled to ensure complete and even coverage of the agar by 
the molten agarose top. The agarose top was allowed to set for 10 minutes at room 
temperature before being incubated overnight at 37°C. Plates that had plaque numbers 
greater than 100 were used and the number of plaques counted. This number was then 
multiplied by the dilution factor to find the plaque forming units(pfu) in 10 !AI of the 
stock solution. The pfu was then multiplied by 100 to provideyfu/mL. 
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2.1.6.2 Spectrophotometry of phage particles (measured in virions/mL) 
Absorbance of phage stock (2 !-lL) at 269 nm and 320 nm was measured using a 
Nanodrop 3300 spectrophotometer (Nanodrop products, Wilmington, Delaware, 
U.S.A.). Absorbance values were used in the equation below to calculate the number of 
virions/mL: 
(A269 - A32o) x 6 x 1016 
Virions/mL = 
Number of bases/virion 
Number of basesl virion for M13KE = 7222 bases. 
Number ofbases/virion for M13K07 = 8669 bases. 
2.1.6.3 Definition of virions/mL and plaque forming units (pfu)/mL 
It must be briefly mentioned here the difference between virions/mL and pfu/mL since 
there is an important distinction between the two terms. Virions/mL relates to the work 
of Day and Wiseman, 1978. Their work focussed on the absorption properties of the 
filamentous phage. They devised an equation to calculate the number of phage particles 
in a solution from the absorbance at 269 nm and 320 nm: 
(A269 - A32o) x 6 x 1016 Virions/mL = ....:............:..;..-------
Number of bases/virion 
The 269 nm value comes from the maxima of the broad peak seen in the absorption 
spectrum between 260 and 280 nm (highlighted by the arrow in Figure 2.4) . The broad 
peak arises from the fact that the filamentous phage has 6 times more protein than DNA 
(Day, 1978). The 320 nm value is used to correct for phage particle light scattering and 
other contaminants. 
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Figure 2.4. Typical absorption spectrum of a purified (PEG/NaCI) M13 particle. 
The other standard measurement of phage is plaque forming units (pfu). This is a direct 
measurement of how many infective particles are contained within a solution. Therefore 
although virions/mL is a measure of all virus particles in a solution it does not 
differentiate between infective and un-infective particles; importantly, with respect to 
Ml3, this is likely to reflect whether the pIlI protein is intact or not. Typically, it is 
found (and was also observed in this work) that the pfu/mL value is 10 times lower than 
virions/mL. 
2.1.7 Colony PCR 
Viral plaques were picked from agar plates using a sterile pipette tip and used to 
inoculate 200 fll of 2xYT broth in a 1.5 mL Eppendorf tube (it is important to tap the 
tube three times on the bench after inoculation) and incubat~d for 1 hour at 37°C with 
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shaking at 220 rpm. Primers were designed to amplify either gene III (Seq-g3-for: 5'-
CACCTCGAAGCAAGCTGATAAAC -3', Seq-g3-rev: 5' - GACAACCCT 
CATAGTTAGCGTAACG -3') or gene VIII (Seq-g8-for: 5'- GCTATGCCT TCGTAG 
TGGCATTACG -3', Seq-g8-rev: 5'- AACGCAGCTTGCTTTCGAGGTG -3'). Figure 
2.5 shows the primer positions. 
120 I CAAAGATGAG TGTITT AGTG T A TTCTITTG CCTCTTTCGT TTT AGGTTGG 
Seq-g8-for ~ 
1251 TGCC7TCGTA GTGGCA7TACGTATTTTACC CGTTTAATGG AAACTTCCTC 
130 I A TGAAAAAGT CTTT AGTCCT CAAAGCCTCT GT AGCCGTTG CT ACCCTCGT 
Pst I Bam HI 
1351 TCCGATGCTG TCTTTCGCTG CAGAGGGTGA GGATCCCGCA AAAGCGGCCT 
1401 TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA TGCGTGGGCG 
1451 ATGGTTGTTG TCATTGTCGG CGCAACT ATC GGT ATCAAGC TGTTT AAGAA 
• Seq-g8-rev 
1501 ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTITT 
Seq-g3-for ~ 
1551 GGAGCCTITT TTTTGGAGAT TTTCAACGTG AAAAAATTAT TA TTCGCAAT 
Ace 65 I Eag I 
1601 TCCTTTAGTG GTACCTTTCT ATTCTCACTC GGCCGAAACT GTTGAAAGTT 
1651 GTTT AGCAAA ATCCCAT ACA GAAAA TTCA T TT ACTAACGT CTGGAAAGAC 
• Seq-g3-rev 
170 I GACAAAACTT TAGATCGTTA CGCTAACTAT GAGGGCTGTC TGTGGAATGC 
Figure 2.5. Position of pIlI and pVIII sequencing primers. gVIII: 1301-1522 (start 
1301), gIll: 1578-2852 (start 1578). The Pst I and Bam HI restriction sites show the 
approximate position of gVIII inserts, whilst the Acc65 I and Eag I sites show the 
position of gIll inserts. gIll PCR product: 237 bp. g VIII PCR product: 279 bp. Sequence 
is M13KE, which is available from New England Biolabs. 
PCR was carried out \)sing 2 !!l of the 1 hour culture as a template in the reaction. 1 U of 
Taq DNA polymerase (Invitrogen, Cat. No. 18038-026), 1 x concentration of provided 
buffer, 1.5 mM MgCh (Invitrogen), 0.5 mM dNTPs (Invitrogen) and 1 pmol/!!l of the 
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relevant primers were used in a final volume of 20 f!l. PCR conditions used were 95°C 
for 30 seconds, followed by 24 cycles of: 95°C for 30 seconds, 55°C for 1 minute, and 
72°C for 1 minute. Final step was 68°C for 10 minutes. An M13KE (grown from a 
plaque as above) and negative ddH20 control were also used in the PCR. Products were 
run directly on a 10% polyacrylamide gel (section 2.1.9.1) 
2.1.8 Transmission Electron Microscopy (TEM) 
5 f-ll of sample was applied directly to charged ultra-thin carbon-coated copper grids 
(Agar Scientific, Essex, U.K.). After 1 minute the liquid was removed carefully with 
filter paper. Staining (if necessary) was done using 2% (w/v) uranyl acetate (in pH 4 
ddH20). A Philips CMlO (Philips Electronics UK Ltd, Guildford, u.K.) or Jeol 1200EX 
(Jeol Inc, Tokyo, Japan) transmission electron microscope was used to visualise the 
samples at 80 keY. 
2.1.9 DNA Gel Electrophoresis 
2.1.9.110 % Polyacrylamide Gel 
A 10% (w/v) polyacrylamide gel was made using: 16.4 mL ddH20, 12 mL 29: 1 bis-
acrylamide (Severn Biotech, Kidderminster, U.K.), 7.2 mL 5x Tris-Borate-EDTA 
(TBE) buffer (MP Biomedicals, Stretton, U.K.), 360 f-ll 10% (w/v) ammonium 
persulfate (APS), and 36 f-ll Tetramethylethylenediamine (TEMED). Samples were 
loaded into wells with an equal volume of 2x DNA loading buffer (Ambion, Austin TX 
U.S.A., Cat. No. AM8546G: 95% Formamide, 18 rnM EDTA and 0.025% each of SDS, 
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Xylene Cyanol, and Bromophenol Blue) and a 10 bp DNA ladder (Invitrogen, Cat. No. 
10821-015, Figure 2.6 A, 10 - 330 bp). Ix TBE buffer was used as running buffer. Gels 
were run for 1 hour at 8 Watts using a Consort E832 power pack (Turnhout, Belgium) 
and stained with ethidium bromide (1 [lg/mL). 
2.1.9.21 % and 3% Agarose Gel 
0.4 g (1 %) or 1.5 g (3%) of agarose was mixed with 50 mL of Ix TBE buffer. Solution 
was heated in microwave until all agarOse had dissolved. Molten agarose was allowed 
to cool to -45°C and 2.5 [ll of ethidium bromide (10 mg/mL) was added. Mixture was 
swirled to mix before being poured into tray and allowed to set. Samples were loaded 
with an equal volume of 2x DNA loading buffer (Ambion) and either a 10 bp 
(Invitrogen) or a 2-log DNA ladder (New England Biolabs, Cat. No. N3200L, Figure 
2.6 B, 0.1 - 10 kb) for 3% and 1% gels respectively. Ix TBE buffer was used as running 
buffer. Gels were run using a Consort E832 power pack. 
2.1.10 Protein Gel Electrophoresis Under Denaturing Conditions 
2.1.10.1 Tris-glycine SDS Gel 
A 10-20% (w/v) Tris-HCI gradient gel with a 4% (w/v) stacking gel (Biorad 
laboratories, Cat. No. 345-0042) was used to run protein samples under denaturing 
conditions. Gels were run in Ix glycine running buffer with a PageRuler™ prestained 
protein ladder (Fermentas, St. Leon-Rot Germany, Cat. No. SM0671, Figure 2.6 C) 
using the Criterion cell system (Biorad laboratories, Cat. No. 165-6001) and a Consort 
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E832 power pack. The gels were then stained overnight whilst rocking gently with 
enough coomassie blue staining solution to cover the gel. The gel was then de-stained 
whilst rocking with de-stain solution until the bands could be visualised. 
Mass (ng) Kilobases kDa 40 10.0 -
40 8.0 -
48 6.0 ~ 
-170 
40 5.0 
32 4.0 
-130 bp 120 3.0 
40 -100 
57 15 -70 
45 -55 
'22 
-40 34 100 31 0.8 
80 27 0.7 -35 
23 
60 124 -25 
40 49 
37 03 -15 
20 
32 
-10 
10 61 0.1 
Figure 2.6. Gel ladders for DNA and proteins. A) 10 bp ladder image taken from 
Invitrogen. 10 bp ladder was run on a 4 % (w/v) low melting point agarose gel in Tris-
acetate (pH 7.6) and stained with ethidium bromide. B) 2-log ladder image taken from 
New England Biolabs. 2-log ladder was run on a 1 % (w/v) agarose gel in TBE. Mass 
values are for 1 I-tg, i.e. 1 I-tL, of ladder. C) PageRuler™ pre-stained protein ladder 
image taken from Fermentas. Ladder was run on a 4-20% (w/v) Tris-glycing SDS-
PAGE gel. 
Page 66 
Chapter 2 
2.1.11 Molecular biology techniques 
2.1.11.1 Polymerase Chain Reaction (PCR) 
PCR was carried out using Tag DNA polymerase (Invitrogen, Cat. No. 18038-026) 
which is provided with a lOx buffer (200 mM Tris-HCl pH 8.4 and 500 mM KCl) and 
50 mM MgCh solution. One unit of Tag DNA polymerase is defined by Invitrogen as: 
"incorporating 10 nmol of deoxyribonucleotide into acid-precipitable material in 30 
minutes at 74°C. Unit assay conditions: 25 mM TAPS (pH 9.3), 50 mM KCl, 2 mM 
MgCl2, 1 mM DTT, 0.5 mg/mL activated salmon sperm DNA, 0.2 mM dATP, dCTP, 
dGTP, dTTP". Primers, provided by MWG-Biotech (Ebersberg, Germany), were spun 
at max. speed on a table-top centrifuge for 5 minutes to pellet the lyophilised DNA. 
MWG-Biotech informs you how much buffer is needed to re-suspend the primers so 
that the concentration is 100 pmole/llL. Primers were re-suspended in EB buffer from 
the QIAguick PCR purification kit (Qiagen, Cat. No. 28704). Template oligos were re-
suspended in the same way but before use diluted 1 in 1000 in ddH20. The 10 mM 
dNTP mixture (containing 10 mM of dATP, dCTP, dGTP, and dTTP) was created from 
a 100 mM dNTP set (Invitrogen, Cat. No. 10297-018). 
For a single PCR reaction the following was added to a 250 ilL PCR tube on ice: 
• 2 ilL lOx Invitrogen buffer (final concentration 20 mM Tris-HCl pH 8.4, 50 mM 
KCl), 
• 0.6 ilL Invitrogen 50 mM MgCh solution (final concentration 1.5 mM), 
• 0.2 ilL 100 pmole/IlL primer 1 (final concentration 1 IlM), 
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• 0.2 ilL 100 pmole/IlL primer 2 (final concentration 1 IlM), 
• 0.4 ilL 10 mM dNTP mixture (final concentration 200 IlM), 
• 2 ilL 0.1 pmole/IlL template (final concentration 1 nM), 
• 0.2 ilL Taq polymerase (1 unit), 
• 14.4 ilL ddH20 (final volume 20 ilL). 
When no template was used it was replaced by 2 ilL of ddH20. For most PCR reactions 
a 100 ilL master mix, i.e. five PCR reactions, was made and then 20 ilL aliquoted into 
five 250 ilL PCR tubes. For 100 ilL master mix the following was added to a 1.5 mL 
Eppendorf tube on ice: 
• 10 ilL lOx Invitrogen buffer, 
• 3 ilL Invitrogen 50 mM MgCh solution, 
• 1 ilL 100 pmole/IlL primer 1, 
• 1 ilL 100 pmole/IlL primer 2, 
• 2 ilL 10 mM dNTP mixture, 
• 10 ilL 0.1 pmole/IlL template, 
• 1 ilL Taq polymerase, 
• 72 ilL ddH20 (final volume 100 ilL) 
The PCR reaction was placed into a thermocycler (pelter thermal cycler PTC-200, 
Global Medical Instrumentation Inc., Minneapolis, MN, U.S.A., Cat. No. BC-
MJPC200) using the following programme: 
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• 95°C for 30 seconds, 
• followed by 24 cycles of: 
o 95°C for 30 seconds, 
o XOC for 1 minute (the annealing temperature depends on the Tm of the 
primers), 
o 72°C for X minutes (1 minute per kb of DNA with 1 minute being the 
minimum), 
• The final step was 68°C for 10 minutes. 
Unless otherwise stated, an annealing temperature of 55°C and extension time of 1 
minute was used. 
2.1.11.2 Phenol Chloroform extraction of DNA and ethanol 
precipitation 
The DNA solution was first made up to 200 ilL with ddH20 in a 1.5 mL Eppendorf 
tube. As an example: with a 100 ilL PCR reaction, which had been aliquoted into 5 x 20 
ilL, the 5 reactions were pooled and 100 ilL of ddH20 added. To the 200 ilL of DNA, 
400 ilL of phenol solution (Sigma-Aldrich, Cat. No. P4557) was added and vortexed for 
1 minute before being spun at max speed for 1 minute in a table top centrifuge. This 
resulted in two phases with the DNA contained in the top phase. The top phase was 
aspirated with a pipette, with care taken to avoid taking any of the lower phase, and 
placed into a fresh 1.5 mL tube. 
400 ilL of chloroform was added to the 200 ilL of aspirated DNA and vortexed for 1 
minute and spun at max speed for 1 minute. Once again two phases appeared and the 
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top phase, which contained the DNA, was aspirated to a fresh 1.5 mL tube. The 
chloroform step was then repeated again to remove any trace of phenol. 
To the - 200 I-lL of DNA containing solution, 20 I-lL, i.e. 10% (v/v) of original DNA 
solution, of 3 M sodium acetate was added and vortexed for 30 seconds. Ice cold 100 % 
(v/v) ethanol was then added and vortexed briefly before the tube was placed at -20°C 
overnight to precipitate the DNA. The following day, the tube was spun at 4°C for 20 
minutes at max. speed in a table-top centrifuge to pellet the DNA. The ethanol was 
poured away and 400 I-lL of ice cold 70 % (v/v) ethanol was carefully added and the 
tube spun again at 4°C for 20 minutes at max speed in a table-top centrifuge. With both 
centrifugation steps it is important to keep the tube facing the same way so that it is 
known which side the pellet of DNA is on. The ethanol was removed with a pipette and 
care taken to keep the pipette tip on the side opposite the DNA pellet. The DNA pellet 
was re-suspended in 50 I-lL of EB buffer from the QIAquick PCR purification kit 
(Qiagen, Cat. No. 28704). To remove trace ethanol the tube was placed in a GeneVac 
EZ_2p1us (GeneVac, Ipswich, Suffolk, u.K.) for 10 minutes. The amount of DNA was 
then estimated using a Nanodrop 3300 spectrophotometer (Nanodrop products). 
2.1.11.3 Insertional peR 
Insertional PCR is a variation of site directed mutagenesis (Wang, 1999). However, in 
order to limit primer dimer formation, the two primers are used in two separate site 
directed mutagenesis reactions before being mixed together to complete the reaction. A 
QuikChange® Site-directed mutagenesis kit (Agilent Technologies, Stockport, 
Cheshire, u.K., Cat. No. 200519) was used to perform the insertional PCR. Primer 
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design is the same as for site directed mutagenesis: 20 bp overlap of the template DNA 
both before and after the DNA sequence to be inserted. Primers were ordered from 
MWG-biotech with High Purity Salt Free (HPSF) purification. 
For a single insertional PCR reaction, two separate 250 !!L were used. Each contained 
the following: 
5 !!L lOx buffer (provided with QuikChange® Site-directed mutagenesis kit) 
1 !!L dNTP solution (provided with QuikChange® Site-directed mutagenesis kit) 
1 !!L of template DNA (50 to 200 ng of plasmid or RF DNA) 
1 !!L of 10 pmol/!!L primer (EITHER primer 1 OR primer 2) 
42 !!L of ddH20 
The two reactions, with only differ by which primer is added, were mixed on ice. O. 4 
!!L (1 unit) of pfu polymerase (provided with QuikChange® Site-directed mutagenesis 
kit) was then added. The two reactions were then placed into a thermocycler (Pelter 
thermal cycler PTC-200) and the following programme used: 
• 95°C for 30 seconds, 
• followed by 10 cycles of: 
o 95°C for 30 seconds, 
o 55°C for 1 minute, 
o 68°C for X minutes (1 minute per kb of DNA with 1 minute being the 
minimum), 
• The final step was 68°C for 10 minutes. 
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Unless otherwise stated, an extension time of 8 minutes was used. 
25 I-lL of each reaction was then taken and mixed together (so that a single PCR tube 
contained 25 I-lL of each reaction) and 0.4 I-lL of pfu polymerase added. The PCR tube 
was then placed back into the thermocycler and the same programme used. However, 
the number of cycles was increased to 18. 1 I-lL (10 units) of dpn I (provided with 
QuikChange® Site-directed mutagenesis kit) was then added to the reaction and 
incubated at 37°C for 3 hours. Dpn I digests methylated DNA and therefore it should 
only digest the template DNA. 1 I-lL of the dpn I digested insertional PCR reaction was 
then transformed into 5-alpha F Iq Competent E.coli (New England Biolabs, Cat. No. 
C2992H) as in section 2.1.3. 
2.1.11.4 Ligation of DNA fragments 
100 ng of phage DNA was mixed with 1 !!L of restricted PCR product (concentration 
was irrelevant) and 1 I-lL (3 Units) of T4 DNA ligase (Promega, Cat. No. M1801). 1 !!L 
of buffer (provided with ligase) was added and the final volume made up to 10 I-lL with 
ddH20 in a 1.5 mL Eppendorf tube. The sample was then incubated at room 
temperature for 3 hours. 3 I-lL of the ligated DNA was then transformed into 5-alpha F 
Iq Competent E.coli (New England Biolabs, Cat. No. C2992H) as in section 2.1.3. 
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2.2 Specific Methods for Chapter 3 
2.2.1 Creation of the microphage plasmid (pMicro) 
The packaging signal (PS) was amplified from the Fl origin (4894-5349) of the vector 
pET26-b (Novagen, Cat. No. 69862-3) using step lfor and step 1 rev primers (Table 2.1) 
which flanked the 9lbp PS. The PCR, and subsequent purification was carried out as 
described in section 2.1.11.1. 
Table 2.1 A list of the primers used in creating the microphage plasmid pMicro. 
Primer I Sequence 5'-3' 
Steplfor I ATGCACGCGCCCTGTAGCGG 
Step 1 rev I ATGCGGAGCGGGCGCTAGG 
Step2for I AACACTCAACCCTATCTCGGGCAAGCTTGGACGCGCCCTGTAGCGGCGCA 
Step2rev I TCCCCGAAAAGTGCCACCTGTCCGATCCCGGGAGCGGGCGCTAGGGCGCT 
Step3for I ACTGCCATCGCCCTGATAGAC 
Step3rev I ACTGTTCCAGTTTGGAACAAGAG 
Step4for I CGCCCGCTCCCGGGATCGGAATTCCGGCCATCGCCCTGATAGACG 
Step4rev I TCCCCGAAAAGTGCCACCTGAGACGTTTTCCAGTTTGGAACAAGAGT 
Microamplifyfor 1 ATCGGATCCAGACGTTTTCCAGTTTGG 
Microamplifyrev I ATGCTCT AGACCATCGCCCTGAT AGAC 
pJetfor ICGACTCACTATAGGGAGAGAGGCC 
pJetrev I GAAGAACATCGATTTTCCATGGCAG 
The PCR fragment from step 1 was then used as the template to produce the primers for 
insertional PCR of the PS into the pET26-b vector. PCR was carried out with the step 1 
PCR fragment as the template and Step2for and Step2rev primers; these primers overlap 
the step 1 fragment and add 20 bp at the 5' and 3' ends which is complementary to 
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pET26-b. This PCR fragment was then used as the primer for insertional PCR (section 
2.1.11.3), using pET26-b as the template, in order to insert the PS downstream of the 
origin of replication and create the plasmid pET26-bPS 
A truncated origin of replication, lacking 29 bp from domain B, was amplified from 
pET26-b using Step3for and Step3rev primers using PCR (section 2.l.1l.1). As before, 
this fragment was then used as the template for PCR using Step4for and Step4rev 
primers resulting in a fragment that contained overlaps that were complementary for 
pET26-bPS. This PCR fragment was then used as the primer for insertional PCR 
(section 2.1.11.3) with pET26-bPS as the template, in order to insert the truncated origin 
of replication downstream of the PS and create the plasmid pM 1. 
The 310 bp microphage cassette was then PCR amplified (section 2.1.11.1) from pM 1 
using microamplifyfor and microamplifyrev (Table 2.1). This fragment was then cloned 
into the pJET1.2 vector (Fermentas) using the C10neJet™ PCR cloning kit (Fermentas, 
Cat. No. K1232) following the method provided to produce pMicro. Briefly, the PCR 
fragment was blunted and then ligated into the pJET1.2 vector between the Xho1 and 
Xba1 sites (Figure 2.7). The pJET1.2 vector is pre-cut before use to interrupt the 
ec0471R gene. Upon ligation, if no PCR product is present to continue to interrupt the 
gene, the gene becomes active and is lethal to the E.coli host: thus only pJET1.2 vectors 
containing the PCR insert allow the E.coli to grow, making selection of the correct 
clone simple. pMicro was sequenced using the pJET 1.2 forward sequencing primer 
(pJetfor) and pJET1.2 reverse sequencing primer (pJetrev) (Fermentas Cat. No. K1232) 
to confirm microphage cassette was present. 
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Insertion site for blunt 
~ ended peR product 
ecor47lR' 
Multiple 
cloning sites 
i Ampicillin ecor471R 
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, gene 
2974 bp 
~ pMB I origin 
Figure 2.7. Vector Map of pJETl.2. Adapted from Fermentas. 
2.2.2 Creation of longer microphage cassette (pMicroKan) 
Kanamycin resistance gene was PCR amplified (section 2.1.11.1) from pET-26b 
(Novagen) using KanforecoRI (ATCGGAATTCAGGCGGTGCTACAGAG) and 
KanrevecoRI (ATCGGAATTCATATGTATCCGCTCATGAAT). pMicro and the 
amplified kanamycin resistance gene were cut with EcoRI (New England Biolabs, 
R0101) and ligated together (section 2.1.11.4) to create pMicroKan. pJetfor and pJetrev 
were used for sequencing reactions to confirm insertion of the kanamycin resistance 
gene. 
2.2.3 Creation of the helper plasmid pM13CP 
The chloramphenicol resistance gene was PCR amplified (section 2.1.11.1) from the 
plasmid pACYC184 using the primers pACYC184camfor and pACYC184camrev 
(Table 2.2). M13KE (New England Biolabs) was PCR amplified using Expand high 
Fidelity PCR system (Roche, Cat. No. 11732641001) and the two outward facing 
primers M13MLulfor and M13MLulrev (Table 2.2); this amplifies the entire M13KE 
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genome, terminating with MLu 1 sites. The protocol for this PCR amplification was 
provided with the kit. The amplified M13KE genome and chloramphenicol resistance 
gene were cut with MLul (New England Biolabs, ROI98L) and ligated together (section 
2.1.11.4) to create M13C. 
Table 2.2 A list of the primers used in creating the helper plasmid M13CP. 
Primer Sequence 5'-3' 
M13MLulfor TTGATGACGCGTCCTATTGGTTAAAAAATGAGCTG 
M13MLulrev TTGATGACGCGTCCGAAATCGGCAAAATCC 
pACYC 184camfor TTGATGACGCGTGTCCGAATTTCTGCCATTC 
pACYC 184camrev TTGATGACGCGTCGAATAAATACCTGTGAC 
M13cpfor TGATTTCCATGGACGCGTGTCCGAATTTCTGCCATTCATCC 
M13cprev CCACACCCATGGCGCTTAATGCGCCGCTACAGGGCGCGTACT 
p15afor TATCGCCATGGGCGCTAGCGGAGTG 
p15arev TATCGCCATGGACAACTTATATCGTATGGGGC 
M13CPseql AATGCTACTACTATTAGTAGAATTG 
M13CPseq2 GTATTCCTAAATCTCAACTGATG 
M13CPseq3 CTTTAACTCCCTGCAAG 
M13CPseq4 GTTACTCAAGGCACTGACC 
M13CPseq5 GAAAGACAGCCGATTATTG 
M13CPseq6 GGTAATTCAAATGAAATTG 
M13CPseq7 CTGACCGCCTCACCTCTGTTTTATC 
M13CPseq8 GCTGCACCGGTGCGTCAG 
M13CPseq9 CGTTTTCAGAGCAAGAGATTAC 
M13CPseql0 CAAGAATGTGAATAAAGGCCG 
M13CPseqil CATATTGATGGTGATTTGACTG 
The p15a bacterial origin was amplified from pACYC184 using the p15afor and 
p15arev primers (Table 2.2). M13C was amplified using the Expand high Fidelity PCR 
system (Roche, Cat. No. 11732641001) and the two outward facing primers M13cpfor 
and M13cprev (Table 2.2). This amplified the entire M13c genome minus the intergenic 
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region that contains the M 13 origin of replication. Both PCR fragments were cut with 
Nco1 (New England Biolabs, Cat. No. R0193L) and ligated together (section 2.1.11.4) 
to create the bacterial plasmid M13CP. The entire M13CP plasmid was then sequenced 
using M 13CPseq 1-11 (Table 2.2). 
2.2.4 Production of shorter length phage particles using M13K07 
pMicro, pMicroKan and the phagemid pLitmus28i (New England Biolabs, Cat. No. 
N3528S) were each transformed (section 2.1.3) into DH5-a F' fI E.coli (New England 
Biolabs, Cat. No. C2992H) and grown overnight on LB agar plates containing 
ampicillin and tetracycline at 37°C. The next day a single colony was picked and grown 
overnight at 37°C in 10 mL SB medium with ampicillin and tetracycline with vigorous 
shaking (250 rpm). 1 mL of the overnight culture was then added to 100 mL of SB 
medium in a 500 mL conical flask containing ampicillin and tetracycline and grown 
until slightly turbid (OD600 - 0.05, typically 1 hour) at 37°C with vigorous shaking. 100 
f,lL of M13K07 was added (New England Biolabs, N0315S) to a final concentration of 
1 x 109 pfu and grown for a further 2 hours at which point kanamycin was added (70 
f,lg/mL) and the culture grown overnight at 37°C with vigorous shaking. When growing 
M13K07 the same protocol was carried out but with DH5-a F' fI E.coU containing no 
plasmid. Controls were also grown in same manner with DH5-a F' fI E.coli, pMicro, 
pMicroKan and pLitmus28i only but with no addition of M 13K07 or kanamycin. 
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2.2.5 Production of shorter length phage particles using M13CP 
pMicro, pMicroKan and the phage mid pLitmus28i (New England Biolabs, Cat. No. 
N3528S) were each transformed (section 2.1.3) into DH5-u F' fI E.coli and grown 
overnight on LB agar plates containing ampicillin at 37°C. The next day a single colony 
was picked and grown overnight at 37°C in SB medium with ampicillin with vigorous 
shaking (250 rpm). Cells were then made chemically competent (section 2.1.2) and 
transformed (section 2.1.3) with M13CP and grown overnight on LB agar plates 
containing ampicillin and chloramphenicol at 37°C (DH5-u F' fI E.coli was also 
transformed with M13CP only to act as a control). To produce the shorter phage 
particles a single colony was grown overnight in 100 mL of SB medium containing 
ampicillin and chloramphenicol at 37°C and vigorous shaking. Controls were also 
grown in same manner with DH5-u F' fI E.coli, M13CP, pMicro, pMicroKan and 
pLitmus28i only. 
2.2.6 Purification of shorter phage particles 
Purification of shorter length phage particles followed a modification of the Yamamoto, 
et al. (1970) and Specthrie, et al. (1992) methods. The overnight cell culture was 
centrifuged at 10,000 x g for 10 minutes to pellet the cells. The supernatant was 
removed and added to a fresh centrifuge tube containing 15 g PEG 8000 (GE 
Healthcare) and 2.922 g NaCl for a final concentration of 15 % (w/v) PEG and 0.5 M 
NaC!. Supernatant was mixed thoroughly by 100 inversions and then left overnight at 
4°C to precipitate the phage particles. Phage were pelleted by centrifugation at 10,000 x 
g for 1 hour. Supernatant was removed and centrifuge tubes inverted for 10 minutes to 
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allow remaining liquid to drain away. Pellet was re-suspended thoroughly in 100 mL 
PBS pH 7.4. PEGINaCI purification was then repeated as above and the pellet re-
suspended in 1 mL PBS pH 7.4. 
2.2.7 Caesium chloride purification of shorter length phage particles 
PEG precipitated shorter length phage particles were occasionally further purified on a 
CsCI gradient (section 2.1.5.2) and dialysed against three changes of PBS, pH 7.4, 
buffer using a 100 kDa molecular weight cut off, cellulose ester, dialysis membrane 
(Spectra/Por, Cat. No. 131408). 
2.2.8 Linear sucrose density ultracentrifugation of shorter length 
phage particles 
1 mL of PEG precipitated shorter length phage particles was loaded onto a 30-60% 
linear sucrose gradient (section 2.1.5.3). Samples were then spun at 30,000 rpm for 18 
hours before being fractionated (section 2.1.5.4). Peaks containing the relevant phage 
were collected and PBS added to bring the fraction up to 10 mL. The phage were then 
PEG precipitated (15% PEG-8000, 0.5 M NaCl) and spun at 10,000 rpm for 1 hour. 
Phage pellets were re-suspended in 500 ilL of PBS pH 7.4. 
2.2.9 Size exclusion chromatography of shorter length phage particles 
Phage samples (up to 250 III maximum) in PBS were applied to a Tricorn™ column (1 
cm diameter, 25 mL volume, 30 cm bed height) packed with superose 6™ (column was 
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purchased pre-packaged from GE healthcare: Superose 6 10/300 GL, Cat. No. 17-5172-
01). Superose 6 is a highly cross-linked agarose matrix with a protein separation range 
of 5 x 103_5 X 106 Da and an exclusion limit of 4 x 107 Da. An AKTAexplorer™ (GE 
healthcare) using the UNICORN software was used to control and monitor the column. 
The column was first equilibrated with PBS pH 7.4 overnight at a flow rate of 0.1 
mLlmin. The samples were applied under a flow rate of 0.5 mUmin and eluted with 1.5 
times the column volume of PBS. 1 mL fractions were continuously collected in 1.5 mL 
Eppendorf tubes. The absorbance at 260 nm and 280 nm were monitored using the 
monitor UV-900 included with the AKTAexplorer™. 5 [!L of each fraction was used 
for TEM (section 2.1.8). 
2.2.10 Titering of shorter length phage particles 
10 [!L of phage were serially diluted to 10-4 and 10-6 in 90 [!L 2x YT medium or used 
directly from the stock solution. 10 [!L of each was then mixed with 90 [!L of an 
overnight growth of ER2738 E.coli (New England Biolabs, Cat. No. E4104S) and 
mixed briefly. 10 [!L was then plated onto LB agar plates containing either ampicillin, 
kanamycin, chloramphenicol, or a mixture of the three. The plates were then grown 
overnight at 37°C. The number of colonies were counted the following day. 
2.2.11 Measurement of shorter length phage particle length by TEM 
10 [!L of phage were serially diluted to 10-4 and 10-6 in 90 [!L of ddH20. 5 [!L was then 
viewed using TEM (2.1.8). Images were taken at a magnification of x20000. Ten 
images for each phage particle were taken at arbitrary positions upon the grid in order to 
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get a representative cross-reference of phage particles. The images were used to obtain 
an average length of each phage particle using ImageJ, version 1.43u (Abramoff, 2004). 
From each of the ten images, 50 phage particles were measured using imageJ to get an 
average length from 500 particles. Lengths were measured using the point selection 
tool which had been calibrated with the TEM scale bar. 
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2.3 Specific Methods for Chapter 4 
2.3.1 Insertion of selenocysteine into gIll 
The selenocysteine containing peptide (S A R V U H G P S V A G L H Q S A, where U 
is selenocysteine) was inserted into position 1 of the mature pIlI coat protein between 
the Acc65 I and Eag I sites located in gIll of the commercial strain M13KE (New 
England Biolabs, Cat. No. N0316S). Cutting of the M13KE genome using the Acc65 I 
and Eag I restriction enzymes results in the removal of part of the leader sequence (V P 
F Y S H S) - needed for correct localisation of pIlI to the cell membrane (Clackson, 
2004) - along with the first amino acid (alanine) of the mature pIlI coat protein. 
Therefore these amino acids, along with the selenocysteine sequence, were inserted: the 
full inserted peptide sequence was V P F Y S H S S A R V U H G P S V A G L H Q S 
A. 
The DNA sequence corresponding to the selenocysteine containing sequence (V P F Y 
S H S S A R V U H G P S V A G L H Q S A) was PCR amplified (section 2.1.11.1) 
using overlapping DNA primers (Biotinfor 5'- ATC GGG TAC CTT TCT ATT CTC 
ACT CTA GCG CTC GTG TCT GAC ACG GC -3', Biotinrev 5'- ATC GCG GCC 
GAT TGG TGC AGA CCT GCA ACC GAT GGG CCG TGT CAG ACA C -3'). 
PCR products were then purified using the QIAquick PCR purification kit (Qiagen, Cat. 
No. 28704) and the entire eluate (typically 25 ilL) was cut with 6 ilL (60 units) each of 
Acc65 I and Eag I (New England Biolabs, Cat. No. R0599L and R0505L respectively) 
using 9 ilL buffer 3 and 0.9 ilL BSA (provided with the enzymes) and made up to 90 ilL 
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with ddH20. The mixture was then split into three 30 ~L aliquots and dispensed into 
0.25 mL PCR tubes. They were then incubated at 37°C for 4 hours before recombining 
the three aliquots and mixing with 110 ~L of ddH20 (for a total of 200 ~L) and the 
sample phenol:chloroform purified and ethanol precipitated (section 2.1.11.2). 
M13K07 and M13KE RF DNA were purified from 10 mL of overnight culture in 2xYT 
medium containing 5-alpha F'f' E.coli (New England Biolabs, Cat. No. C2992H) 
infected with either M13K07 or M13KE phage. The phage DNA was purified from the 
E.coU using the QIAprep spin miniprep kit (Qiagen, Cat. No. 27106). As with the 
selenocysteine PCR product, the entire eluate (typically 25 ~L) was cut with Acc65 I 
and Eag I. The 90 ~L of cut DNA was then purified using the QIAquick PCR 
purification kit. The entire eluate (typically 25 ~L) was then treated with 15 ~L (15 
Units) of shrimp alkaline phosphatase (Promega, Cat. No. M8201), 9 ~L of 10 x buffer 
(provided with the phosphatase) and made up to a final volume of 90 ~L with ddH20. 
This enzyme removes the phosphate groups from the 5' terminus of the DNA which 
prevents the DNA from being re-ligated when treated with a ligase. The mixture was 
then split into three 30 ~L aliquots and dispensed into 0.25 mL PCR tubes. They were 
then incubated at 37°C for 1 hour before recombining the three aliquots and mixing with 
110 ~L of ddH20 (for a total of 200 ~L) and the sample phenol:chloroform purified and 
ethanol precipitated (section 2.1.11.2) 
The restricted and purified phage RF DNA (either M13KE or M13K07) and 
selenocysteine PCR DNA were ligated together (section 2.1.11.4). 2 ~L of the ligated 
sample was then transformed (section 2.1.3) into 50 ~L of chemically competent 5-
alpha F'f/ E.coli (New England Biolabs, Cat. No. C2992H) and plated on LB agar 
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plates containing tetracycline and 2 !!M sodium selenite (Sigma-Aldrich, Cat. No. 
S9133). The sodium selenite was essential since clones containing selenocysteine would 
not grow without it present. The plates were then incubated overnight at 37°C. 
The following day, 14 plaques were picked for each phage (M13KE and M13K07) and 
colony PCR carried out (section 2.1.7) using seq-g3-for (5' -CAC CTC GAA AGC 
AAG CTG ATA AAC -3') and seq-g3-rev (5'- GAC AAC CCT CAT AGT TAG CGT 
AAC G -3'). 10 successful clones were sent for sequencing using the seq-g3-rev primer 
and a single clone containing the correct sequence was used in further experiments. 
M13KE containing selenocysteine was termed M13pIIISel and M13K07 containing 
selenocysteine was termed M13K07pIIISel. 
2.3.2 Production of selenocysteine containing phage 
M13pIIISel and M13K07pIIISei RF DNA was transformed into 5-alpha F'fl E.coli and 
plated onto tetracycline, sodium selenite LB agar plates using top agar and overnight 
E.coli stock (section 2.1.3) and incubated overnight at 37°C. Phage stocks were then 
grown and purified as in section 2.1.5.1 but with 2 !!M sodium selenite supplement in 
the growth medium. Phage particles were then CsCI purified (section 2.1.5.2). 
2.3.3 Production of microphage containing selenocysteine 
Microphage containing selenocysteine were produced and purified as in sections 2.2.2 
and 2.2.6. However, M13K07pIIISei was used instead ofM13K07. 
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2.3.4 Creation and production of pIlI cysteine mutant 
The cysteine at position 7 of the mature pili coat protein (A E T V E S C) was 
substituted with a glycine via a single nucleotide substitution (T to G at position 1650 of 
the M13KE genome). This was done using the QuikChange™ site directed mutagenesis 
kit (Stratagene, Cat. No. 200519) which uses the high fidelity pfu polymerase. 
Mutagenesis was carried out as in kit instructions using 100 ng of M 13KE RF DNA as 
the template. The mutagenesis product was digested for 3 hours with dpn I before being 
transformed into NEB 5-alpha F'{l Competent E. Coli (New England Biolabs, Cat. No. 
C2992H). The primers used were pllIremovalfor (5'- CTG TTG AAA GTG GTT TAG 
CAA AAT CCC ATA C -3') and pllIremovalrev (5'- GTA TGG GAT TTT GCT AAA 
CCA CTT TCA ACA G -3'). Successfully created mutants were grown and purified as 
in section 2.1.5.1 and then stored at 4°C. 
2.3.5 Binding of M13pIIISei and wild-type M13 to gold nanoparticles 
1012 virions/mL of M13plllSei or wild-type M13 in 100 f!L PBS buffer pH 7.4 were 
mixed with citrate stabilised 5 nm or 10 nm gold nanoparticles (Ted Pella via Agar 
scientific, the U.K. distributor, Cat. No. 15703-20. 15702-20). The gold nanoparticles 
were supplied in water with trace amounts of citrate, tannic acid and potassium 
carbonate (precise amounts unknown). The 10 nm gold nanoparticles came as a 
monodisperse solution at a concentration of 5.7 x 1012 particles/mL whilst the 5 nm 
were supplied at a concentration of 5 x 1013 particles/mL. The phage and gold 
nanoparticles were vortexed briefly in a 1.5 mL Eppendorf tube and then rolled 
overnight at room temperature. 
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2.3.6 Binding of M13pIIISei and wild-type M13 to quantum dots 
Quantum dots were purchased from Invitrogen where they are sold under the trade 
name of Qdot® Nanocrystals. Qdot ITKTM amino (PEG) quantum dots (8 IlM solution 
supplied in borate buffer pH 8.3) were purchased that have a fluorescence emission 
wavelength at 525 nm (Cat No. Q21541MP) and 800 nm (Cat. No. Q21571MP). There 
are a number of differences between these quantum dots (Table 2.3). 
Table 2.3. Dimensions and composition of Qdot® nanocrystals. Core/Shell diameter 
size was measured by TEM. Core/Shell/Polymer size and Core/Shell/Polymer/PEG size 
relates to the hydrodynamic size of the quantum dots as measured by size exclusion 
chromatography. Sizes were determined by retention times relative to a standard curve 
of protein standards. PEG layer size relates to the difference in Core/Shell/Polymer size 
and Core/ShelllPolymer/PEG size. Information provided by Invitrogen upon request. 
NaIre Core/Shell cOIqJosition Core/Shell size (run) Core/ShelVPo~Irer size (run) Core/ShelVPo~Irer/PEG size (run) PEG layer size (run) 
Qdot 525 CdSeiZnS 3 to 4 12 13 1 
Qdot545 CdSellnS Approx.4 13 14 1 
Qdot 565 CdSellnS 4.6 14 15 1 
Qdot 585 CdSellnS 5.3 15 16 1 
Qdot605 CdSeiZnS Ellipsoid: 4 x 9.4 16 16 Unknown 
Qdot625 CdSeiZnS 8.1 Approx.17 Approx. 16 to 20 Unknown 
Qdot 655 CdSellnS Ellipsoid: 6 x 12 18 20 2 
Qdot705 CdSeTeflnS Ellipsoid: 6 x 12 18.5 20.5 2 
Qdot800 CdSeTeiZnS Ellipsoid: 6 x 12 19 21 2 
Qdots consist of a nanocrystal (the core) made of either cadmium selenide (CdS e) or 
cadmium seleno-telluride (CdSeTe) surrounded by zinc sulphide (the shell). This is then 
further encased within a polymer (propriety information) and a PEG layer to make the 
Qdot soluble in water (Figure 2.8) 
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15-20 nm 
Figure 2.8. The Qdot quantum dot from Invitrogen. The diagram was taken from 
Invitrogen and shows the main structural elements of the Qdot; they are drawn roughly 
to scale relative to one another. 
The Qdots were functionalised with sulfo-SMCC (Sulfosuccinimidyl-4-(N-
maleimidomethyl)cyc1ohexane-l-carboxylate). Sulfo-SMCC is a water soluble 
compound that contains an amine reactive NHS-ester (N-hydroxysuccinimide) at one 
end and a sulfhydryl-reactive maleimide group at the other end (Figure 2.9). 
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Figure 2,9. The structure of sulfo-SMCC (Sulfosuccinimidyl-4-(N-
maleimidomethyl)cyc1ohexane-l-carboxylate). Molecular weight is 436.37. Image was 
taken from Themo scientific Pierce Protein Research Products. 
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Since maleimide hydrolyses rapidly in water, sulfo-SMCC was always used fresh: to 
achieve this it was purchased as the pre-weight format (Thermo scientific Pierce Protein 
Research Products, Cat. No. 22622) where 2 mg of sulfo-SMCC come pre-weighed and 
sealed. The following protocol was adapted from that provided by Evident 
Technologies for their EviTag quantum dots. 2 mg of sulfo-SMCC (using the pre-
weighed format) was mixed with 400 ilL 50 mM sodium phosphate buffer pH 704. 
Typically it was found that sulfo-SMCC dissolved poorly; therefore, after 5 minutes of 
vigorous vortexing, 200 ilL of the cloudy mixture was added to 62.5 ilL 8 IlM Qdot 
(525 nm or 800 nm) and l37.5 ilL 50 mM sodium phosphate pH 704 (final volume 400 
uL) in a 1.5 mL Eppendorf tube. The mixture was vortexed briefly and then left to stand 
at room temperature for 1 hour with brief vortexing every 15 minutes. Excess sulfo-
SMCC was removed using a PD-10 desalting column (PD-10, GE Healthcare product 
number: 17-0851-01). 
The PD-lO column was equilibrated with 25 mL of conjugation buffer (100 mM 
sodium phosphate buffer pH 7.2, 1mM EDT A). The 400 ilL Qdot/sulfo-SMCC mixture 
was loaded on the top of the PD-10 column and allowed to enter the column. 2.1 mL of 
conjugation buffer was then added on to the column and allowed to enter. It is important 
to allow the Qdots to enter the column before adding the 2.1 mL of conjugation buffer. 
The Qdots were then eluted from the column using 3.5 mL of conjugation buffer. In the 
case of 525 nm Qdot, they can be followed using UV light, whereas 800 nm can be 
followed with the naked eye as a brown band moving through the column. Typically the 
quantum dots eluted in a 1 mL fraction (a 16 fold dilution of the quantum dot stock). 
This gave a maleimide-functionalised Qdot solution of 500 nM (confirmed by 
spectrometry) in conjugation buffer. 
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100 f!L of 1012 virions/mL phage (M13pIIISel or wild-type) were mixed with varying 
amounts of 500 nM maleimide-functionalised Qdot solution in a 1.5 mL Eppendorf tube 
and vortexed briefly before rolling overnight at room temperature. 
2.3.7 Purification of phage:nanoparticle complexes on a linear sucrose 
gradient 
A 12 mL 30-60% linear sucrose gradient was prepared as in section 2.1.5.3. Phage 
mixed with nanoparticles (as in 2.3.4 and 2.3.5) were loaded onto the top of the gradient 
and spun at 18500 rpm using a SW 40Ti rotor (Beckman Coulter, Cat. No. 331302) and 
the Optima L-XP ultracentrifuge overnight (typically 18 hours). The gradient was then 
fractionated using a gradient fractionator (section 2.1.5.4). 
2.3.8 Purification of higher order structures using size exclusion 
chromatography 
An AKTAexplorer™ (GE healthcare) using the UNICORN software was used to 
control and monitor the column. A 90 cm (length) x 1.5 cm (width) column (volume 
-150 mL) was filled with Sephacryl S-1000SF (superfine), commercially available from 
GE healthcare (Fairfield, Connecticut, U.S.A.), and equilibrated overnight with PBS pH 
7.4. Phage:nanoparticle solutions (1 mL maximum) were applied under a flow rate of 
0.5 mUmin and eluted with 1.5 times the column volume of PBS. 15 mL fractions were 
continuously collected in 15 mL falcon tubes. The absorbance at 260 nm and 280 nm 
were monitored using the monitor UV-900 included with the AKTAexplorer™. 5 f!L of 
each fraction was used for TEM (section 2.1.8). For small-scale experiments, a 
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GenElute™ spin column (Sigma-Aldrich, Cat. No. 5-6500) was used. 200 !-lL of 
sephacryl S-1000SF was loaded onto the column and washed three times with H20 by 
adding 400 !-lL of ddH20 and spinning the column on a table top centrifuge at 5000 xg 
for 5 minutes. This was then followed by a single 400 !-lL wash of PBS pH 7.4. Samples 
were then loaded onto the column and spun at 5000 xg for 5 minutes. 
2.3.9 Fabrication of microphage higher order structures 
100 !-lL (concentration unknown) of M13pIIISel microphage produced as in 2.3.3 was 
mixed with 100 !-lL of citrate stabilised 10 nm gold nanopartic1es in a 1.5 mL Eppendorf 
tube and incubated overnight with rolling at room temperature. 
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2.4 Specific Methods for Chapter 5 
2.4.1 Creation of pCGMTpIXHisA CIDap and pCGMTpIXHisFOS 
The DNA sequences corresponding to the HisACID (HHHHHHAQLEKEL 
QALEKELAQLEWENQALEKELAQLQSGGGSG) and HisFOS (HHHHHHL 
NDTLQAETDQLEDEKSALQTEIANLLNEKEKLEFIL AAHLQSGGGSG) pep tides 
were PCR amplified (section 2.1.11.1) using overlapping DNA primers ACIDfor (ATC 
GAA GCT TCA CCA CCA CCA CCA CCA CGC GCA GCT GGA AAA AGA ACT 
TCA GGC GCT G), ACIDtemplate (GAA AAA GAA CTT CAG GCG CTG GAA 
AAA GAA CTG GCG CAG CTG GAA TGG GAA AAC CAG GCG), and ACIDrev 
(CGA TCT GCA GCT GCG CCA GTT CTT TTT CCA GCG CCT GGT TTT CCC A) 
for HisACID. For HisFOS the overlapping DNA primers FOSfor (A TC GAA GCT 
TCA CCA CCA CCA CCA CCA CCT GAC CGA TAC CCT GCA AGC GGA AAC 
CGA TCA), FOStemplate (GCA GGC GGA AAC CGA TCA GCT GGA AGA TGA 
AAA AAG CGC GCT GCA AAC CGA AAT TGC GAA CCT GCT GAA AGA AA) 
and FOSrev (CGA TCT GCA GAT GCG CCG CCA GAA T AA ATT CCA GTT TTT 
CTT TTT CTT TCA GCA GGT TCG) were used. 
The PCR products were then inserted into the HindIII and Pst! sites of pCGMT -1 b 
(kindly provided by Dr Bin Zhou, The Scripps Research Institute, La Jolla, CA, U.S.A.) 
using the method described in section 2.3.1. However HindIII (New England Biolabs, 
Cat. No. R0104L) and Pst! (New England Biolabs, Cat. No. ROI40L) were used instead 
of Acc65 I and Eag I and pCGMT-lb used instead of M13KE RF DNA. After 
transformation (section 2.1.3) into E.coli ER2738, 5 colonies of 
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pCGMTpIXHisACIDap and pCGMTpIXHisFOS were picked and sent for sequencing 
using pCGMTSEQFOR (AGG AAG CGG AAG AGC GCC CA). 
2.4.2 Production ofM13pIXHisACIDap and M13pIXHisFOS phage 
A single colony of either pCGMTpIXHisACIDap or pCGMTpIXHisFOS was picked 
and grown overnight at 37°C, 220 rpm, in 10 mL SB medium containing tetracycline, 
carbenicillin and 2% (w/v) glucose. The following day, 10 mL of the overnight culture 
was diluted into 1 L of SB medium, in a 5 L conical flask, containing tetracycline, 
carbenicillin and 2% (w/v) glucose. The culture was then grown at 37°C, 220 rpm, for 
-3 hours until an OD600 between 0.5-0.7 was reached. The 1 L of culture was then 
poured into a 6 L conical flask containing 4 L of SB medium. The following was added 
to the 5 L of diluted culture: tetracycline, carbenicillin, IPTG (final concentration 1 
mM) and M13K07 (final concentration 4 x 108 pfu/mL: New England Biolabs, Cat. No. 
N0315S). The 5 L culture was swirled gently to mix and left to stand at room 
temperature for 30 minutes and then incubated at 30°C, 220 rpm, for 2 hours. 
Kanamycin was then added and the 5 L culture divided into 5 x 1 Lin 2 L flasks. The 5 
flasks were then incubated at 30°C, 220 rpm, overnight. The phage were then 
PEGlNaCl purified as in section 2.1.5.1. Purified phage from the 5 L culture were 
pooled and re-suspended in 5 mL of Tris-HCI buffer. 
2.4.3 Purification of M13pIXHisACIDap and M13pIXHisFOS phage 
M 13pIXHisACIDap and M 13pIXHisFOS phage were purified using a 5 mL Hi sTrap TM 
HP column (GE Healthcare, Cat. No. 17-5247-01). These are pre-packed with Ni 
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Sepharose High Performance resin charged with Ne+. An AKTAexplorer™ (GE 
healthcare) using the UNICORN software was used to control and monitor the column. 
The column was first equilibrated with 3 column volumes (15 mL) of Tris-HCI buffer at 
a flow rate of 1 mLimin. The 5 mL of purified phage were then loaded onto the column 
at a flow rate of 0.5 mLimin using Tris-HCI running buffer. 3 column volumes were 
used to wash the column of any phage bound non-specificly. Elution of the bound phage 
was carried out at a flow rate of 1 mLimin using Tris-HCI buffer containing 400 mM 
imidazole (Sigma Aldrich, Cat. No. 10125). The concentration was increased from 0 
mM (0%) so that at 40 mL the concentration of imidazole was 400 mM (100%). The 
column was then washed for a further 6 column volumes (30 mL) with Tris-HCI, 400 
mM imidazole (100%). 1 mL fractions were continuously collected in 1.5 mL 
Eppendorf tubes. The absorbance at 260 nm and 280 nm were monitored using the 
monitor UV-900 included with the AKTAexplorer™. Fractions from 5 - 30 mL (which 
were found to contain the phage) were pooled and PEG/NaCl precipitated as in section 
2.1.5.1. Purified phage were re-suspended in 1 mL PBS pH 7.5. 
2.4.4 Creation and production of M13pIIIACIDap phage 
The DNA sequence corresponding to the ACIDap peptide (AQLEKELQALEKELAQL 
EWENQALEKELAQLQSGGGSG) was PCR amplified (section 2.1.11.1) using 
overlapping DNA primers pIIIACIDrev (A TC GCG GCC GAG CTT CCT CCT CCC 
TGC GCC AGT TCT TTT TCC AGC GCC TGG TTT TCC C), ACIDtemplate (section 
2.4.1) and pIIIACIDfor (ATC TGG TAC CTT TCT A TT CTC ACT CTG CGC AGC 
TGG AAA AAG AAC TGC AG). The PCR products were then inserted into the Acc65 
I and Eag I sites of M13KE using the method described in section 2.3.1. 5 colonies were 
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picked and sequenced with Seq-g3-for (section 2.1.7). One of the phage containing the 
correct sequence was used for further experiments and termed M13pIIIACID. 
M13pIIIACID was grown and purified as in section 2.1.5.1 and then further purified 
using caesium chloride as in section 2.1.5.2. 
2.4.5 HPLC of ACIDap and BASEap peptides 
HPLC was performed on a Dionex (Sunnyvale, CA. U.S.A.) HPLC machine consisting 
of: P680 HPLC pump, ASI-IOO Automated Sample Injection and PDA-IOO photodiode 
(deuterium lamp was used) and controlled using the Dionex Chromeleon ™ version 6.5 
software. A 250 x 4.6 mm Zorbax C-18 silica gel with dimethyl-n-octadecyl silane 
column (Agilent Technologies, Santa Clara, CA. U.S.A.) was used with a C-18 guard 
cartridge (Phenomenex, Torrance, CA., USA, Cat. No. 880952-702). Two running 
buffers were used: Running buffer A was 5% (v/v) acetonitrile, 0.1 % (v/v) 
trifluoroacetic acid (TFA) and B was 90% (v/v) acetonitrile, 0.06% (v/v) TFA in H20. 
The buffers were 0.22 !lm filter sterilised and degassed before use. Column was 
equilibrated overnight with buffer A at a flow rate of 0.1 mLlmin. Peptides were re-
suspended in 200 !lL Tris-HCI buffer (final peptide concentration was 25 mg/mL) and 
loaded onto the column at a flow rate of 0.5 mLlrnin. 0.5 mL fractions were then 
collected in 1.5 mL Eppendorf tubes. 
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2.4.6 Circular dichroism (CD) spectroscopy of ACIDap and BASEap 
peptides 
CD was performed using a Jasco 1715 Spectropolarimeter (Jasco, Great Dunmow, 
Essex, U. K.). 300 !-tL of a 0.2 mg/mL solution of ACIDap or BASEap in PBS pH 7.4 
were used. To measure the two peptides combined, 150 !-tL of each solution were mixed 
in a 1.5 mL Eppendorf tube for 30 seconds before the sample was placed into the 
machine. The following parameters were used. Absorbance range: 190 nm to 260 nm, 
Data pitch: 0.2 nm, Scanning mode: continuous, Scanning speed: 50 nmlmin, Response: 
1, Band width: 1, Accumulate: 9. 
2.4.7 Surface Plasmon Resonance (SPR) analysis 
SPR was performed using a Biacore 3000 (GE Healthcare) and carried out at room 
temperature. Sensor chips containing a bare gold surface (GE Healthcare, Cat. No. BR-
1005-42) were used for experimental work. BASEap (AQLKKKLQANKKKLAQLKW 
KLQALKKKLAQGGGSC) was immobilised using gold-thiol chemistry in PBS pH 7.4 
running buffer. All samples were in PBS pH 7.4 and injections carried out at a flow rate 
of 10 !-tUmin. 50 !-tL of 0.15 mg/mL of the control peptide and BASEap was injected 
across flow cell 2 and 3 respectively. Flow cell 1 was used as a bare gold surface 
control. PBS pH 7.4 buffer was then passed over the flow cells overnight at a flow rate 
of 10 !-tUmin to obtain a stable baseline. 50 !-tL of 1 mg/mL of ACIDap was then 
injected across the flow cells. For the phage samples the phage were PEGlNaCI 
precipitated and resuspended in running buffer so that the final concentration was 1011 
virions/mL. 40 !-tL of each phage was then injected across the flow cells at a flow rate of 
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10 ~Umin. Kinetic data was obtained using the BIAevaluation software, version 3.2 
(GE Healthcare). AI: 1 kinetic binding model was used to fit the SPR sensograms. 
2.4.8 Dual Polarisation Interferometry (DPI) analysis 
DPI was performed using an AnaLight Bi0200 optical evanescent DPI machine 
(Farfield Group Ltd., Manchester Airport, UK) connected to a microfluidics cell 
consisting of a Rheodyne HPLC injector valve and an external pump (Harvard 
Apparatus, PHD2000) which was used to control the flow of liquid through the DPI 
machine. All experiments were performed at 20 DC as controlled by the AnaLight 
Bi0200 thermal control system (able to control temperature to within ±0.002°C). 
Unmodified AnaChipTM were used for experimental work (Farfield Group Ltd, Cat. No. 
2007-11Oc). These are dual sample well silicon oxynitride sensor chips with negatively 
charged hydroxyl surface chemistry. Before experiments were carried out the sensor 
chips were piranha cleaned (section 2.5.4.1) and then immersed in a 4% (v/v) solution 
of mercaptotrimethoxysilane in isopropyl alcohol (IPA) for 18 h, followed by thorough 
rinsing in IP A. This gave the sensor chip waveguides a thiol exposed surface. The phase 
response of the sensor chip, and the PBS pH 7.4 running buffer, was then calibrated as 
follows (Johnson, 2008): PBS pH 7.4, was passed over both sensor sample wells at a 
flow rate of 50 ~Umin until a steady baseline was reached (-2 hours). This was 
followed by an 80% (v/v) ethanol/water solution injected over both waveguides for 2 
min before reverting to PBS. 150 ~L of deionized water was then injected over both 
sample wells for 2 min before returning again to PBS. 
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BASEap (AQLKKKLQANKKKLAQLKWKLQALKKKLAQGGGSC) and a HPLC 
purified control peptide (SLDTLAEQLDPSANNVLSC: kindly provided by Dr Steve 
Johnson) were then immobilised onto the sample wells; sample well 1 with BASE and 
sample well 2 with the control peptide. This was done by injecting 150 ilL of 10 mM 
copper (II) chlorate solution twice over both sample wells. The copper (II) is reduced by 
the thiol surface to copper (I) which in turn can then be used to bind to the thiol group 
within a cysteine. 600 ilL of 1 mg/mL BASEap was then injected across sample well 1 
at a flow rate of 20 ilL/min. This was followed by -5 minutes of PBS running buffer at 
a flow rate of 20 ilL/min. The procedure was repeated to immobilise the control peptide 
onto sample well 2. The flow rate was then increased to 50 ilL/min for -5 minutes to 
remove any unbound material. To study the ACIDaplBASEap interaction, the sensor 
chip was exposed to the ACIDap peptide 
(AQLEKELQALEKELAQLEWENQALEKELAQ). The ACIDap peptide (1 mg/mL) 
was injected over sample well 1 and 2 at a flow rate of 20 ilL/min before returning to 
PBS running buffer and increasing the flow rate to 50 ilL/min. 
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2.5 Specific Methods for Chapter 6 
2.5.1 Display of tyrosine on p VIII 
Tyrosine was inserted into position 4 of the major coat protein of p VIII via a single 
nucleotide substitution: G to T at position 1379 of the M13KE genome. Substitution 
was done using site directed mutagenesis with D to YpVIIlfor (TTC GCT GCT GAG 
GGT TAC GAT CCC GCA AAA G) and D to YpVIIIrev (CTT TTG CGG GAT CGT 
AAC CCT CAG CAG CGA A) with a QuikChange™ site directed mutagenesis kit 
(Stratagene, Cat. No. 200519) which uses the high fidelity pfu polymerase. Mutagenesis 
was carried out as in kit instructions using 100 ng of M13KE RF DNA as the template. 
Mutagenesis product was digested for 3 hours with dpn I before being transformed into 
NEB 5-alpha F'{I Competent E. Coli (New England Biolabs, Cat. No. C2992H). The 
transformation reaction was plated onto agar plates containing tetracycline using top 
agar and overnight E.coli culture as in section 2.1.3. The plates were then incubated 
overnight at 37°C. The following day, 10 plaques were picked and grown overnight at 
37°C in 10 mL of 2xYT medium containing tetracycline. RF DNA was then purified 
from the cultures using a QIAprep spin miniprep kit (Qiagen, Cat. No. 27106). The 10 
clones were then sent for sequencing; 8 were found to contain the correct mutation. One 
clone (termed M13Y) was used for further experiments. 
M13Y RF DNA was transformed into chemically competent ER2738 (section 2.1.3) 
and then phage produced as in section 2.1.5.1. The phage were further purified on a 
caesium chloride gradient (section 2.1.5.2) and ,dialysed against three changes of PBS 
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buffer using a 100 kDa molecular weight cut off, cellulose ester, dialysis membrane 
(SpectraiPor, Cat. No. 131408). 
2.5.2 Fabrication of gold coated phage in solution 
10 ilL of M13Y phage (and as controls 10 ilL of wild-type phage and 10 ilL of PBS pH 
7.4), at a concentration of ~ 1 x 1013 virions/ mL was added to 100 ilL of 6 mM gold salt 
(99.99% chloroauric acid! gold (III) chloride solution which is supplied in approx. 2.9 
M HCl: Cat. No. 484385) in a 1.5 mL Eppendorf tube and left for 1, 10, 30 and 60 
minutes at room temperature. Samples were also left overnight and for 2 days at room 
temperature. 
2.5.3 Deposition of M13Y onto carbon and incubation with gold salt 
5 III of M13Y, wild-type phage (at a concentration of 5 x 1010 virions in 20 ilL ddH20) 
or ddH20 was applied directly to charged ultra-thin carbon-coated copper grids (Agar 
Scientific, Essex, u.K.). After 1 minute the liquid was removed carefully with filter 
paper. 10 ilL of 1 mM gold salt was added to the grid and left for 1 minute, 10 minutes, 
30 minutes and 1 hour. The grids were placed in a humidity chamber (a petri dish with a 
moist cloth covering the bottom). The gold salt was then removed carefully with filter 
paper and the grid washed with 50 ilL of ddH20. The grids viewed using a Philips 
CMI0 or Jeol 1200EX transmission electron microscope at 80 keY. 
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2.5.4 Attempts to deposit gold on M13 adsorbed to Si02 surface 
2.5.4.1 Piranha cleaning of Si02 surface 
1 cm2 Si02 chips were prepared from a single sheet of Si02 (Compart Technology Ltd, 
Peterborough, U. K.). Piranha solution was prepared in a 100 mL beaker with 21 mL 
95-97% sulphuric acid (Cat. No. 30743) and 9 mL of 35 wt. % in H20 fresh hydrogen 
peroxide (Cat. No. 349887). Piranha solution is very corrosive and it is important to 
carry out piranha cleaning in a fume hood and wear the necessary face mask, gloves and 
apron. Only ceramic tweezers should be used for transferring Si02 chips in and out of 
the piranha solution; any other material will corrode. Upon mixing, the solution should 
smoke slightly and the beaker becomes hot to the touch. Si02 chips were placed into the 
piranha solution for 10 minutes with the surface where sample was to be placed facing 
up. The chips should form bubbles on their surface. If not then the hydrogen peroxide is 
inactive and fresh hydrogen peroxide should be used. The Si02 chips were then moved 
to 50 mL of ddH20 in a 100 mL beaker and sonicated (Fisherbrand FB 11020) for 5 
minutes. During this time the piranha solution was poured away and the beaker washed 
thoroughly with ddH20 and dried with N2. This beaker was then filled with 30 mL 
100% (v/v) isopropanol (Fisher Scientific, Cat. No. PI7500/PCI7). The Si02 chips were 
transferred to the beaker containing isopropanol and sonicated for 5 minutes. The chips 
were then removed from the isopropanol and dried for -30 seconds using a nitrogen 
spray gun. The Si02 chips were placed in a humid chamber, sealed with parafilm® 
(Alphalaboratories, Cat. No. WS5000-1O), and aged overnight in a fume hood at room 
temperature. 
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2.5.4.2 Adsorption of M13 particles to Si02 surface and incubation 
with gold salt 
5 X 1010 virions, in 20 f!L ddH20, of either M13Y or wild-type M13 were deposited on a 
piranha cleaned Si02 chip (section 2.5.4.1) for 30 minutes in a humidity chamber. 
Unbound phage were then washed off using distilled water, sprayed on from an angle at 
a constant stream from a bottle. The chip was then dried (from same angle as water) 
using a nitrogen spray gun until dry. Ensuring the angle is the same for the water and 
drying steps ensures that the phage are aligned in the same direction. 20 f!L of gold salt, 
between 1 and 6 mM, (or 1 mM hydrochloric acid) was then placed onto the chip and 
left for a specified time at room temperature in a humid chamber to stop evaporation. 
The Si02 chip was then washed and dried as above. Samples were viewed via atomic 
force microscopy (section 2.5.4). 
2.5.5 AFM (Atomic Force Microscopy) 
AFM was carried out in tapping mode in air using a Veeco Dimension 3100 AFM. For 
scanning of M 13 particles, the tip amplitude was adjusted so that the tip tapped as 
lightly as possible on the phage: i.e. amplitude was reduced until tip lost contact with 
surface and then the amplitude was increased until tip regained contact. Any harder 
tapping tended to result in no virus particle being observed. 
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2.5.6 Scanning Electron Microscopy of gold nanowires 
M13 phage particles were incubated with gold salt as in section 2.5.4.2. The samples 
were then examined using a LEO 1530 Gemini FEGSEM with Oxford Instruments 
INCA 350 EDX system. 
2.5.7 Conductivity measurements 
M13 phage particles were incubated with gold salt as in section 2.5.4.2 on a Si02 
surface with pre-fabricated gold crosses on (kindly fabricated by Dr Steve Johnson). To 
do this a 2 x 2 cm Si02 layer was piranha cleaned as in section 2.5.4.1. A 300 nm thick 
Poly(methyl methacrylate) (PMMA) layer was then spin coated onto the Si02 layer. A 
Raith 50 Electron Beam Lithography machine (Raith, Dortmund, Germany) was used to 
pattern 10 x 10 lAm cross-hairs. The Si02 layer was then incubated in a 3: 1 mixture of 
methyl isobutyl ketone for 70 seconds to dissolve the irradiated PMMA. An electron 
beam evaporator (Oerlikon, Pfaffikon, Switzerland) was then used to deposit a 150 nm 
thick layer of gold onto the Si02 layer. Finally, the Si02 layer was incubated in 100% 
(v/v) acetone overnight to lift off remaining PMMA. After the M13 phage particles had 
been deposited onto the Si02 layer and incubated with gold salt an AFM image was 
taken. The gold deposition process was then repeated using the AFM image to align the 
Raith 50 Electron Beam Lithography machine to pattern the electrodes at the ends of 
phage particles. 
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The Microphage 
This Chapter describes the work carried out to investigate using the 50 nm long 
microphage to produce bespoke length phage particles. The methods to purify these short 
phage were also investigated. 
Chapter 3 
3.1 Introduction 
3.1.1 The Microphage 
Wild-type M13 bacteriophage are approximately 1 ~m long with a diameter of 6 nm 
(Lee, 2002). The length of the phage particle is dictated by the size of the single stranded 
DNA genome of the phage. Increasing the length of the DNA strand results in an increase 
in length of the virion particle (Zinder, 1982). The opposite is also true: by deleting some 
of the DNA genome it is possible to create a smaller phage particle (Specthrie, 1992). 
The explanation for the link between DNA strand length and the length of the phage 
particle is the role played by the positively charged C-terminus on the pVIII coat protein 
in negating the ssDNA's negatively charged backbone (Hunter, 1988). On average each 
pVIII protein interacts with 2.3 nucleotides. It is therefore a physical link between the 
number of nucleotides and the number of p VIII proteins. 
Whether there is an ultimate limit for the length of encapsulated DNA is unknown, 
although it has been observed, both in the literature (Lopez, 1983, Bradley, 1964, Caro, 
1966, Marvin, 1963) and in this present study, that double and triple length phage do 
occur within a typical wild-type phage population. It has been shown that these dimer and 
trimer phage contain multiple phage DNA strands (Lopez, 1983), i.e. a trimer contains 
three distinct strands of wild-type length ssDNA. It is thought that this occurs when the 
plIIIp VI complex fails to "cap" the phage as it extrudes though the viral pore and so other 
ssDNA phage strands are encapsulated before a successful capping event (Lopez, 1983). 
Using pIlI, pIX, pVI and pVII amber mutations, Lopez et ai. (1983) produced phage with 
more than three ssDNA strands; although they faiied to report the length of the longest of 
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these phage. However, the study does highlight that very large phage can be produced, 
with large amounts of DNA contained within. Obviously, the longer the phage, the higher 
the chance of shearing, as noted within Lopez et al.(l983), which perhaps explains why 
the phage genome is very economical with coding capacity and only encapsulates the 
amount of genomic information that is needed to replicate. 
Using genetic engineering it is relatively easy to increase the length of the genome, and 
the intergenic region (IG) has been shown to be highly tolerant of DNA insertion 
(Herrmann, 1980), with up to 12 kb having been inserted in this way. In fact, the phage 
genome DNA sequence is irrelevant for the production of phage particles. All that is 
needed is the M13 origin of replication, which contains the packaging signal (PS) which 
is an invariant loop containing a 32 bp palindromic sequence (Shen, 1979, Lopez, 1983). 
When a bacterial plasmid contains an M 13 origin it is termed a phagemid. Transforming 
the phagemid into an F+ strain of E.coli, which is then super-infected with an infective 
phage particle (a helper phage), results in an ssDNA copy of the phagemid being 
encapsulated in a phage capsid. The explanation for this is that the viral proteins 
produced by the RF DNA of the helper phage recognize the phagemid M13 origin and act 
upon it as if it were a wild-type M13 origin. A huge variety of phagemids have been 
produced for scientific research (Alting-Mees, 1989, Gao, 2002, Krebber, 1997). Large 
numbers of the encapsulated phagemid can be produced allowing for large quantities, a 
few milligrams per milliliter (Vieira, 1987), of phagemid ssDNA to be isolated. DNA that 
has been cloned into the phagemid can then be sequenced (Short, 1988, Dotto, 1981) 
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As discussed above, it is relatively easy to create long phage particles. However, it is far 
more difficult to create a shorter phage particle since the filamentous phage are very 
economical with their genome, with all the viral genes closely packed together. Therefore 
removing enough DNA to create a significantly shorter phage particle requires the 
removal of the genes needed for the production of the phage proteins. Since each of the 
11 genes is vital for phage particle production, the removal of any of them results in the 
loss of production of viable phage particles. 
This does not mean that shorter phage cannot be propagated. It is a well characterized 
phenomenon that shorter phage particles are produced during phage growth in E.coli 
culture after repeated passages (Griffith, 1974). The more passages that are done with the 
phage, the larger the population of shorter phage produced (Horiuchi, 1983). These 
shorter phages, or miniphages, are typically 100 to 500 nm in length but are otherwise 
morphologically identical to wild-type phage (Griffith, 1974, Hewitt, 1975). The 
minimum length of these mini phage may be an artifact of the purification method used in 
the studies (see below). These phage only propagate in the presence of full-length phage 
(Hewitt, 1975), and even appear to have an advantage over full-length phage with regard 
to encapsulation (Griffith, 1974). Within the DNA packaged by miniphage it was found 
that the origin of replication was always present. 
Specthrie et al. (1992) took this knowledge and showed that an even shorter 
"microphage" could be produced by creating a plasmid, termed pLS7, that synthesized a 
221 base long piece of ssDNA containing only the M13 packaging signal. This 221 base 
ssDNA fragment leads to the production of a phage particle45-50 nm long (Figure 3.1). 
At 50 nm long, it is half the length of the 100 nm long rruniphage described by Griffith et 
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al. (1974). However, as mentioned above this may be due to the purification method 
used. Both of the original studies (Griffith, 1974, Hewitt, 1975) used a concentration of 
polyethylene glycol (PEG) concentration of between 4 and 10% w/v. PEG is used to 
"crowd" the phage out of solution, resulting in phage precipitates which can be pelleted. 
Specthrie, et al. had to use 15% w/v PEG in order to precipitate the 50 nm long 
microphage. Therefore, phage <100 nm may well be produced by multiple passages of 
wild-type infected E.coli, but they would not be purified by the methods used. Griffith 
and Hewitt highlight this weakness of their studies within their papers. 
M 13 helper phage 
~ 
Figure 3.1. An electron micrograph of microphage particles. Taken from Specthrie, et 
al., (1992). Scale bar equals 50 nm. 
In order to create pLS7 (Specthrie, 1992) a functioning M13 viral origin of replication 
was placed upstream of the packaging signal (PS). A truncated (29 bases are deleted) 
M13 origin acts as a terminator of single strand DNA synthesis downstream of the PS. In 
between these two components is the packaging signal itself (Figure 3.2). The PS is 
needed for efficient encapsulation of the single stranded DNA by viral coat proteins 
(Clackson, 2004). By transfecting an E.coli cell containing pLS7 with a helper phage, a 
full-length phage which acts to provide all the proteins needed for encapsulation, 
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mlcrophage particles can be produced. However, only 1- 3% of the phage population, by 
mass, was found to be mlcrophage, the remainder consisted of helper phage. 
Specthrie, et ai. determlned how small a phage particle could be produced. However, 
their work has an obvious application for Ml3 bacteriophage in respect for its use in 
bionanotechnology, i.e. the ability to control the length of a phage particle in order to 
produce a nanowire of a desired length. By inserting DNA into either the Hind III or 
EcoRI site of the microphage cassette (Figure 3.2) it should be possible to produce a 
phage particle longer than 50 nm, and this increase should be proportional to the amount 
of inserted DNA (Clackson, 2004). For many bionanotechnology applications the wild-
type M13 bacteriophage, at 1 !lm, is too long. The ability to tailor the length of the M13 
particle to a specific purpose has a great appeal and would greatly increase the versatility 
of the M13 phage for bionanotechnology. It could be argued that different size phagemlds 
could be used for the same purpose. However, a very small phagemid is typically 1000 bp 
long, resulting in a phage particle of around 200 nm; therefore the mlcrophage cassette is 
the only way to make phage particles smaller than 200 nm. 
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221 base ssDNA fragment 
Hind III EeoRI 
Microphage cassette 
(310 bp) 
pLS7 
Figure 3.2. The structure of the microphage cassette. Diagram showing the structure 
of the microphage cassette situated within the pLS7 plasmid (A) created by Specthrie, et 
al., (1992). Shows: origin of replication (+) Ori; packaging signal (PS); and (+) Ori~29, 
which acts as ssDNA synthesis terminator. B shows the DNA sequence of the 
microphage cassette, with the sequences highlighted: (+) Ori (red); PS (blue); and (+) 
Ori~29 (green). Adapted from Specthrie et al. (1992). 
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3.1.2 The Helper phage M13K07 
As described above, M 13 helper phage have been used to produce large amounts of 
ssDNA from phagemid vectors (Vieira, 1987) for use in sequencing reactions (Short, 
1988, Dotto, 1981). However, a problem which was encountered was that the phagemid 
interfered with the replication of the helper phage (Ene a, 1982). The decrease in helper 
phage replication resulted in lower production of phage proteins, and so lower yields of 
phage and phagemid particles (typically 10 - 100 fold, Dotto, 1981). Further studies 
produced phage mutants that showed interference resistance (Enea, 1982; Levinson, 
1984) and increased the levels of phage and phagemid ssDNA by 10 fold, i.e. 
approaching wild-type levels. 
However, there was still another problem. The amount of phagemid ssDNA produced 
was about equal to that of helper phage ssDNA (Mead, 1986). Obviously what was 
needed was a way to produce far more phagemid than helper phage ssDNA. In 1987, 
Vieira and Messing created the now commercially available M13K07: a helper phage 
that preferentially packs phagemid ssDNA and results in higher yields of phagemid 
ssDNA. Although other helper phage have been created which show preferential 
packaging, such as those described in Specthrie et al. (1992), M 13K07 is still the most 
widely used. 
Gene II of the M 13 bacteriophage produces a protein (pII) that creates a site-specific nick 
in the (+) strand of the RF dsDNA (Figure 3.3) within the origin of replication and so 
initiates the rolling circle replication of both ds and ssDNA. It also acts to terminate 
ssDNA synthesis by cleaving the displaced (+) strand (at the same site) and ligating the 
Page 110 
Chapter 3 
two ends to form the circular strand of ssDNA. The 140 bp (+) strand origin of DNA 
synthesis (Figure 3.3) can be divided into two domains. Domain A which at 40 bp long 
contains the pII recognition site, the removal of which results in negligible phage particle 
production (0.01 % of wild-type M13 levels, Dotto, 1984). Domain B is 100 bp long and 
contains sequences needed for (+) strand initiation and has been termed the pH enhancer 
sequence (Dotto, 1984; Horiuchi, 1997). Disruption or deletion of the B domain results in 
100-fold decrease in the number of phage produced (Dotto, 1984) and is therefore 
thought to be of less importance to ssDNA replication than domain A (Dotto, 1984; 
Horiuchi, 1997). However, the decrease in phage yield resulting from domain B 
disruption or deletion can be compensated for by mutations elsewhere in the genome 
(Dotto, 1984). Typically these result in the overproduction of pII to compensate for the 
loss of domain B. 
In the case of M13K07, a single G to T substitution at position 6125 results in the 
replacement of a methionine with an isoleucine, M40I, in pII and allows production of 
wild-type levels of phage particles. Although the exact mechanism is unknown, the single 
substitution allows pII to recognize domain A in the absence of B (Dotto, 1984). Within 
M13K07, domain B has been displaced at the Ava I site (Figure 3.3) with the low copy 
number bacterial origin of replication p 15a and a kanamycin resistance gene. The p 15a 
origin of replication allows M 13K07 to replicate within the cell independently of viral 
proteins, specifically plI. This means the phage can continue to express the correct levels 
of viral proteins for the production of ssDNA when in the presence of phagemid DNA, 
which as explained earlier, interferes with the helper phage DNA and lowers the 
expression of viral proteins. The kanamycin gene permits the for selection of the helper 
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phage, thus only allowing E.coli cells super-infected with the helper phage to grow, 
increasing the yield of encapsulated phagemid DNA (Vieira, 1987). 
~ Hairpin loop 
gene IV ~~~~ ______ ~~genell 
Packaging Signal A B 
II 
(+) strand origin of DNA synthesis 
Figure 3.3. The intergenic region of the M13 bacteriophage. Adapted from Vieira, 
(1987). 
Although the methionine to isoleucine substitution allows pH recognition of domain A at 
wild-type efficiency, when a phagemid is present within the cell with a fully wild-type 
origin of replication, the pH protein preferentially binds to the wild-type origin (Vieira, 
1987). This results in the phagemid ssDNA being packaged instead of the helper phage 
DNA (Vieira, 1987) and leads to higher yields of phagemid ssDNA, e.g. > 1011 colony 
forming units (cfu) compared to 1010 cfu when using a wild-type helper phage. Although 
the phagemid DNA is preferentially packaged, some M13K07 DNA is also packaged and 
this therefore results in a heterogeneous population of phage. 
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3.1.3 The Helper Plasmid 
When Specthrie et al. (1992) produced the microphage they used a helper phage which 
resulted in 1-3% of the mass of phage produced being microphage. Further purification 
was used to purify a homogenous population of microphage, i.e. 15% w/v PEG, in order 
to remove the helper phage downstream. Although these techniques are straightforward, a 
simpler method to create a homogenous population of microphage is to remove the helper 
phage altogether from the production of microphage. 
In 2006, Chasteen et al. at the Los Alamos National Laboratory in the U.S.A produced 
the plasmid pM13CP, or as they described it: "an M13 based helper plasmid" (Chasteen, 
2006). They were attempting to overcome the same issue of helper phage contamination. 
At its most basic, it is merely an evolution of the M13K07 helper phage. Instead of an 
interrupted origin of replication, and a compensatory mutation, they completely removed 
the viral origin of replication (Figure 3.4) and replaced it with the p15a origin of 
replication. The p 15a origin is a low copy number bacterial origin of replication and 
plasmids containing the p 15a origin are typically present at 10-15 copies per E.coli cell. 
As with MI3K07, the p15a origin allows for the viral plasmid to produce all the viral 
coat proteins. However, the lack of any viral origin of replication, specifically the 
packaging signal, results in no M 13CP ssDNA being encapsulated (Chasteen, 2006) and 
so only phagemid ssDNA is packaged into phage particles. The yield was also found to 
be equivalent to M13K07, thus making the M13CP helper plasmid an ideal replacement 
of the M13K07 helper phage. 
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Figure 3.4. Schematic of method used to create pM13CP. Red indicates deletion of 
DNA whilst green indicates the addition of DNA. To create M13CP the lacZ gene was 
deleted (A) and replaced with a chloramphenicol resistance (cam) gene (B). The M13 
origin was then deleted (C) and replaced with the p 15a bacterial origin of replication (D). 
3.1.4 Aims of the work described within this Chapter 
1. To re-create the microphage plasmid and produce microphage using the M13K07 
helper phage 
2. To re-create the M13CP helper plasmid and investigate its use in producing a 
homogenous population of microphage. 
3. To investigate alternating the length of the microphage DNA cassette to produce 
different length phage. 
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3.2 Results and Discussion 
3.2.1 Creation of microphage 
The pMicro cassette (Specthrie, 1992) was recreated and inserted into the pJet1.2 vector 
(purchased from Fermentas, York, U.K.): a high copy number vector containing the 
pMB 1 bacterial origin of replication (Figure 3.5 A). 
gene pJet1.2 
2974 bp 
resistance 
gene pMicro 
3284 bp 
Figure 3.5. Maps of the pJetl.2 (A) and pMicro (B) vectors. 
(+) Ori Microphage 
cassette 
(+) Ori~29 
The creation of the microphage cassette involved four steps (Chapter 2, TabJe 2.1 lists the 
primers involved). Step 1 involved amplifying the packaging signal (PS), to create a 99 
bp long fragment from pET26-b (Figure 3.6 A); this was followed by step 2 which 
involved further amplification of the PS fragment to add 25 bp flanking sequences either 
side of the PS that were complementary to pET26-b (Figure 3.6 B). 
The DNA fragment from step 2 was then directly used as a primer for insertional PCR, 
which is a variation -of site directed mutagenesis (Wang, 1999). Insertional PCR was 
performed to insert the PS downstream of the M 13 origin of replication found in the 
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pET26-b vector. Figure 3.6 C shows that mutagenesis was successful due to the 
formation of an insertional PCR product. After transformation of the insertional PCR 
product, one colony was found . This was picked and cultured and the plasmid DNA 
(termed pET26-bPS) purified. To confirm that the PS had been successfully inserted into 
pET26-b, pET26-bPS and pET26-b were cut with the restriction enzyme HindIII. The 
microphage cassette contains a single HindIII site (Figure 3.6). Successful creation of 
pET26-bPS will result in two HindIII sites present within the plasmid compared to the 
single HindIII site present in pET26-b. Therefore restriction of pET26-bPS with HindIII 
should release a fragment of - 1kb, whilst restriction of pET26-b with HindIII should 
result in the linearization of the plasmid. After restriction with HindIII only pET26-bPS 
produced a fragment -1 kb in size (Figure 3.6 D). pET26-bPS was then sent for 
sequencing and the correct sequence was confirmed. 
The next two steps (3 and 4) involved the amplification of the defective origin, to act as a 
ssDNA terminator, and its insertion downstream of the PS. Step 3 amplified the defective 
origin from pET26-b to produce a 90 bp fragment (Figure 3.7 A). This was then 
amplified further with the step 4 primers to put pET26-bPS complementary overlaps onto 
the 90 bp fragment to produce a 136 bp fragment (Figure 3.7 B). The 136 bp fragment 
from step 4 was then used as the primer in insertional PCR with pET26-bPS as the 
template. After PCR a product was present (Figure 3.7 C) indicating that the reaction was 
successful. When transformed it gave a large number of colonies, ten of which were 
picked and used for sequencing. Eight of these confirmed the creation of the desired 
sequence (Appendix A, section 1.0). One was carried forward for further experiments and 
was termed pM 1. 
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Microphage cassette 
A Ikb Step I 
Ladder PCR 
C I kb 
100 bp 
-150 bp 5 kb -MI:::::::: 
Step 1 Step 2 Insertional-peR 
Step 1 peR Product: 99 bp 
Step 2 peR Product: 151 bp 
Cut 
PS 
fragment 
HindIII restriction 
confirmation 
Complementary to pET26-b vector 
AACACTCAACCCT 
pET26-b 
5360 bp 
pBR3220rigin 
Complementary to pET26-b vector 
Insertional peR 
Using step 2 PCR 
product as primer 
pET26-bPS 
5472 bp 
pBR322 origin 
Figure 3.6. Insertion of packaging signal (PS) into the pET26-b vector. Shows 0.8% 
(w/v) agarose gels run at 120 V for 1.5 hours and stained with ethidium bromide. 
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B IObp Step 4 
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Insertional 
peR product 
Step 4 Insertional PCR 
Step 3 PCR product: 90 bp 
Step 4 PCR product: 136 bp 
Complementary to pM 1 vector 
pET26-bPS 
5472 bp 
pBR322 ori gin 
Insertional PCR 
Using step 3 PCR 
product as primer pMl 
5568 bp 
pBR322 origin 
Figure 3.7. Insertion of defective origin, (+) OriL129, into the pET26-bPS vector. 
Shows 0.8% (w/v) agarose gels run at 120 V for 1.5 ho~rs and stained with EtBr 
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The microphage cassette, created in Step 4 (pMl), was then amplified using the 
Microamplifyfor and Microamplifyrev primers (Chapter 2, Table 2.1) which flank the 
310 bp microphage cassette. This was then ligated into the pJet1.2 plasmid (Fermentas), a 
precut plasmid with blunt ends and allows for simple insertion of peR fragments into the 
plasmid. This was necessary because pET26-b contains a functional M13 origin of 
replication which would interfere with microphage production. pJet1.2 has no viral origin 
of replication and so avoids this problem. After ligation into pJet1.2, and transformation 
into E.coli, colony PCR was carried out on eight colonies using the Microamplifyfor and 
Microamplifyrev primers to confirm microphage cassette insertion. Four plasmids were 
found to contain the microphage cassette. These four were sent for sequencing which 
confirmed that they did contain the correct microphage sequence (Appendix A, section 
2.0). Of these four, only one was carried forward for further experiments and was termed 
pMicro (Figure 3.5 B). 
3.2.2 Creation of pMicroKan 
A kanamycin resistance gene (1165 bp) was PCR amplified using the KanforecoRl and 
KanrevecoRl primers from pET26-b (Novagen). The kanamycin resistance gene was 
ligated into the middle of the microphage cassette in pMicro using the EcoRl restriction 
site, which is located upstream of the packaging signal (Figure 3.3), to create pMicroKan 
(Figure 3.8). This was done to examine whether the microphage cassette could 
accommodate inserts of DNA that would result in changes to the length of the phage 
particle. The kanamycin gene was chosen to allow for easy selection of successful 
mutants that carried the correct insert. Ten colonies that grew on LB agar plates 
containing kanamycin were sequenced to confirm that the microphage cassette sequence 
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was correct and contained the kanamycin resistance gene in the correct position. One was 
used in further experiments and was termed pMicroKan (Appendix A, section 3.0). 
A B 
310bp 
pMicro pMicrokan 
1165 bp 
Figure 3.8. Controlling the length of phage particles. The plasmid pMicro (A) can be 
used as a scaffold to vary the length of phage. By inserting DNA into the 310 bp 
microphage cassette it is possible to control the length of the phage particles. In this case, 
a kanamycin gene was inserted to produce pMicroKan (B). 
3.2.3 Creation of the pM13CP helper plasmid 
Following the original paper (Chasteen, 2006), the lacZ gene and multiple cloning site 
(MCS), present in commercial strains of M13, were removed from M13KE (New 
England Biolabs) by PCR amplification using a high fidelity polymerase and the outward 
facing primers M13Mlulfor and M13Mlurev. These primers flanked the lacZ gene and 
MCS and resulted in a PCR fragment -7 kb in length (Figure 3.9 A) which lacked the 
lacZ gene and MCS with Mlu 1 restriction enzyme sites at either end. A chloramphenicol 
resistance gene (Figure 3.9 B) was then amplified from pACYC184 (New England 
Biolabs) using the primers pACYC184camfor and pACYC184carnrev which resulted in a 
PCR fragment -1 kb in length with Mlu 1 restriction enzyme sites at either end. The 
chloramphenicol resistance gene was then ligated into the Mlu 1 sites to produce a 
functional M13 bacteriophage (MI3C) with chloramphenicol resistance. 
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The viral M13 origin of replication was then replaced by the low copy number p15a 
origin of replication by once again amplifying M13C with a high fidelity polymerase and 
the outward facing primers M13cpfor and M13cprev which produced a PCR fragment of 
-8 kb in length (Figure 3.9 C) with Nco1 restriction sites at either end. The outward 
facing primers flanked the M13 origin of replication, resulting in this region being absent 
from the PCR fragment. 
The p15a origin of replication (Figure 3.9 C) was amplified from pACYC184 using the 
- primers p15afor and p15arev and then cloned into the Nco1 sites of the 8 kb M13C PCR 
fragment producing pM13CP. The low copy number bacterial origin of replication (p15a) 
was used in the original paper so that pM13CP mimicked the RF DNA form of the viral 
genome (Chasteen, 2006). There are 10-15 copies of RF DNA per cell, which is a similar 
copy number to a plasmid containing the p15a origin. By using this origin, a bacterial 
plasmid was produced lacking the M 13 origin of replication and reported to produce all 
the proteins needed for phage assembly without packaging itself (Chasteen, 2006). 
pM13CP was then fully sequenced (Appendix A, section 4.0) and five silent mutations 
were found (highlighted in Appendix A, section 4.0). 
3.2.4 Production of shorter phage using the helper plasmid pM13CP 
pMicro was first transformed into E.coli ER2738. A single colony was then grown, 
competent cells produced, and transformed with pM13CP so that a colony of E.coli 
contained pMicro and pM 13CP. After growing overnight in a rich medium containing 
chloramphenicol and carbenicillin, the phage particles were purified using 15% w/v PEG 
and 0.5 M NaCl. 
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Figure 3.9. Creation of pM13CP helper plasmid. Shows 0.8% (w/v) agarose gels run at 
120 V for 1.5 hours and stained with ethidium bromide. 
Examination of the purified microphage with transmission electron microscopy (TEM) 
showed that only microphage particles were present (Figure 3.10 A). No wild-type 
length phage were seen. To confirm that the M13CP plasmid was not being packaged into 
phage particles an experiment from the original paper was repeated (Chasteen, 2006). 
M13CP was co-transformed with the commercial ph~gemid pLitmus28i. This phagemid 
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contains both a bacterial and an M13 origin of replication. Therefore when M13 assembly 
proteins are present, the pLitmus28i phagemid should be packaged. This was done so that 
phage concentrations could be titered since the microphage cassette is unable to replicate 
inside an E.coli cell and contains no antibiotic resistance gene. 
Figure 3.10. Phage produced using pM13CP and pMicro (A) and pLitmus 2Si (B). 
Scale bar equals 200 nm. 
E.coli containing either, pM13CP, pLitmus28i, both pM13CP and pLitmus28i, or no 
plasmid, were grown overnight and phage particles PEG precipitated and re-suspended in 
1 rnL of PBS. 10 f-tL of each sample was mixed with E.coli for one hour before being 
spread on agar plates containing either ampicillin or chloramphenicol. After incubation 
overnight at 37°C the number of colonies on each plate was counted (Figure 3.11). Only 
samples originating from ~. coli containing both plasmids produced colonies and grew 
only on the ampicillin plates. These results indicate that the M13CP plasmid was 
behaving as expected, i.e. that it was unable to package itself into a phage particle and 
could only produce phage particles when a plasmid containing the M13 origin of 
replication was presel)t. This was further confirmed by electron microscopy where only 
phage particles approximately 400 nm long, the predicted length of phage particles 
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encapsulating pLitmus28i, were seen in the sample originating from cells containing both 
the plasmids (Figure 3.10 B). Once again no wild-type length phage were observed. 
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Figure 3.11. Titer of pLitmus28i and pM13CP. Results an average of 3 titers. Error bar 
shows standard deviation . 
However, the phage titer was very low (-5 X 106 cfu/mL). The original paper (Chasteen, 
2006) states that titer levels using pM13CP were equivalent to those using the M13K07 
helper phage (_1011 cfu/mL). No satisfactory explanation can be given for such a wide 
discrepancy in phage titer. With no sequence data available for the original pM13CP 
plasmid it is impossible to compare the plasmid produced in this study with the original. 
It may be that their plasmid contains a beneficial mutation that increases phage titer. 
The amount of phage produced by pM13CP in this study was too low to allow for further 
experiments; therefore pM 13CP was not used to. create any further phage particles. 
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3.2.5 Production of shorter phage using the helper phage M13K07 
Since M13CP failed to work to expectations, the M13K07 helper plasmid was used to 
produce different length phage. Therefore a colony of E.coli ER2738 containing pMicro 
was grown until early log phase, super-infected with the commercial helper phage 
M13K07 and grown overnight. The phage were then purified from the supernatant by 
precipitation with 15% (w/v) PEG and 0.5 M NaCl. Upon centrifugation a small pellet 
was observed. This was resuspended in PBS and a sample was viewed using TEM. It was 
- found that the sample contained a mix of helper phage (Figure 3.12 B) and 50 nm long 
particles (Figure 3.12 A), morphologically similar to the helper phage. 
Figure 3.12. Production of microphage. A representative electron micrograph of 
microphage (A) produced by the super-infection of E.coli containing pMicro with 
M13K07 helper phage (B). Due to the insertion of the chloramphenicol resistance gene 
and p15a origin of replication the M13K07 phage are -1350 nm long. Scale bar equals 
100 nm. 
Page 125 
Chapter 3 
3.2.6 Production of different length phage and purification 
Using the same method as in 3.3.5 two other shorter phage particles were produced. This 
was done using pMicroKan (1324 bases) and the commercial phagemid pLitmus28i 
(2832 bases). pLitmus28i was chosen as a cheaply available phagemid control. 
pLitmus28i contains an ampicillin resistance gene and since the entire phagemid is 
encapsulated to produce phage it could be used to measure phage titers. After production 
of the shorter phage particles, including M13K07 helper phage, and PEG purification 
(15% PEG, 0.5 M NaCI) the phage were further purified on a linear sucrose gradient 
(Figure 3.13) in order to separate the shorter phage from the M13K07 helper phage. 
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Figure 3.13. Linear sucrose gradient fractionation of different length phage 
particles. 100 ml of overnight culture of E.coli containing the different length phage 
particle plasmids, super-infected with MI3K07, were precipitated with 15% (w/v) PEG, 
0.5 M NaCI and resuspended in 500 ilL PBS. The 500 III was then loaded on top of a 12 
mL 30-60% (w/v) linear sucrose density gradient and centrifuged for 20 hours at 18500 
rpm. The gradients were then fractionated and the absorbance at 260 nm recorded. 
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It was observed that each phage particle sedimented different distances into the sucrose 
gradient (Figure 3.12). pMicroKan, pLitmus28i and M13K07 gave relatively sharp peaks 
(B, C and D, respectively). pMicro gave a very broad peak (A). Each peak was collected 
and a sample viewed under TEM (Figure 3.14). Each peak contained a homogenous 
population of phage (Figure 3.17). Most importantly, the shorter phage particle peaks 
(pMicro, pMicroKan and pLitmus28i) contained no helper phage. 
Figure 3.14. Transmission electron micrographs of gradient fractionated phage 
particles; pMicro (A); pMicroKan (B); pLitmus (C); and M13K07 helper phage 
(D). Scale bar equals 200 nm. Arrows highlight phage particles. A to C inset show image 
at same scale but at higher contrast and brightness. 
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Figure 3.15. Size exclusion purification of microphage particles. Microphage particles 
applied to a Superose 6™ column (A) and TEM images of peaks 1, 2 and 3 (B). 
Microphage particles, produced from E.coli containing pMicro and super-infected with 
M13K07, were precipitated with 15% (w/v) PEG-8000, 0.5 M NaCI and pelleted by 
centrifugation. These were re-suspended in PBS and loaded onto a 30-60% (w/v) linear 
sucrose gradient. After centrifugation, the peak containing microphage (Figure 3.13 A) 
was collected and dialyzed against PBS. Phage were then PEG precipitated and re-
suspended in 500 f.tL of PBS. 10 f.tL was then loaded onto a Tricorn™ column (1 cm 
diameter, 25 mL volume, 30 cmbed height) packed with Superose 6™ (protein 
separation range of 5 x 103_ 5 X 106 Da). The column buffer (PBS) was run at a flow rate 
of 0.5 mUmin and absorbance measured at 260 and 280 nm. 35 I mL fractions were 
collected. 5 f.tL of each fraction was viewed using TEM. Scale bar equals 200 nm. 
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As a final step of purification, the microphage from the sucrose gradient were 
fractionated by gel filtration on a Superose 6™ column (GE Healthcare, Little Chalfont, 
U.K.) . The molecular weight of a wild-type M13 particle is 12 x 106 Da (Berkowitz, 
1980; Ling, 2004). This is outside the fraction range of a Superose 6™ column, which 
has a range of 5 x 103 to 5 X 106 Da, and so the phage would be eluted in the column void 
volume. At 50 nm, the microphage is approximately 20 times shorter than the wild-type 
phage (at 1 micron), therefore a rough estimate of the molecular weight provides the 
figure of 0.6 x 106 Da, indicating that the microphage should interact with the Superose 
6™ column and therefore allowing for separation. Applying the purified microphage 
sample to the column resulted in three peaks (labeled 1 to 3 in Figure 3.15 A). 
Examination of these peaks showed that the first peak contained a pure fraction of 
microphage (Figure 3.15 B 1). The third peak (Figure 3.15 B 3) contained spherical 
particles of -10 - 15 nm in diameter with a central hole or pore. This is a similar 
morphology to the chaperonin GroEL, which is a dual-ringed tetradecamer comprised of 
60 kDa subunits and is involved in the folding of proteins (Zeilstra-Ryalls, 1991). 
Running peak 3 on a denaturing poly-acrylamide gel revealed a single band at -60 kDa 
(Figure 3.16), which is the size of the GroEL subunit, and further indicates the presence 
of GroEL in the sucrose purified microphage sample. Examination of the original TEM 
image of the microphage (Specthrie, 1992, Figure 3.1) indicates that GroEL 
contamination of the microphage particle has always been an issue. The second peak 
(Figure 3.15 B 2) appeared to be a mix of GroEL, microphage and irregular structures, 
most likely aggregated protein. 
Page 129 
Chapter 3 
60kDa GroEL subunit 
Figure 3.16. Denaturing PAGE analysis of GroEL. Peak 3 from Figure 3.15 was run 
on a 10% (v/v) denaturing poly-acrylamide gel. Gel was run for 2 hours at 8 Wand 
stained with coomassie blue. 
3.2.7 Examination of shorter phage particles 
The shorter phage all exhibited similar morphology to wild-type phage (Figure 3.14); 
with pIlI molecules clearly present on the microphage after purification (see Figure 3.15 
B 1 inset). Since there is a linear relationship between the length of ssDNA and the length 
of the phage (Specthrie, 1992), populations homogenous in length should be produced by 
pMicro, pMicroKan and pLitmus28i after purification from helper phage. Therefore 500 
individual phage particles, from each purified phage peak on the sucrose gradient (Figure 
3.13 A to D), were measured using ImageJ (Abramoff, 2004) to ascertain the 
homogeneity of the population (Figure 3.17). The result clearly shows that the shorter 
phage particles (pMicro and pMicroKan) have less homogeneity than the longer 
pLitmus28i phage. However, this has probably arisen from measuring errors. Figure 3.17 
also highlights a result which differs to that of the original microphage paper (Specthrie, 
1992). Within the microphage they produced, two distinct populations were observed at 
45.5 and 50.5 nm. However, within this study, those popUlations were not observed 
Page 130 
Chapter 3 
(Figure 3.17) with only a single population between 46 and 49 nm: a result more in 
agreement with the theoretical length of 49 nm. Whether this is an important result or 
down to different measurement methods or degradation of their phage particles is 
difficult to ascertain. 
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Figure 3.17. Homogeneity of shorter phage particle populations. 500 individual 
particles were measured from phage produced from pMicro, pLitmus28i and pMicroKan 
using M13K07 helper phage and purified on a 30-60% (w/v) linear sucrose gradient to 
remove M13K07. These samples were not gel purified. Phage particles were measured 
using ImageJ (see Chapter 2, section 2.2.11). 
The different phage particles produced showed the expected length dependency with the 
amount of DNA being packaged (Figure 3.18 A). As the phage length increased the 
phage population also showed greater length variance, e.g. M13K07 has a wide range of 
lengths (Figure 3.18 A). There are two reasons for this variance. The first is that longer 
phage are produced by the natural phenomenon of incorrect pIIIIp VI capping of mature 
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phage particles (Griffith, 1974) resulting in the phage particle not detaching from the 
E.coli cell and so allowing for a second or third M13 genome to enter the phage particle 
before successful capping. The second is that shorter phage are likely to result from 
shearing during purification. The longer the phage particle, the more the likelihood of 
shearing. This also explains the broader peak seen in Figure 3.17 for pLitmus28i phage. 
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Figure 3.18. The length of different phage particles. A graph showing the relationship 
between the length of phage particles and the length of the ssDNA genome (A) with the 
error bars showing standard deviation (N = 500). B s~ows representative images of each 
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phage particle where the phage have been aligned from separate images using Adobe 
Photoshop TM . Scale bar equals 200 nm. 
The linear relationship between the length of ssDNA and length of phage particle should 
result in each phage particle having the same density, since the mass/unit length should 
remain constant. To examine whether this was true for the shorter phage particles, the 
phage were analysed on a caesium chloride gradient. This is an isopycnic equilibrium 
centrifugal technique that separates particles by their different densities . Each phage 
particle, regardless of length, banded at approximately the same place on the gradient 
- (Figure 3.19). This result shows that each phage particle has the same density and that 
therefore, even down to the 50 nm long microphage, the linear relationship between 
ssDNA length and phage length holds true. 
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Figure 3.19. CsCI gradient of different length phage particles. 100 mI of overnight 
culture of E.coli containing the different length phage particle plasmids and super-
infected with M13K07, were precipitated with 15% (w/v) PEG-8000, 0.5 M NaCl and 
pelleted by centrifugation. These were re-suspended in 500 ~l PBS. The 500 ~l was then 
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loaded onto a 12 mL 30% CsCI gradient and centrifuged for 60 hours at 30000 rpm. The 
gradients were then fractionated and the absorbance at 260 nm recorded. 
The number of phage particles produced from the microphage cassette when super-
infected with Ml3K07 was then investigated. Since the pMicro cassette produces only a 
short piece of ssDNA, that is not infectious, it is impossible to titer. Therefore the titer of 
the pLitmus28i was used as an indication of pMicro titer. Since pLitmus28i is a bacterial 
plasmid, after transfection into E.coli it can replicate and produce ampicillin resistant 
E.coli colonies (the resistance gene located on pLitmus28i). This method results in a titer 
given in colony forming units (cfu/mL). 
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Figure 3.20. Titer of different length phage. Purified phage particles (15% PEG w/v, 
0.5 M NaCl) were serially diluted to 106 or used from stock. They were then mixed with 
E.coli ER2738 expressing F-pili for one hour and then plated onto agar plates containing 
Page 134 
Chapter 3 
ampicillin or kanamycin and incubated overnight at 37°C. Colonies were then counted on 
each plate. 
Therefore after the initial 15% PEG (w/v), 0.5 M NaCI purification, the phage were 
titered to quantify the yield of each respective phage particle (Figure 3.20). The titer was 
carried out by mixing the purified phage particles with E.coli and then plating on agar 
plates containing ampicillin or kanamycin. Packaged pLitmus would provide ampicillin 
resistance whilst packaged M 13K07 would provide kanamycin resistance. Packaged 
- pMicro and pMicrokan would provide no antibiotic resistance. 
The results show (Figure 3.20) that no colonies were observed on ampicillin plates for 
phage particles produced from pMicro, pMicroKan and MI3K07; which was expected 
and indicates that the pMicro cassette functions correctly and that only the pMicro 
ssDNA is encapsulated and not the entire pJet1.2 plasmid which carries an ampicillin 
resistance gene. The titer of pLitmus28i was approximately 2.5 x 1012 cfu, which is 
equivalent to the titer expected from M13K07 produced phage pa11icles (Chasteen, 
2006). This titer can assumed to be similar for pMicro since it was produced using the 
same method as pLitmus packaged particles. Figure 3.14 A and C further support this 
assumption, since within the images there are similar numbers of phage. 
3.3 Conclusions and Future Work 
At 50 nm long, the microphage is the shortest known M13 particle. It is this small size 
that makes it an attractive tool in bionanotechnology. The M13 bacteriophage has already 
been utilized for various nano-scale devices; e.g. a lithium ion battery (Lee, 2009); 
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various metal and semi-conducting nanowires (Flynn, 2003; Mao, 2003); and for the 
production of simple higher order structures (Nam, 2004). However, each of these 
devices has had to use wild-type M13 and were therefore restricted to a particle that was 
a micron in length. The result of this restriction was that each nanoscale device had a 
minimum length which could potentially inhibit these devises' applications, e.g. all 
nanowires created using M 13 are a micron in length which limits the number of wires 
that could be deposited on a surface. 
To date, no-one has exploited the microphage. The work described in this Chapter shows 
that the microphage can act as a blueprint for the bespoke creation of M13 particles; 
where the length of each M 13 particle can be controlled in a predictable and rational 
manner. By using the pMicro cassette and inserting pre-determined lengths of DNA, then 
any desired length phage, greater than 50 nm long, can be produced. In this case, the 
insertion of a kanamycin resistance gene resulted in a -214 nm long phage particle where 
the amount of DNA inserted showed a linear relationship with the length of the phage 
particle produced. Further investigation needs to be carried out to study whether this 
linear relationship continues when longer pieces of DNA are inserted into the microphage 
cassette. 
It is possible that the microphage has not been used due to its difficulty in purification, 
and discussions with other academics indicates this may be the case (personal 
communication). The need for a 15% (w/v) PEG purification step results in the 
precipitation of DNA and other unwanted proteins that normally, with regard to wild-type 
M 13 purification, would not be an issue. The work here has shown that performing a 
straight forward sucrose density gradient step followed by size exclusion chromatography 
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results in a pure microphage population with a yield of 2.5 x 1012 cfu: roughly analogous 
to wild-type phage titers. 
In the future it would be interesting to attempt the combination of the pMicro plasmid 
with the helper plasmid (pMI3CP) created by Chasteen, et al. (2006) to investigate 
whether the plasmid they created produces higher phage titers. If so then it would be a 
better way to produce the microphage. Using helper phage is less desirable since you first 
need to produce the helper phage which takes times and resources, and also when 
growing the microphage it is necessary to allow the E.coli host to attain the log phage of 
growth before adding the helper phage. By using the helper plasmid these time 
consuming aspects of microphage production would be eliminated. It is also possible to 
envisage a single plasmid being utilized by cloning the microphage cassette into the 
helper plasmid. Different length phage could then be created by adding DNA to this 
single plasmid and therefore resulting in a library of plasmids that each produces a 
different length phage particle. These could then easily be transformed into an E.coli host 
to produce the different phage. 
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Fabrication of Higher Order Structures 
This Chapter describes the work carried out to fabricate higher order structures using 
wild-type length phage and microphage. It also describes the attempts to purify these 
higher order structures. 
Chapter 4 
4.1 Introduction 
4.1.1 The importance of new fabrication techniques 
Since the 1970s the number of transistors on a chip has approximately doubled every 
two years. This is known as Moore's law (Moore, 1965) named after the co-founder of 
Intel, Gordon Moore, who predicted the rate of development in a 1965 paper in 
Electronics magazine. From millimetres across, transistors can now be fabricated that 
are just 50 nm in size. This rapid rate of miniaturization has been possible due to the 
photolithography fabrication technique (Figure 4.1). 
Photolithography uses light shone through a transparent material, termed a mask, onto a 
material (photo-resist) that undergoes a chemical change upon exposure to the light. The 
mask contains the pattern of the transistor by blacking out certain areas . This blocks the 
light and therefore the pattern is imprinted onto the photo-resist. Various etching and 
material deposition steps are then used to remove the patterned photo-resist and create 
the transistor. 
Photolithography's strength lies in its ability to print large numbers of transistors on a 
small area in a very reproducible manner, i.e. although only one transistor is shown in 
Figure 4.1, by using sophisticated masks large numbers of transistors can be patterned at 
the same time. However, the fundamental limitation with photolithography is the light 
source (Berkowski, 2005). The size of the fabricated features, i.e. the distance between 
the electrodes of the transistor is dictated by the wavelength of the light (Lin, 1986). 
Page 140 

Chapter 4 
193 nm photolithography (Lin, 2006). Despite these limitations, the desire to stay with 
photolithography is because you can pattern large numbers of devices reproducibly in a 
short space of time. 
Alternatives to photolithography do exist, e.g. ion beam lithography is widely used in 
research to create nanodevices. This technique can fabricate impressively small 
structures. For example, a research team in Manchester has created a transistor, where 
the structures were under 20 nm, from graphene (Ponomarenko, 2008). Graphene is a 
sheet of carbon atoms arranged in a honey-comb lattice structure. The thickness of the 
graphene is a single carbon atom. They carved all the features of the transitor from the 
graphene using an electron beam, including the central island and the electrodes 
surrounding it. However, although these techniques can produce very small devices, 
they are not industrially viable due to the mechanism by which they operate. Ion beam 
lithography uses an electron beam to pattern a material. It is inherently slow in creating 
a device since it has to draw each component individually and cannot pattern large 
numbers of them simultaneously. Therefore, if a new technique is to replace 
photolithography in the next generation of transistors it is going to have similar 
properties to it; namely, it must be able to produce large numbers of devices quickly and 
reproducibly. 
4.1.2 Self-assembly of molecular transistors 
Rather than patterning a surface, another method may be to design molecules that self-
assemble into a transistor when mixed together. This is called a 'bottom up' approach to 
fabrication (with lithography being a 'top down' example). Self-assembly can be further 
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divided into two broad categories. The first being in vitro manufacture where molecules 
are created synthetically before being mixed together. The other category recognises 
the fact that Nature has been creating self-assembling nanodevices for millennia, e.g. 
the ribosome, and is termed bionanotechnology. What Nature shows is that biological 
molecules can be "programmed" to self-assemble reproducibly into higher order 
structures in large numbers. These are the exact properties that are needed for a new 
method to replace photolithography. 
4.1.3 Viral self-assembly into higher order structures 
The use of viruses to create higher order structures is a relatively novel field. As 
discussed in Chapter 1, the M 13 bacteriophage can be modified at the genetic level to 
display small peptides on its surface. Harnessing this property has led to the self-
assembly of M 13 particles into discrete architectures in an effort to create scaffolds for 
nanoscale devices. An example of this has been the display, on M13, of an anti-
streptavidin peptide on pIlI (SWDPYSHLLQHPQ) and a hexahistidine peptide on pIX 
(i.e. on the opposite end of the phage). This mutant phage, displaying the two peptides, 
was mixed with a "linker molecule" consisting of streptavidin conjugated with nickel-
nitrilotriacetic acid, which binds tightly to hexahistidine. By controlling the 
stoichiometry of the phage and the linker it was possible to create a nano-ring (Figure 
1.9, Chapter 1) from individual phage (Nam, 2004). These nano-rings have the potential 
to act as scaffolds in the nucleation of various inorganic materials by using p VIII 
displayed peptides. Within the original paper they highlight the potential of nucleating a 
magnetic material to create a magnetic nano-ring that could function as a memory 
device (Zhu, 2000). Aside from the nano-ring, it was found that by altering the 
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stoichiometry, so that there were 10 mutant phage per linker, radial (Figure 4.2 A) and 
linear (Figure 4.2 B) structures were created. 
Figure 4.2. AFM images of M13 bacteriophage higher order structures. M13 
bacteriophage were created displaying an anti-streptavidin peptide on the minor coat 
protein pilI and a hexahistidine peptide on pIX. The mutant phage were mixed with a 
streptavidin conjugated with nickel-nitrilotriacetic acid linker molecule at a ratio of 
10: 1. Taken from Nam, (2004). 
The AFM images given as evidence (Figure 4.2 A and B) for the existence of these 
radial and linear higher order structures are, however, less than convincing. Neither 
AFM image is particularly conclusive with most of the phage having a broken 
appearance (highlighted by arrows in Figure 4.2 B). A more worrying aspect is the large 
degree of variability in length of the phage particles (Phage 1 and 2 in Figure 4.2 B). 
The phage were produced using the typical phagemid and helper phage system (Chapter 
1, section 1.7.1) and within the paper it is claimed that the phagemid particles vary in 
length from 300 to 600 nm. As shown in Chapter 3 (Chapter 3, Figure 3.17), although 
phagemid systems do produce some variation in phage length, it is not usually as 
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extreme as seen in Figure 4.2. It is more likely that the phage used by Nam, et ai. were 
sheared during the purification process. Assuming that higher order structures can be 
created using this method, the lack of homogeneity in the phage length would make 
them difficult to use. For instance, attempting to get them to self-assemble onto pre-
fabricated electrodes would be very difficult since the lengths would change for every 
higher order structure. 
Further work has been done with the anti-streptavidin peptide by the same group. By 
combining this peptide on pIlI with a gold nanoparticle binding peptide (VSGSSPDS) 
on pVIII further higher order structures have been created (Figure 4.3; Huang, 2005). 
By mixing these phage with streptavidin coated 15 ' nm gold nanoparticles it was 
possible to see phage bound to the particles and in some cases multiple phage bound to 
a single particle. By then adding 5 nm gold nanoparticles, which bound specifically to 
the gold nanoparticle binding peptide, it was possible to coat the phage with the gold 
nanoparticles. 
Howe,ver, once again the images given to demonstrate these higher order structures are 
not convincing. Examining the structure consisting of three phage (Figure 4.3 B) it 
appears more likely that there is one phage bound to the 15 nm gold nanoparticle and 
then another phage intercepting it (I have highlighted these phage in red in Figure 4.3 
C). The other figures are £imilarly ambiguous with no further data to back up the TEM 
images. A further major flaw with using the gold nanoparticles in this instance to create 
nanowires is that upon enhancement of the gold nanoparticles, i.e. using the 
nanoparticles as "seeds" for further deposition of gold to create continuous and current 
conducting nanowires, the various nanowires would fuse at the point where they 
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intersect therefore creating an amorphous gold area with no use as a nanodevice. As 
with the previous paper from the group (Nam, 2004) no further mention is made to 
these higher order structures and no further papers have been published regarding them. 
Figure 4.3. Gold coated M13 bacteriophage higher order structures. M 13 
bacteriophage displaying an anti-streptavidin peptide on the pIlI coat protein were 
mixed with streptavidin coated 15 nm gold nanoparticles. A shows two phage bound to 
a single nanoparticle. B shows three phage bound to a gold nanoparticle. C shows the 
same image as B but with two phage highlighted in red. Taken from Huang, 2005. 
It therefore seems feasible that distinct higher order structures using the M13 
bacteriophage can be created, although the evidence in the literature is not convincing 
(Nam, 2004; Huang, 2005). The challenge appears to be finding a way to create 
homogenous higher order structures that is reproducible, and then purify them. 
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4.1.4 Selenocysteine 
Selenocysteine is the 21 st genetically encoded amino acid, first identified in 1986 
(Chambers, 1986 and Zinoni, 1986). It is an analogue of cysteine except the sulphur 
atom is replaced with a selenium atom. It is one of only two genetically encoded amino 
acids that fall outside of the 20 standard amino acids; the other being pyrrolysine which 
is found only in methanogenic archaea and bacteria species (Atkins, 2002) . In contrast, 
selenocysteine has been found in every domain in life, from simple bacteria to humans 
(Fischer, 2007). Selenocysteine containing proteins are more common in higher 
eukaryotes (Johansson, 2005). 
Almost all of the proteins that have been identified containing selenocysteine (called 
selenoproteins) are enzymes involved in the catalysis of oxidation/reduction reactions 
(Bock, 1991). An example is glutathione peroxidise, an enzyme which reduces free 
hydrogen peroxide to water and so protecting the cell from oxidative damage (Flohe, 
1973). Selenocysteine, although chemically similar to cysteine, has a number of unique 
properties including high electrophilicity (Stadtman, 1996) and a low pKa (5.2 vs 8.3 
for cysteine - Huber, 1967). The consequence of the low pKa is that at physiological 
pH, the selenol group is mainly in its anionic selenolate form whilst the thiol group of 
the cysteine is protonated. The result of this is that at -pH 7, selenocysteine is -10 times 
more reactive than cysteine (Sandman, 2000, Johansson, 2005) and it remains reactive 
down to pH 5.2 (Sandman, 2000). 
Perhaps the most interesting aspect of selenocysteine (and also pyrrolysine) is their 
incorporation into proteins. There are 64 possible triplet codons using the four nucleic 
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acid bases. 61 of these are used for the incorporation of the twenty standard amino acids 
and three act as a terminator of protein synthesis, i.e. stop codons. It is the opal stop 
codon (TGA/UGA) that is utilised for selenocysteine incorporation. 
The incorporation of selenocysteine requires four gene products (Bock 1991). The first 
gene, SetC, encodes a unique tRNA molecule associated with selenocysteine known as 
tRNASec . The tRNASec molecule has evolved to have a different primary and secondary 
structure to the standard tRNAs. It has a longer acceptor stem and variable arm, and has 
base substitutions at several positions which are conserved amongst the other standard 
tRNAs (Bock, 1991, and Schon, 1989). tRNASec is initially synthesised containing a 
seryl residue (Ser-tRNA) which is then converted to a selenocysteinyl moiety (Sec-
tRNA) by the enzyme selenocysteine synthase (SetA product). The synthase uses 
selenomonophosphate (synthesised from a sodium selenite source and A TP by the SelD 
gene product selenophosphate synthetase) as the selenium donor (Bock, 1991, Fischer, 
2007). 
Incorporation of tRNA Sec into the opal stop codon requires the SelB gene product and a 
38 nucleotide long hairpin stem loop contained within the mRNA of the selenoprotein 
known as the "SElenoCysteine Insertion Sequence" (SECIS) element (Figure 4.4, Bock, 
1991). Within prokaryotes the SECIS element is located immediately downstream of 
the opal stop codon (Sandman, 2003), whereas it can be located further away in 
eukaryotes. This aspect makes expressing eukaryotic selenoproteins in E.coli 
problematic. The SECIS element's function is to recruit the SeLB gene product to the 
ribosome where it catalyses selenocysteine insertion into the opal stop codon using 
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tRNASec and GTP (Johansson, 2005): The exact mechanism of these events is still not 
known in detail (Fischer, 2007). 
Ser-tRNA Sec-tRNA 
SelA + SeP 
) 
Ribosome 
Figure 4.4. Incorporation of selenocysteine into the opal stop codon in prokaryotes. 
In 2000, Sandman et ai, working for New England Biolabs, inserted selenocysteine into 
position 1 of the M13 pill coat protein. Their aim was to increase the diversity of phage 
display libraries by allowing specific targeting of the selenocysteine with small 
molecules using thiol-like (selenol) chemistry, i.e. iodoacetyl or maleimide chemistry. 
The specificity of the selenocysteine targeting was needed because of the endogenous 
M13 cysteines. pIX, pVI and pVil all have one cysteine, whilst pIlI has 8 and pVIII has 
none. To date, this mutant phage has only been used to tag the M13 bacteriophage with 
biotin. Khalil, et al. have used this method to tether the M13 molecule to a streptavidin-
coated bead, allowiJ;lg for stretching experiments to be performed to measure the 
persistence length of the M13 particle (Khalil, 2007). 
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However, there is no reason why the selenocysteine residue, when displayed on pIlI, 
cannot react specifically with spherical gold nanoparticles or maleimide-coated 
quantum dots to create higher order structures where multiple phage are bound to a 
single nanoparticle. Higher order structures created in this manner, i.e. with either two 
phage or three phage bound to a single nanoparticle, could be used as scaffolds to create 
a molecular transistor (as described in Chapter 1, section 1.7 and Figure 1.16) with the 
nanoparticle acting as the island and the phage acting as a template for specific gold 
deposition on their surface to create the source, drain and gate electrodes. 
4.1.5 Aims of the work described within this Chapter 
The aims were as follows: 
1. To reproduce pIlI selenocysteine displaying phage (M13pIIISel). 
2. To fabricate higher order structures using M 13pIlISel and bind gold 
nanoparticles and quantum dots specifically to the selenocysteine amino acid. 
3. To purify the higher order structures. 
4. To fabricate higher order structures using microphage. 
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4.2 Results and Discussion 
4.2.1 Display of selenocysteine on pIlI 
A clone was constructed to insert the selenocysteine containing peptide (S A R V U H 
G P S V A G L H Q S A, where U is selenocysteine) into position 1 of pIlI, creating the 
M 13 mutant termed M 13pIlISel. The selenocysteine sequence was first devised by 
Sandman, et al. (2000) to allow for greater diversity within a phage display library, e.g. 
by covalently attaching small molecules to the selenocysteine. Therefore, the four 
upstream amino acids (S A R V) and three downstream amino acids (H G P) are the 
result of a randomized library. Within the original paper 10 sequences were created 
containing selenocysteine. All 10 were found to produce viable phage but only one (S A 
R V U H G P S V A G L H Q S A) was used for further experiments. Therefore instead 
of S A R V H G P any arbitrary amino acids could be used or perhaps removed 
altogether. Since the selenocysteine containing peptide had been shown to react 
successfully with small molecules (Sandman, 2000) it was decided to use the same 
sequence within this study. The remaining downstream amino acids (S V A G L H Q S 
A) are far more restricted since the DNA sequence encoding these amino acids creates 
the SECIS element needed for selenocysteine incorporation. 
To create M 13pIIISel, PCR amplification was carried out using the overlapping primers 
Biotinfor and Biotinrev (Chapter 2, section 2.3.1) to produce a product -70 bp in length 
(Figure 4.5 A). This was cloned into gIll between the Acc65 I and Eag I sites of M 13KE 
(New England Biolabs, Ipswich, MA, U.S.A.). This corresponds to position 1 of the 
mature pIlI protein (Figure 4.5 B). Therefore selenocysteine was displayed at position 5 
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of the altered pIlI. The ligation reaction was transformed into E.coli and plated onto 
agar containing 2 11M sodium selenite (explained in section 4.2.2). Ten colonies were 
then picked and sequenced which confirmed that they contained the selenocysteine 
sequence. One was carried forward for further experiments and was termed M13pIlISel 
(Appendix B, section 1.0). 
A IObp ladder peR 
70bp - 70 bp selenocysteine DNA fragment 
B Position 1 
+ 
N-terminus -S A R V U H G P S V A G L H Q S A S A E T V ESC L A 
-+ First 10 amino acids of pIli 
Position 5 
Figure 4.5. Amplification of DNA fragment encoding for selenocysteine containing 
peptide. Shows 0.8 % w/v agarose gel run at 120 V for 1 hour and stained with 
ethidium bromide (A). The DNA fragment was created by PCR amplification using 
biotinfor and biotinrev primers. B shows the position of the selenocysteine (U) 
containing peptide within the mature pIlI protein of t,he M13pIIISel phage. 
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4.2.2 Incorporation of selenocysteine into M13pIIISel 
Production of selenocysteine containing proteins requires the addition of 2 !AM sodium 
selenite (Sandman, 2000) to a culture of E.coli. The sodium selenite acts as a source of 
selenium atoms for the SelA protein (Figure 4.4). This extra selenium is added to ensure 
that enough selenocysteine is produced by the E.coli cells to be incorporated by the 
phage displaying selenocysteine. When the E.coli cell has insufficient selenocysteine, or 
there is incorrect incorporation, the ribosome reads the selenocysteine codon as a stop 
codon and so terminates protein synthesis. This aspect of selenocysteine insertion acts 
as an in-built control. Since the selenocysteine containing peptide was cloned into 
position 1 of pIlI, it should mean that if selenocysteine is not incorporated into pIlI then 
the rest of the pIlI protein should not be produced. pIlI is needed for successful phage 
assembly (Clackson, 2004), and therefore any pIlI particles incorporated into a 
M 13pIIISel particle must contain selenocysteine. Therefore any viable phage should 
also contain selenocysteine. It was found that when M13pIIISel replicative form (RF) 
DNA was transformed into E.coli and plated on agar plates lacking any sodium selenite 
supplement that no plaques were observed. When 2 !AM sodium selenite was added the 
transfection efficiency was equivalent to that of wild-type M13KE DNA (-1 x 108 
plaques/ng of DNA). 
4.2.3 Titer of M13pIIISel 
The display of peptides on pIlI has been reported to lower phage titer (Loset, 2008). The 
addition of 2 !AM sodium selenite to produce M13pllISel may also affect titer, although 
this was not discussed in Sandman et al. (2000). To examine the effect of sodium 
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selenite on infectivity, the RF DNA of M13pIlISei and wild-type was transformed into 
E.coli and plated on agar containing 2 ~M sodium selenite. The plaques of M13pIIISel 
were observed to be approximately half the size of wild-type phage plaques. This is 
consistent with a lower infectivity (Petrenko, 2000). M13pIIISel and wild-type M13 
phage were grown in 1 L of E.coli cultured in super-broth (SB) medium supplemented 
with 2 ~M sodium selenite and then PEG purified. Using an average of five 1 L 
cultures, the M 13pIlISei phage were found to have a lower titer than wild-type M 13 (-2 
X 109 pfu/mL vs -4 x 1012 pfu/mL). The absorbance at 269 nm of the phage stocks were 
also used to calculate the number of phage particles within the solution (Chapter 2 
section 2.1.6.2). The absorbances suggested values of -20 x 1013 virions/mL for 
M13plIISei compared to -3 x 1013 virions/mL for wild-type phage. The observation 
that during PEG purification that M 13pIIISel produced more precipitate than wild-type 
indicates that the virions/mL values are correct. 
Obviously there is a large discrepancy between the pfu/mL and virions/mL values. The 
likely reason for the differences is that display of peptides on pIlI decreases infectivity 
(Loset, 2008) and the titer is a direct measurement of phage infectivity. The presence of 
the selenocysteine containing peptide therefore appears to have an adverse affect on the 
function of pIlI. However, to produce the phage particles, a single plaque of the phage 
was added to an overnight culture of E.coli which had been diluted 1 in 100 within the 
SB medium, i.e. 10 mL of E.coli within 1 L of SB. Therefore if infectivity is adversely 
affected by the insertion of the peptide within pIlI then one would expect the infection 
of the E.coli to be slower for M13pIlISel than wild-type and so fewer phage particles 
produced. However, the virions/mL values indicate that the selenocysteine containing 
peptide increases the number of phage particles produced. A suitable explanation for the 
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increase in phage numbers cannot be provided. However, these differences between 
pfu/mL and virions/mL highlight the difficulty in relying on phage titer to determine 
phage particle numbers. For the work described in this Chapter I decided that the 
virions/mL values would be used since the M 13plIlSel particles must contain pIli 
molecules displaying selenocysteine (section 4.2.2). 
4.2.4 Fabrication of higher order structures with gold nanoparticies 
As described in Chapter 1, a molecular transistor is made of three electrodes (source, 
drain and gate) surrounding an island. Preferably the island should consist of a semi-
conducting material, allowing for greater control and use of the transistor at room 
temperature. However, a purely metallic island can also be used, although these are 
restricted by needing extremely low temperatures to operate (Yamaguchi, 2010). 
Therefore in this study, two types of nanoparticle were examined as possible islands: 
gold nanoparticles and semi-conducting quantum dots. Although gold nanoparticles 
would be a disadvantage in the final device, they are cheaper and therefore they were 
used initially to establish reaction conditions and so on. 
100 !!L of 1 x 1012 virions/mL M13pIIlSel phage were mixed with sodium citrate 
stabilised 10 nm gold nanoparticles (GNPlOnm/cit) at a ratio of 35 phage particles per 
gold nanoparticle. Sodium citrate is a commonly used stabilising agent which also acts 
as the reducing agent in the formation of the gold nanoparticles. It adsorbs onto the 
surface of the nanoparticles, leading to a net negative charge that repels nanoparticles 
from one another and stops aggregation. 
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A set of conditions were established for the mixing and purification of the GNPlOnmlcit 
and phage structures. The mixture was incubated overnight at room temperature and 
loaded onto a 12 mL 30-60% w/v linear sucrose gradient. The tubes were then 
centrifuged at 18500 rpm for 18 hours at 4°C before being fractionated whilst measuring 
the absorbance at 260 nm. These conditions were used for all the linear sucrose gradient 
experiments discussed in this chapter and are described as sucrose purification. 
Sucrose purification of M13pIlISel particles only (with no GNPI0nmlcit present) 
showed that the phage migrated principally as a single band (Figure 4.6 A) through the 
gradient. When only GNPI0nmlcit were sucrose purified, they were observed to form a 
red pellet at the bottom of the tube (the same colour as the nanoparticle solution). When 
M13pIlISei and GNPlOnmlcit were mixed, two peaks were observed (Figure 4.6 A and 
B). Examination of peaks A and B with TEM revealed that peak A consisted of phage 
only (Figure 4.6 C) whilst B contained phage (the vast majority were 2 to 4 phage) 
bound to single gold nanoparticles (Figure 4.6 D-F). Importantly, gold nanoparticles 
were never seen at both ends of a phage particle, suggesting that the gold nanoparticles 
only bound to the selenocysteine displayed on pIlI. 
Gold nanoparticles are very dense and it is unsurprising that they pellet to the bottom of 
the centrifuge tube. In an attempt to stop the gold nanoparticles from forming a pellet a 
70% w/v sucrose cushion was used for a single experiment. A cushion is commonly 
used to stop a sample pelleting. A 30-60% w/v linear sucrose gradient was created with 
a 1 mL 70% w/v cushion at the bottom. 500 ilL of - 10 nM GNPI0nmlcit were then 
loaded onto the sucrose gradient and centrifuged at 18500 rpm for 18 hours at 4°C. 
However, it was observed that the gold nanoparticles. still pelleted. 
Page 156 
100 
A260 (a.u.) 
Chapter 4 
IISel and GNPlOnmlcit 
IISel 
,e blank 
)nmlcit 
A 
3 6 9 
Elution volume (mL) 
B 
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Figure 4.6. Linear sucrose gradient purification of M13pIIISel phage particles 
bound to gold nanoparticles. C-F show TEM images of phage higher order structures 
found in peak A and B. Scale bar equals 200 nm. Arrows highlight gold nanoparticles. 
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Gold nanoparticles bound to phage particles did not pellet, suggesting that the phage act 
as a "parachute", providing enough drag to keep the gold nanoparticle within the 
gradient. Obviously, the reverse is also true: when phage are bound to a gold 
nanoparticle, the increased density of the nanoparticle acts as an anchor and drags the 
phage away from any unbound phage and so produces the second peak (Figure 4.6 B). 
As a control, 100 f.lL of 1012 virions/mL M13pIIISel or wild-type M13 were mixed with 
GNPlOnmlcit (at a 35 phage to 1 gold nanoparticle ratio) and sucrose purified (Figure 
4.7). Three peaks were observed. Peak 1 did not contain phage or gold nanoparticles 
(results not shown). This peak corresponds with a yellowish area observed at the top of 
the gradient after centrifugation. The colour suggests that this is the buffer that the gold 
nanoparticles are suspended in which contains tannic acid: a solute with a yellowish 
colour. Peaks 2 and 3 corresponded with peaks A and B in Figure 4.6. Unexpectedly, 
wild-type M13 also bound to gold nanoparticles, although with much less efficiency 
than with M13pillSel phage, i.e. peak 3 was -40% smaller for wild-type. It has been 
reported that selenocysteine is more reactive to gold(I) than cysteine (Isab, 1994) and so 
selenocysteine may also be more reactive than cysteine to metallic gold. If, however, 
selenocysteine and cysteine have the same reactivity to gold, then the presence of -5 
copies of selenocysteine would naturally increase the affinity of the phage particle for 
the gold nanoparticles . What this result does show is that out of the eight endogenous 
pIli cysteines, one or more of them are accessible to the gold nanoparticle. 
The most obvious candidate cysteine to investigate is located at position 7 of the mature 
pIn coat protein nearest the N-terminus (A E T V E S C). It was thought that removal of 
this cysteine might decrease phage viability. There~ore M13C (Chapter 3), a wild-type 
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Figure 4.7. Linear sucrose gradient purification of M13pIIISei and wild-type M13 
phage particles bound to gold nanoparticles. 
phage containing a chloramphenicol resistance gene to allow for selection, was used to 
create a pIlI (C7G) mutant. This was achieved by substituting T by a G at position 
1650 of the published M13KE sequence (New England Biolabs, Ipswich, MA, U.S.A.) . 
The substitution was done by site directed mutagenesis using the primers pIIIremovalfor 
and pIIIremovalrev (Chapter 2, section 2.3.4). After mutagenesis the clones were 
transformed into E.coli and plated onto agar plates containing chloramphenicol. Ten 
colonies were then picked and sequenced which confirmed that they all contained the 
desired sequence. One was carried forward for further experiments and was termed 
M13pIIIC (Appendix B, section 2.0). However, all attempts to produce M13pIIIC phage 
failed. Therefore, it appears that removal of the Cys7 makes the phage non-viable. No 
further work was carried out to ascertain which naturally occurring cysteine is 
accessible to the gold nanoparticle. Since M 13pIIISel was more efficient at binding to 
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gold nanopartic1es than wild-type phage, and could be produced in greater amounts, it 
was decided to continue using it in further experiments. 
Another experiment was carried out using phosphine (PH3) stabilised gold nanopartic1es 
to investigate the mechanism by which the phage were binding to the citrate stabilised 
gold nanopartic1es. Phosphine is another commonly used stabilising agent in 
nanopartic1e synthesis (Shem, 2009). When M13pIIISel were mixed with phosphine 
stabilised gold nanopartic1es it was found that no phage bound to the gold nanopartic1es, 
as evidenced by the lack of the second peak in the gradient (Figure 4.8). Therefore the 
M13pillSel phage appear to only bind to citrate stabilised gold and not when phosphine 
is used. This may suggest that the phage are interacting with the citrate instead of the 
gold. However, no reports of citrate interacting with cysteine or selenocysteine have 
been published. It is therefore more likely that the citrate is more easily displaced than 
the phosphine, allowing direct interaction with the gold surface. 
100 
- Phosphinc Slabili sl..'<I 
- Cilrtl1C stabilised 
A 260 (a.u.) 
3 6 9 12 
Elution volume (mL) 
Figure 4.8. Linear sucrose gradient purification of M13plIISei and phosphine 
stabilised gold nanoparticles. 
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4.2.5 Investigation into the concentration relationship between 
M13pIIISei and gold nanoparticles 
How the higher order structures identified above depended on the relative 
concentrations of M13pllISel and gold nanoparticles was then investigated. To this end, 
M13pIIISel was mixed with varying concentrations of GNPIOnm/cit. The M13pIIISel 
concentration (-1 x 1012 virions/mL) was kept constant and the GNPI0nm/cit were 
titrated from 35: 1 (phage:GNPIOnm/cit) to 1 :5. The mixtures were then allowed to 
equilibrate overnight at room temperature and then purified on a 30-60% w/v linear 
sucrose density gradient as described earlier. 
Upon fractionation four peaks were observed (Figure 4.9). The first three peaks (1-3 
Figure 4.9) migrated similarly to peaks observed in earlier experiments (Figure 4.7). 
Peak 4 (Figure 4.9) was not present in earlier experiments where high phage to 
GNPlOnm/cit ratios were used. As the ratio decreased, peak 4 increased. Only at ratios 
of 3.5: 1 and below was peak 4 substantial. 
Peak 1 once again corresponded to the buffer GNPlOnm/cit were suspended in. This 
conclusion is further supported by the increasing size of peak 1 as more gold was used, 
cf. 35: 1 and 1:5 samples. 
Peak 2 (Figure 4.9) contained single phage particles only. The size of the peak 
decreased at lower phage: GNPlOnm/cit ratios, and was completely absent in the 1:5 
sample (the grey line in Figure 4.9 A). 
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Figure 4.9. Concentration dependence of M13pIIISei and GNPIOnm/cit in 
fabricating higher order structures. Mixtures were purified on a 30-60% w/v linear 
sucrose gradient and fractionated at 260 nm. Scale bar equals 200 nm. 
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Figure 4.10. Quantitation of sucrose purified higher order structures. Shows the 
number of higher order structures found in peak 3 of Figure 4.9 (A) and peak 4 of 
Figure 4.9 (B) . Peaks 3 and 4 were collected as 1 mL fractions from three different 
experiments (highlig~ted in Figure 4.9 A) and the number of structures counted using 
TEM (n = 50 for each fraction). 
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Peak 3 (Figure 4.9) was found to contain higher order structures (Figure 4.9 B). These 
consisted of two, three of four phage particles attached to a single gold nanoparticle. At 
the highest levels of phage to GNPlOnm/cit (35: 1), ~85% of the population consisted of 
3 or more phage bound to a single gold nanoparticle (Figure 4.10 A). At lower 
phage:GNPlOnm/cit ratios (3.5: 1 and lower) the 3 or more phage bound to a single gold 
nanoparticle population fell to ~O, whilst the population consisting of one or two phage 
bound to a single gold nanoparticle increased. A small percentage of the population 
consisted of single phage and phage attached to multiple gold nanoparticles. 
Peak 4 (Figure 4.9 A) contained a mixture of phage bound to mUltiple GNPIlOnmcit; 2 
phage bound to a single gold nanoparticle; and single phage bound to single gold 
nanoparticles (Figure 4.9 C). When an excess of GNPlOnm/cit was used (l phage 
particle per 5 GNPlOnm/cit) the majority of the population (76%) comprised of single 
phage bound to single gold nanoparticles (Figure 4.10 B). 
In order to try and improve separation, other linear sucrose gradients were tried: 5-60% 
w/v, 10-60% w/v, 25-60% w/v, 25-50% w/v, 10-45% w/v, 10-25% w/v and 5-45% w/v 
(results not shown). However, they did not produce as good a separation as the 30-60% 
w/v linear sucrose gradient. 
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4.2.6 Fabrication of higher order structures with M13pIIISeJ and 
quantum dots 
4.2.6.1 Fabrication using 14 nm quantum dots 
As discussed earlier, quantum dots (QD) would be the preferred island within a 
molecular transistor since they would allow it to be used at room temperature. Therefore 
experiments were undertaken to fabricate higher order structures with quantum dots and 
M13pIIlSei phage. 
Commercially available quantum dots were used with a fluorescence emission of 525 
nm. These quantum dots consist of a CdSe/ZnS core with a surrounding PEG layer 
terminating in an amino group that is available for functionalisation with sulfo-SMCC; 
a hetero-bifunctional cross-linker that endows the quantum dots with a maleimide group 
(see Chapter 2, Table 2.3 for more details). The theoretical diameter of the QD after 
functionalisation with sulfo-SMCC is approximately 14 nm. This is slightly larger than 
the 10 nm gold nanoparticles used earlier. The maleimide group was then used to create 
a covalent selenol bond with the pIlI displayed selenocysteine. 
To create higher order stfUctures using maleimide-functionalised QDs, the knowledge 
gained from working with GNPlOnmlcit was used. 100 /-lL of M13pIlISel (-1 x 1012 
virions/mL) was mixed with freshly created maleimide functionalised QDs (maleimide 
hydrolyses very quickly in aqueous solutions at pH 7.5 and therefore cannot be stored 
successfully) at different ratios of phage to QD (from 35 phage per QD to 1 phage to 5 
QD). Once again, the concentration of M13pIIlSel was kept constant whilst increasing 
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that of the QDs. The mixtures were then allowed to equilibrate overnight and analysed 
on a 30-60% w/v linear sucrose gradient (the same set of conditions was used as above 
in section 4.2.4) A very different result was obtained (Figure 4.11 A) compared with 
gold nanoparticles (Figure 4.9). 
Peak 1 contained no phage or quantum dots (Figure 4.11 A). This peak had no colour 
but is likely to be the buffer that the quantum dots were suspended in. Peak 2 contained 
quantum dots only (Figure 4.11 B) and peak 3 contained what appeared to be a mixture 
of single phage only and higher order structures (Figure 4.11 C-E), although the contrast 
of the images was poor. However, there was no separate higher order structure peak. 
Measuring the emission of the peaks at 525 nm (results not shown) showed that QDs 
were present in peaks 2 and 3. The presence of QDs in peak 3 may explain the rising 
absorbance seen as the amount of QDs increased since the quantum dots have a high 
absorbance at 260 nm, cf. 35: 1 to 1:5 ratios in Figure 4.11. 
Although the phage may have been binding to the QDs (although the results are less 
than convincing) the result shows that a linear sucrose gradient does not separate phage 
bound to QD from unbound phage. The reason for this is the molecular weight of the 
525 nm emission QD. Unlike GNPlOnm/cit, QDs don't pellet at the bottom of the tube 
but instead migrate above the phage. Therefore the QDs don't have enough mass to 
drag the bound phage away from the unbound phage. 
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Figure 4.11. Fabrication of higher order structures using M13pIIISei phage and 
525 nm emission QDs. Purified using 30-60% linear sucrose gradient (A) . Scale bar 
equals 200 nm. Arrows highlight quantum dots. 
Page 167 
Chapter 4 
4.2.6.2 Fabrication using 22 nm quantum dots 
The results of M13pIIISel mixed with gold nanoparticles and 525 emission QDs shows 
that the mass of the nanoparticles is the most important aspect for the separation of 
bound phage from unbound phage. To test this hypothesis, and to fabricate higher order 
structures with QDs, the heaviest commercially available QDs were used. 
The 800 nm emission QD (which inconveniently emits at the near-infrared wavelength 
and was unable to be detected with the instruments available) consists of a core of 
CdTeSe/ZnS and when functionalised with maleimide has a diameter of 22 nm, i.e. 64% 
larger than the 525 nm emission QDs. The same experiment was repeated with these 
larger QDs (with the different ratios of M13pIIISel to 800 nm emission QDs) and 
analysed on a linear sucrose gradient. Four peaks were observed (Figure 4.12 A). Peak 1 
contained single phage only. Peak 2 contained higher order structures consisting of two 
or three phage attached to a single quantum dot (Figure 4.12, B-E). Peak 3 contained 
single phage attached to 1 or 2 QDs (Figure 4.12, F and G). Peak 4 contained QDs only 
and shows that the 800 nm emission QDs, whilst heavier than the 525 nm QDs, were 
still lighter than the 10 nm gold nanoparticles. This difference in mass resulted in the 
peaks being far closer together (when compared to M13pillSel and GNPlOnmlcit in 
Figure 4.9) and therefore there were high levels of cross contamination between the 
peaks. 
Therefore, even with the heaviest QDs available, using linear sucrose gradients still 
didn't provide ideal separation of higher order structures from unbound phage and 
phage bound to a single QD. 
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Figure 4.12. Fabrication of higher order structures using M13pIIISel phage and 
800 nm emission QDs. Purified on a 30-60% linear sucrose gradient (A). Scale bar 
equals 200 nm. B, E, F and G taken on CCD camera. 
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4.2.7 Purification of higher order structures using size exclusion 
chromatography 
Linear sucrose gradients are relatively successful in the purification of higher order 
structures, i.e. they can roughly separate higher order structures from single phage and 
single nanoparticles. However, what is needed is a method to separate the higher order 
structures from one another so that three phage bound to a nanoparticle can be separated 
from two phage bound to a nanoparticle. The work described above shows that linear 
sucrose gradients cannot provide that resolution. Therefore size exclusion 
chromatography was used in an attempt to purify the individual higher order structures. 
The size of M13 has been given as -20 megadalton (Zakharova, 2005; Smith, 2005, 
Donzeau, 2006), which is a relatively large particle. At 2 x 107, only Sephacryl S-
1000SF (superfine), commercially available from GE healthcare (Fairfield, Connecticut, 
U.S.A.), provides the separation range needed: -5 x 105 to -5 X 108. To maximise 
resolution, a 90 cm (length) x 1.5 cm (width) column was used with a volume of -150 
mL. 
The higher order structures were created as described previously with 100 I-tL of 
M13pIIISel phage (1 x 1012 virions/mL) mixed with nanoparticles, gold or 525 nm 
emission QD, at a ratio of 1.4 phage per nanoparticle. The final volume of the reactions 
was typically 200 I-tL, which is far lower than the recommended 1 % of column volume 
for sample loading to have a good resolution. Once again, since the gold nanoparticles 
were cheaper than the QDs, the gold nanoparticle higher order structures were ran first 
on the column. Upon loading of the gold nanoparticles and phage it was observed that a 
red band appeared at the top of the column. After 1.5 column volumes to elute anything 
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passing through the column nothing was observed to elute off the column (result not 
shown). Repeated attempts resulted in the red band at the top of the column to increase 
in size. Repeated washing of the column failed to move the band. On the suspicion that 
the gold nanoparticles were associating tightly with the sephacryl S-1000, smaller scale 
experiments were undertaken. 
These experiments consisted of using a 1 mL spin column loaded with 200 [,lL of 
sephacryl S-1000, which was washed with H20 and then PBS buffer pH 7.2. Addition 
of 100 [,lL of 10 nm gold nanoparticles, followed by low speed centrifugation (5000 xg), 
resulted once again in a red band at the top of the sephacryl. Washes with 5 M NaCl, 0.5 
M NaOH and 30% isopropanol (standard wash techniques provided by GE Healthcare) 
failed to move the red band. With no thiols present in Sephacryl S-1000 there is no 
obvious chemistry to account for the tight binding of the gold nanoparticles to the resin. 
The same result was obtained when 10 nm gold nanoparticles coated in phosphine (as 
opposed to citrate) were used. Interestingly, when the gold nanoparticles were coated in 
streptavidin (provided commercially by Ted Pella, Redding, California, U.S.A) they 
passed through the resin with no retention. Therefore although phage: gold higher order 
structures cannot be purified using Sephacryl S-1000 it appears that the resin could be 
used to separate coated gold from bare gold, e.g. gold nanoparticles coated by a bio-
molecule or encapsulated within a spherical virus. 
Next, M 13pIIISei mixed with QDs to create higher order structures, were loaded onto 
the 90 cm column. The column was then eluted with 1.5 column volumes (-225 mL) 
and 15 mL fractions collected whilst measuring absorbance at 280 nm (Figure 4.13 A). 
Three main peaks were observed. The counting of different structures within each 
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Figure 4.13. Purification of higher order structures using size exclusion 
chromatography. M13pIIISel were mixed with maleimide functionalised 525 nm 
emission QDs. Mixture loaded onto a 150 mL Sephacryl S-1000SF resin column and 
eluted with 1.5 column volumes (A). The eluate was collected as 15 mL fractions 
(shown by red lines) and number of structures counted using TEM, n = 100 (B). 
Page 172 
Chapter 4 
fraction (Figure 4.13 B), n = 100, shows that although there are discrete peaks, none of 
them appear to relate to any distinct structure. All of the peaks contain a majority of 
single phage with some higher order structures mixed in. Although it is not possible to 
identify any specific structures to account for peaks 1 and 2, peak 3 contained countless 
QDs. Disappointingly, size exclusion also failed to purify higher order structures. In fact 
it performed worse than linear sucrose gradients . 
4.2.8 Fabrication of higher order structures using microphage 
The work described above has shown that higher order structures can be created using 
the M13 bacteriophage. However, since the length of the M13 phage particle is 1 !-lm, it 
means that when two phage are attached to a nanoparticle that the entire device is 2 !-lm 
in size. With regards to a transistor, it is the distance between the source and drain 
electrodes that is important. Since the phage are to be used as scaffolds for the 
deposition of gold to create the electrodes, then the distance between the electrodes will 
be the size of the quantum dot, i.e. 14 or 22 nm. Therefore the 2 !-lm length will not 
affect this important aspect. However, the size limits the number of the transistors that 
could be deposited on a surface. They are also very flexible with a persistence length of 
-1.3 !-lm (Khalil, 2007). This flexibility increases the chance that the phage particles 
attached to the nanoparticle will overlay upon each other; making the device useless. 
The microphage (Chapter 3), at 50 nm in length, would be an ideal way to decrease the 
size of the higher order structures. MicrophagepIIlSel were therefore produced using 
M13K07 helper phage displaying selenocysteine on pIll (M13K07pIllSel). Using 
M13K07pIIlSel resulted in microphagepllISel displaying selenocysteine on pilI. 
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MicrophagepIIISel were then purified using PEGIN aCI followed by Superose 6 size 
exclusion chromatography and resuspended in PBS pH 7.4. The specific amount of 
microphageplIISel is difficult to define since, as discussed in Chapter 3, the microphage 
cannot be titered. It was also found that the peak at 269, used to calculate virions/ mL, 
shifts towards 260 nm. 
3 microphage bound to a 
10 nm gold nanoparticle 
~ 
• 
Figure 4.14. Higber order structures using micropbagepIIISel. Microphage 
displaying selenocysteine on pIlI were mixed with citrate stabilised 10 nm gold 
nanoparticles (A and B). C and D have been digitally altered using Adobe PhotoshopTM 
to compare the higher order microphage structures with higher order structures created 
with wild-type length (-1 !lm) M 13plIISei phage. Scale bar equals 200 nm. 
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The microphagepIIISel solution was measured at the following absorbances; 260 nm: 
1.130; 269 nm: 0.975; 280 nm: 0.664: 320 nm: 0.009. The Abs269 value was used to 
calculate the number of microphagepllISel particles (with a genome size of 221 bases): 
~25 x 1016 virions/mL. A very high value relative to typical phage yields. 
Although the number of microphagepllISel particles was unknown, 100 f!L of the 
microphageollISel solution was mixed with 100 f!L of GNPlOnrnlcit and equilibrated 
overnight at room temperature. Due to time constraints no purification was attempted. 
- However, some of the mixture was placed on a carbon coated TEM grid. The same 
structures were observed (Figure 4.14 A and B) as with wild-type length M13pllISel 
with two and three microphagepIIISel bound to a single gold nanoparticle (inset Figure 
4.14 A) along with single microphagepIIISel bound to single gold nanoparticles (inset 
Figure 4.14 B). When compared with wild-type length higher order structures (Figure 
4.14 C and D) it becomes clear how much smaller the microphagepIIISel higher order 
structures are. At ~ 100 nm in size, they are ~ 20 times smaller. 
4.3 Conclusions and Future Work 
The main aim of the work described within this chapter was to fabricate higher order 
structures. This aim was achieved by engineering M13 bacteriophage to display a highly 
reactive selenocysteine on pilI which would preferentially form a covalent bond with a 
nanoparticle. A secondary aim was to try and purify these structures from unbound 
reactants. As has been shown, the M13 bacteriophage can self-assemble into higher 
order structures with' multiple phage capable of binding to a single gold nanoparticle or 
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quantum dot. The creation of higher order structures with M 13 bacteriophage has been 
investigated before by Huang, et al. (2005). They created an M13 bacteriophage 
displaying a streptavidin-binding peptide on pili and mixed it with gold nanopartic1es 
and quantum dots coated in streptavidin. Although the original publication produced 
higher order structures, of two and three phage bound to a nanopartic1e, the results were 
not convincing (Figure 4.3). The work in this chapter is far more definitive with many 
more examples of higher order structures being fabricated. The method used to create 
the higher order structures was also different. The use of a covalent selenol bond, 
instead of a streptavidin bond, to attach the phage to the nanopartic1es, should result in 
far more stable structures being fabricated. The use of selenocysteine also allows for 
easier fabrication of higher order structures with different nanopartic1es. Instead of 
having to attach a streptavidin to a nanopartic1e, the selenocysteine can be used with just 
the nanopartic1e. Future work could involve fabricating higher order structures with 
different nanopartic1es, e.g. a magnetic nanopartic1e. 
A weakness within this study is the differences between the pfu/mL and virions/mL 
values. For this study I decided to use the virions/mL values since I was more interested 
in the number of phage particles. However, if that assumption is wrong, then all 
comparisons between M 13pllISei and M 13 wild-type are called into question. This 
finding of differences between pfu/mL and virions/mL also calls into question the 
results of previous studies on M 13pIIISel (Sandman, 2000) since pfu/mL values were 
used. 
The observation that gold nanoparticles and quantum dots only bind to one end of the 
M 13 particle strongly indicates that it is the selenocysteine that is forming the bond. 
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However, it was also observed that wild-type phage can also bind to gold nanopartic1es, 
indicating that there is an accessible cysteine within the pIlI molecule. Obviously this is 
an area of future work to ascertain which cysteine (of the eight within pIlI) this is and to 
investigate if it can be removed without affecting phage yield. However, since none of 
the cysteines at the other end of the phage (within pIX and pVII) appear accessible to 
the nanopartic1es then it may not be an issue for the future fabrication of higher order 
structures. 
With regard to purifying the higher order structures there was less success, with linear 
sucrose gradients able to purify the structures away from reactants, e.g. single phage and 
nanopartic1es, but unable to separate the individual structures. There also appeared to be 
a trade off between the purity of the purified higher order structures and the yield. Using 
a large excess of phage to gold nanopartic1es, e.g. 35 phage per gold nanopartic1e, 
provided a sample that comprised -88% of higher order structures (2 or more phage 
bound to a single gold nanopartic1e). However, the size of the peak containing the 
higher order structures (Peak 3 Figure 4.9) was smaller than the peaks found with other 
phage to gold ratios, indicating that the yield is low. Whereas using a small excess of 
phage, e.g. 7 phage per gold nanopartic1e, results in a higher yield but lower purity of 
higher order structures: -60% of the population. 
Future work needs to find a method that can purify the individual higher order 
structures, e.g. two phage bound to a single nanopartic1e from three phage bound to a 
single nanopartic1e. Due to the flexibility of the phage it is unlikely that this will be 
possible with many purification techniques, e.g. agarose electrophoresis and size 
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exclusion chromatography, optimised for globular proteins of regular size. This problem 
may be overcome by using the microphage. 
As has been shown, the microphage can be used to display selenocysteine and fabricate 
higher order structures with two or three microphage bound to a single nanoparticle. By 
using microphagepIIISel it has been possible to miniaturise the higher order structures 
created within this study by 20 times to just 100 nm across. Due to their smaller size, 
they appear to be more rigid and therefore it may be possible to purify these higher 
order structures using caesium chloride or agarose gel electrophoresis. Future work 
would ideally focus on purifying these smaller structures instead of the larger ones. 
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Phage Particle Attachment to a Gold Surface 
The work described within this Chapter investigates whether the coiled-coil ACID:BASE pair 
can be used to anchor M13 phage particles to a surface. 
Chapter 5 
5.1 Introduction 
5.1.1 Coiled-coils 
A coiled-coil forms when two or more amphipathic alpha helices twist around one 
another to form a stable, yet reversible (O'Shea, 1993), left-handed super-coil (Figure 
5.1; O'Shea, 1992). Coiled-coils are known to form dimeric, trimeric and up to 
octomeric structures (Burkhard, 2001; Kohn, 1998). The coiled-coil structure motif is 
found in a large number of proteins: -2 to 5% of all known proteins contain coiled-coils 
(Wolf, 1997), where the motif mediates the oligomerisation of protein subunits 
(Burkhard, 2001). Leucine zippers are well characterised coiled-coils, e.g. the yeast 
transcriptional factor GCN4 (Figure 5.1), which bind to DNA and act as transcription 
factors (O'Shea, 1992). However, coiled-coils are also involved in a wide range of other 
cellular functions, e.g. the creation of the cytoskeleton (Herrmann, 1999) whereby 
coiled-coils form the building blocks of the cytoskeletal filaments. 
N-terminal 
Coil 2 Coil I 
C-terminal 
Figure 5.1. Structure of a coiled':coil. The x-ray crystal structure of the leucine zipper 
GCN4 in a parallel orientation, at 1.8 A resolution, PDB accession code 2zta. 0' Shea, et 
al. (1991). 
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Coiled-coils typically consist of a repeated pattern of 7 amino acids, where the residues 
are conventionally labelled "abcdefg" (Figure 5.2 A), termed a heptad repeat: a coiled-
coil can contain between 2 to 200 repeats (Burkhard, 2000; Kohn, 1997). The heptad is 
repeated every 2 turns of the coil (Landschulz, 1988), and the interactions between the 
amino acids of the heptad repeat are vital to the structure of the super-coil. Coiled-coils 
have been termed "peptide Velcro" (O'Shea, 1993) since the amino acids at positions 
"a" and "d", at the core of the super-coil, overlap one another, much like Velcro, 
forming interactions that stabilise the super-coil. 
The amino acids at positions "a" and "d" are hydrophobic, e.g. leucine, alanine or 
isoleucine, which interact to create the hydrophobiC core of the coiled-coil. This 
hydrophobic core is the main element that stabilises the super-coil. Amino acids at 
positions "b", "c" and "f' play little role in the super-coil, although they must be 
hydrophilic (Graddis, 1993) since they are solvent exposed. The amino acids at 
positions "e" and "g" are charged and are commonly found to be glutamic acid or 
lysine. The charge of these amino acids dictates whether a homo- or hetero-dimer is 
formed (Figure 5.2 B; Shuermann, 1991). When the amino acid residues at "e" and "g" 
are oppositely charged then a homodimer is preferred, e.g. a positively charged lysine at 
"e" and a negatively charged glutamic acid at "g". The oppositely charged residues of 
the coil mean that homodimer formation would result in favourable electrostatic 
interactions, e.g. positive charge to negative charge. Likewise, when the amino acid 
residues at "e" and "g" have similar charge then a heterodimer is preferred due to 
electrostatic repulsion between the charged amino acids. 
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interactions 
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Coil 2 
Figure 5.2. Schematic showing coiled-coil interactions. A shows helical wheels of the 
coiled-coils with the view shown looking along the super-coil axis . a - g represent the 7 
amino acids that make up the coiled-coil heptad repeat. B shows the different 
orientations that coiled-coils can have. 
Page 182 
Chapter 5 
The knowledge of the different roles that each amino acid has within a heptad means 
that coiled-coil pairs have been designed in silico. Perhaps the most well known being 
the ACID:BASE leucine zipper pair designed by O'Shea, et al. (1993). This pair of 
coils are identical except at positions "e" and "g" (Figure 5.3 A) with glutamic acid (E) 
present at positions "e" and "g" within the ACID peptide. Whilst at the same positions 
within BASE there is a lysine (K) residue. The result of this is that heterodimers are the 
pre-dominant species due to the electrostatic attraction of the oppositely charged 
glutamic acid and lysine residues. In the presence of BASE, ACID has a lOS -fold 
preference for heterodimers over homodimers (O'Shea, 1993). An asparagine residue 
(N) was placed within the third heptad repeat at position 14 of ACID and BASE (Figure 
5.3 A). The polar residue stabilises the coiled-coil into the parallel orientation (Figure 
5.2 B) via a hydrogen bond between the asparagine residues of ACID and BASE 
(O'Shea, 1991; O'Shea 1993). By moving the asparagine residues it was possible to 
create ACID:BASE coiled-coils that favoured the anti-parallel (ap) orientation (Oakley, 
1998): termed ACIDap and BASEap (Figure 5.3 B). Within the anti-parallel orientation 
the amino acids at position "a" of ACID interact with those at position "d'" of BASE. 
The ACIDap:BASEap pair has been utilised to create multimeric M13 phage 
nanostructures (Figure 5.3 D; Sweeney, 2006). The ACIDap leucine zipper was 
displayed on pIlI whilst its complementary partner, BASEap, was displayed on the 
opposite end of the phage particle on pIX (Figure 5.3 C). A phagemid system (Chapter 
1, Figure 1.6 A) was used to accomplish the pIlI and pIX display resulting in one 
ACIDaplBASEap pair displayed per phage particle. 
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Multimeric phage nanostructure 
Figure 5.3. The ACID:BASE leucine zipper pair. Shows the sequence of ACID and 
BASE to create parallel (A) and anti-parallel (B) coiled-coils. C shows a schematic of 
the structure of the M13 phage particle created by Sweeney, et al. (2006), whilst D 
shows how the phage bound to one another. 
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Long filaments, the aforementioned multimeric phage nanostructures, were created by 
mixing these altered phage together: on average, -8 phage particles were joined end to 
end via the ACIDaplBASEap interactions. However, in some instances -30 phage 
particles were observed to have formed a 15 !lm long filament (Sweeney, 2006). This 
result suggests that the ACIDaplBASEap pair can be displayed upon the M13 phage 
particle and retain their function . 
5.1.2 Attachment of M13 phage particles to a surface 
The work of Sweeney, et al. (2006) raises the possibility that their use of the 
ACIDaplBASEap leucine zippers on M13 can be extended to attach an M13 particle to 
a gold surface (Figure 5.4 A). The work described within this chapter addresses this 
possibility. The rationale was as follows: firstly, display the ACIDap peptide on pIlI and 
pIX of the M 13 phage particle. The BASEap peptide would then be immobilised onto a 
gold surface using a cysteine-containing linker sequence (OOOSC) that had been added 
to the C-terminus of the peptide. By washing the M13 phage particle displaying the 
ACIDap over the gold s~rface the two coils would interact, forming the coiled-coil, and 
so anchoring the phage particle. This anchoring could then be taken further and used for 
the attachment of the higher order structures created in Chapter 4 to gold electrodes 
(Figure 5.4 B). Using the ACIDaplBASEap pair to attach the higher order structures to 
a surface adds another level of self-assembly and means that the structures can be 
accurately placed onto a surface instead of randomly deposited. 
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A 
pIli M13 phage particle 
BASEap 
B 
M13pIIISel phage higher order structure 
Quantum dot 
Figure 5.4. Schematic of M13 phage particle attachment to a gold surface. The 
rationale of the work described within this chapter to attach a phage (A) and a higher 
order structure (B) to a gold surface. 
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It was expected that the BASEap peptide would retain its function upon immobilisation 
given that other studies have attached coiled-coils to gold surfaces (Schlizerman, 2010; 
Stevens, 2004). However, these studies attached pre-formed coiled-coils to gold 
surfaces, i.e. the coiled-coil was formed in solution and attached to the surface. The 
coiled-coil, comprised of coils between 24 and 76 amino acids long, contained a C- or 
N-terminal cysteine residue on one or both of the coils so they could be immobilised 
onto the gold surface via thiol:gold bonds. A single study has been performed 
investigating coiled-coil formation on a surface (Johnson, 2005). However, he used 
- 210-355 amino acid long proteins containing coiled-coils to perform the experiments. 
5.1.3 Aims of the work described within this Chapter 
The aims were as follows: 
1. To display the ACIDap peptide on pIlI and pIX. 
2. To immobilise BASEap peptide to a gold surface using a cysteine residue. 
3. To investigate the functionality of the BASEap peptide and its ability to interact 
with its complementary partner, ACIDap, and a phage displayed ACIDap 
peptide, using Surface Plasmon Resonance (SPR) and Dual Polarisation 
Interferometry (DPI). 
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5.2 Results and Discussion 
5.2.1 Production and purification of ACIDap and BASEap peptides 
ACIDap (AQLEKELQALEKELAQLEWENQALEKELAQ) and BASEap 
(AQLKKKLQANKKKLAQLKWKLQALKKKLAQGGGSC) were purchased from 
Peptide Protein Research Ltd. (Wickham, Hampshire, u.K.). Peptide Protein Research 
Ltd. had desalted the peptides using High-Performance Liquid Chromatography 
(HPLC) and analysed them using mass spectrometry which confirmed they were the 
correct sequence. However, further HPLC purification was carried out once the peptides 
had arrived. 
Each peptide was HPLC purified usmg a reverse phase CI8-silica Zorbax ODS 
(dimethyl-n-octadecyl silane) column (Agilent Technologies, Santa Clara, CA, U.S.A.). 
The absorbance at 280 nm of the sample was measured and the peaks fractionated 
(Figure 5.5). Both samples were relatively pure with a single large peak (Figure 5.5 A 
and B). However, the BASEap sample gave a trailing peak (Figure 5.5 A) which 
suggested that larger peptides were present. The tail of this peak was also collected 
(Fraction 2). These samples were then analysed using mass spectrometry (Micromass 
Platform II, Waters Corporation, Milford, MA, U.S .A.) which confirmed that the 
peptides contained within fraction 1 were of the correct size (Appendix C, section 1.0). 
The tail of the BASEap sample peak was found to contain peptides -100 Da larger 
(Appendix C, section 1.0). Therefore only the BASEap fraction 1 was used for further 
experiments. 
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Figure 5.5. HPLC purification of ACIDap and BASEap peptides. Purification of 
200 f.tL of 25 mg/mL BASEap (A) and ACIDap (B) peptides using a reverse phase 
Zorbax ODS column (comprised of C-18 silica gel with dimethyl-n-octadecyl silane). 
Running buffer A was 5% v/v acetonitrile, 0.1 % v/v trifiuoroacetic acid (TFA) and B 
was 90% v/v acetonitrile, 0.06% v/v TFA. 
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5.2.2 Analysis of ACIDaplBASEap coiled-coil formation 
Although the ACIDaplBASEap coiled-coil pair has been extensively studied (O'Shea 
1991; O'Shea, 1993; Oakley, 1998), the addition of the GGGSC linker sequence to the 
C-terminal end of the BASEap peptide may have had a deleterious effect on the 
formation of the coiled-coil. Therefore circular dichroism (CD) analysis was carried out 
on the peptides. CD is a technique that uses circularly polarised light to determine the 
secondary structure of a protein sequence. Certain secondary structures produce 
characteristic traces, e.g. an alpha-helix produces a W -like shape. 
The ACIDap and BASEap peptides were re-suspended in phosphate buffer pH 7.5. The 
two peptides were analysed separately and showed no clear evidence of helical structure 
(Figure 5.6). Upon mixing the two peptides together for 30 seconds, the helical content 
of the sample increased dramatically with strong CD minima at -208 and 222 nm 
(Figure 5.6). This strongly suggested that the peptides were forming a coiled-coil 
structure. This repeats a previously published CD experimental result using the 
ACIDplBASEp pair (0' Shea, 1993) which formed parallel coiled-coils and lacked the 
GGGSC linker sequence (O'Shea, 1993). Therefore the addition of the GGGSC peptide 
sequence appeared to have no effect on the formation of the coiled-coil within solution. 
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Figure 5.6. Circular dichroism of the ACIDaplBASEap leucine zipper pair. 300 r-tL 
of 0.2 mg/mL ACIDap and BASEap peptide were measured separately and then mixed 
together. 
5.2.3 Display of leucine zippers on the M13 bacteriophage 
5.2.3.1 Display of ACIDap on pIX 
N-terminal display of peptides on pIX is problematic because the start codon (ATG) of 
pIX overlaps with the stop codon (TGA) of p VII. The standard practice is to use a 
phagemid system of display (Chapter 1, section 1.4.1). To this end, the phagemid 
Page 191 
Chapter 5 
pCGMT-lb (kindly provided by Dr Bin Zhou, The Scripps Research Institute, La Jolla, 
CA, U.S.A.) was used (Figure 5.7 A). Using this phagemid system resulted in the 
ACIDap peptide displayed at position 1 of pIX with a hexahis (HHHHHH) tag at the N-
terminal end of ACIDap (Figure 5.7 B). The hexahis tag was used for downstream 
purification of the ACIDap displaying phage particles from phage that did not display 
the peptide. 
The ACIDap DNA sequence was created by PCR usmg the overlapping primers 
ACIDfor, ACIDtemplate and ACIDrev (Chapter 2, section 2.4.1). The PCR product was 
then ligated into the pIX gene of the phagernid pCGMT-lb between the Pstl and 
HindliI restriction sites. Following transformation into E.coli, 5 colonies were picked 
and sent for sequencing which confirmed that the ACIDap DNA sequence had 
successfully been inserted into pIX. One was carried forward for further experiments 
and termed pCGMTpIXHisACIDap (Appendix C, section 2.0). 
5.2.3.2 Production and purification of M13pIXHisACID 
M13K07 phage displaying ACIDap on pIX were produced from 
pCGMTpIXHisACIDap using the method of Gao, et al. (2002). 5 L of super-broth 
medium, inoculated with E.coli ER2738 containing pCGMTpIXHisACIDap, were 
grown to an OD6oo of -0.5 in the presence of carbenicillin and tetracycline. The pIX 
gene within pCGMT -1 b is under the control of the lac promoter. Therefore Isopropyl p-
D-l-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM along 
with 1 x 1012 pfu/mL of the helper phage M13K07. The culture was then incubated at 
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37°C with shaking for a further 2 hours before kanamycin was added and the culture 
grown overnight at 2SoC with shaking. The phage were then purified using the standard 
PEGlNaCl method. These phage displaying the ACIDap peptide were termed 
M13pIXHisACIDap. 
A 
B 
Leucine zipper DNA 
sequence inserted here 
" Pst! Hind'" 
THP terminator 
0 pIX 
tJ ompA leader sequence 
pCGMT-1b 
3170 bp . Ampicillin 
Hexahis tag pIX 
HHHHHHAQLEKELQALEKELAQLEWENQALEKELAQSGGSGMSVLVYSFASFVLGWCLRSGITYFTRLMETSS 
ACIDap 
C 
Hexahis tag pIX 
HHHHHHLTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHSGGGSGMSVLVYSFASFYLGWCLRSGITYFTRLMETSS 
FOS 
Figure 5.7. Display of the ACIDap peptide on pIX. Shows the phagernid pCGMT -1 b 
(A) used to display the ACIDap (B) and FOS (C) peptides on pIX. 
The use of phagemid vectors to display peptides typically results in 10% of the phage 
population displaying the desired peptide (Clackson, 2004). The rest are termed "bald" 
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since they display no peptide. Therefore the N-terminal hexahis tag was utilised to 
purify the phage displaying the ACIDap peptide (Figure 5.7 B). The PEGlNaCI purified 
phage were washed across a HisTrapTM column (GE Healthcare, Little Chalfront, 
Buckinghamshire, UK.). These are pre-packed with Ni Sepharose High Performance 
resin and charged with Ni2+ ions. Hexahistidine tags have a high affinity for the Ni2+ 
and therefore associate tightly with the column (Schmitt, 1993). Therefore the phage 
displaying ACIDap on pIX could be purified from the bald phage. When the 
M 13pIXHisACIDap phage were loaded onto the column it was observed that large 
numbers of phage, confirmed by titering, did not interact with the resin (Figure 5.8 A) . 
Bound phage were then eluted with an increasing imidazole concentration (Figure 5.8 
B): imidazole competes for the Ni2+. Two peaks were observed at -120 mM and -200 
mM imidazole concentration (Figure 5.8 B, peaks 1 and 2). These likely represent one 
or two pIXHisACIDap peptides being displayed on the phage. If so then the majority of 
the purified population consisted of phage displaying a single ACIDap peptide (Figure 
5.8 B, peak 1). When wild-type M13K07 phage were loaded onto the column instead of 
M13pIXHisACIDap then no peaks were observed upon imidazole elution (Figure 5.8 
B). The purified M13pIXHisACIDap phage, and the bald phage that passed through the 
column, were then titered. On average it was found that between 5 - 10% of the initial 
phage population displayed at least one pIXHisACIDap peptide. Mass spectrometry was 
then attempted upon the phage to determine if ACIDap was present. However, the 
signal from the major coat protein pVIII, -2700 copies per phage, dwarfed that of pIX, 
-5 copies per phage, so the display of ACIDap could not be confirmed. However, the 
presence of the hexahis tag, together with the correct DNA sequence of this construct, 
means that the ACIDap peptide must be present. 
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A. Loading of M13pIXHisACIDap on HisTrap column 
3500 
Phage di splaying no pIXHisACIDap 
3000 I r· -~ ,f , I 
2500 
A 280 (mAu) 2000 
1500 
- M13pIXHisACIDap 
1000 
500 
O +---~L---~--~----~--~----~~~ 
o 2 4 6 8 10 
Elution volume (mL) 
12 14 
B. Elution of phage from HisTrap column using imidazole 
890 , 
-------------- -
100 
1 , - Ml 3plXHisAClDap , 
790 , - MI 3p IXHisFOS 90 , 
, - Wild-type 
I 
- Buffer only 80 690 I I 
- - Imidazole I 
I 70 590 I I 
I Imidazole I 60 
490 I I 50 concentration (%) A280 (mAU) I I 
390 I 
I 40 I 
290 I 
I 
I 30 
190 I I 20 
90 10 
-10 0 
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Elution volume (mL) 
Figure 5.S. HisTrapTM column purification of M13pIXHisACIDap and 
M13pIXHisFOS. PEGlNaCI purified phage were loaded onto a 5 mL HisTrapTM 
column (A). M13pIXHisFOS loading can be overlaid that of M13pIXHisACIDap. 
Phage associated with column resin were then eluted with an increasing imidazole 
concentration (B). . 
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5.2.3.3 Display of the leucine zipper FOS on pIX 
As a control to test ACIDap:BASEap specificity another phage was produced. This 
phage displayed the leucine zipper FOS (LTDTLQAETDQLEDEKSALQTEIANLLKE 
KEKLEFILAAH) which interacts with its partner JUN (O'Shea, 1992). 
pCGMTpIXHisFOS was created and displayed on pIX in the same way as ACIDap 
(Figure 5.7 C). The FOS DNA sequence was created by PCR using the overlapping 
primers pIXHisFOSfor, pIXHisFOSrev and pIXHisFOStemplate (Chapter 2, section 
2.4.2) and ligated into the HindIII and PstI sites of pCGMT -1 b. Following 
transformation into E.coli, 5 colonies were picked and sent for sequencing which 
confirmed that the correct sequence been inserted into pIX. One was carried forward for 
further experiments and termed pCGMTpIXHisFOS (Appendix C, section 3.0). 
Growth of the phage, termed M13pIXHisFOS, and purification by PEGlNaCI was 
carried out as described for M13pIXHisACIDap. Once again, the use of a HisTrapTM 
column (GE Healthcare) resulted in two peaks eluting at similar imidazole 
concentrations as M13pIXHisACIDap (Figure 5.8 B). However, the second peak of 
M13pIXHisFOS was far larger than the equivalent peak for M13PIXHisACIDap. It 
may be that the pIXHisFOS peptide is more compatible with wild-type phage infectivity 
than pIXHisACIDap, allowing for more phage to display two peptides. After repeated 
cultures and purifications it was found that the titer of M13pIXHisFOS was -10 times 
that of M13pIXHisACIDap (-7 x 1013 against -0.7 x 1013 virions/mL). This further 
indicates that the pIXHisFOS peptide is more compatible with wild-type phage 
infectivity than pIXHisACIDap. 
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5.2.3.4 Display of ACIDap on pIlI 
A positive control was created by displaying ACIDap, with no hexahistidine tag, on 
pIlI. The rationale behind this was that cloning into gIll results in all the copies of pIlI 
displaying the desired peptide. Therefore no hexahis tag, which may have interfered 
with ACIDap:BASEap interactions, was needed to purify this altered phage. The 
ACIDap DNA sequence was created by PCR using the overlapping primers 
pllIACIDfor, plllACIDrev and ACIDtemplate (Chapter 2, second 2.4.4). The product 
was cloned into the Acc65 I and Eag I sites of MI3.KE resulting in a phage where 
ACIDap was displayed at position 1 of the pIlI protein. After transformation into E.coli, 
5 plaques were picked and sent for sequencing which confirmed that the phage RF 
DNA contained the correct sequence. One of these clones was used for further 
experiments and termed MI3plllACIDap (Appendix C, section 4.0). The phage were 
grown in 1 L of super-broth containing E.coli ER2738 and tetracycline. After growth 
overnight the phage were purified using PEG/NaCl. The phage were then further 
purified on a caesium chloride gradient before being dialysed against PBS pH 7.5. On 
average, this method produced a titer of -1.5 x 1013 virions/mL. 
Therefore in summary three altered phage were created and purified: 
I. M 13pIXHisACIDap: displaying HisACIDap on -I copy of pIX per phage, 
2. M13pIXHisFOS: displaying HisFOS on -I copy of pIX per phage (negative 
control), 
3. MI3pIIlACIDap: displaying ACIDap on -5 copies of pilI (positive control). 
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5.2.4 Surface Plasmon Resonance (SPR) and Dual Polarisation 
Interferometry (DPI) analysis of ACIDap:BASEap interaction 
DPI and SPR are similar techniques in that they can both be used to measure mass 
adsorption onto a surface and are useful in probing peptide interactions. In both 
methods, a peptide is immobilised onto the surface of a sensor chip (Homola, 1999; 
Cross, 2003). In the case of SPR the sensor chip is a gold surface to which cysteine 
containing peptides can be directly immobilised using a thiol:gold bond. With DPI, the 
immobilisation chemistry is slightly different because the sensor chip is made from 
silicon oxynitride. To immobilise the peptide the sensor chip must first be 
functionalised with a silicon reactive heterobifunctional cross-linker which reacts with 
the silicon and produces exposed thiols to solution. A copper (II) solution is then 
washed over the sensor chip. The copper is reduced by the exposed thiols to copper (I) . 
This reduced copper is then used to form a covalent bond with the thiol contained 
within the peptide (Johnson, 2008). 
The goal of using the ACIDap:BASEap coiled-coil was to orientate phage displaying 
the ACIDap peptide onto a surface using an immobilised BASEap peptide. Therefore 
SPR and DPI were used to investigate whether the ACIDap:BASEap coiled-coil would 
form when the BASEap peptide was first covalently immobilised on a surface and the 
ACIDap peptide washed over it. Before continuing it must be noted that although SPR 
and DPI are powerful techniques that can, when used properly, provide useful data, e.g. 
association and dissociation kinetics of peptide interactions, within this study the two 
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techniques were primarily used as a method to detect binding between the 
ACIDap:BASEap peptides or between phage and BASEap. 
5.2.4.1 SPR analysis of BASEap:ACIDap coiled-coil formation 
SPR and DPI instruments have multiple channel sensor chips: SPR has 4 flow cells and 
DPI has 2 sample wells (Figure 5.9). The sample well and flow cell are both just 
channels within the sensor chip upon which experiments can be carried out. The 
presence of multiple sample wells or flow cells allows for simultaneous experiments to 
be performed independently of one another on the same sensor chip. 
A. DPI sensor chip B. SPR sensor chip C. SPR sensor chip 
Sample well 1 and 2 are Flow cells 1 to 4 are Fluid passes over each flow 
independent of one anotqer independent of one another flow cell sequentially 
Figure 5.9. Schematic of DPI and SPR sensor chips. Shows how the fluid flows 
(denoted by arrows) through each DPI sample well (A) or SPR flow cell (B and C). In 
the case of SPR the micro-fluidics can be changed so the flow cells are independent (B), 
or in series (C), so that a single analyte can be passed over all 4 flow cells. 
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Although SPR has four channels, only two were used: one to immobilise BASEap and 
the other to immobilise a control peptide (SLDTLAEQLDPSANNVLSC) which was 
provided by Dr Steve Johnson (School of Electronic and Electrical Engineering, 
University of Leeds, u.K.). The control peptide was chosen as it was an unrelated non-
leucine zipper peptide that was available within the lab. The SPR microfluidics were 
configured so that each flow cell was independent of one another (Figure 5.9, B). The 
control peptide and HPLC purified BASEap were immobilised onto flow cell 2 and 3, 
respectively, of a bare gold SPR sensor chip. Flow cell 1 and 4 were left as bare gold. 
Two 50 !!L injections of each peptide were performed. Previous studies have shown that 
gold:thiol bonds are formed within minutes (Lee, 2005). Therefore at a flow rate of 10 
!!Llmin it was expected that the peptides would be immobilised. These injections were 
followed by a 10 mM NaOH wash to remove any unbound peptide (Figure 5.10 A). 
This resulted in -90 response units (RU) of each peptide being immobilised. One RU 
has been defined as 1 pg of protein per mm2 of the flow cell (Stenberg, 1991). Therefore 
- 90 pg/mm2 (0.009 ng/mm2) of the two peptides were deposited upon the gold surface. 
The microfluidics were then changed so that the PBS pH 7.4 running buffer flowed 
sequentially over the flow cells, i.e. 1 then 2 then 3 (Figure 5.9, C), and left overnight to 
equilibrate with the running buffer at a flow rate of 10 !!Llmin. It was observed that the 
base line changed with an increase to - 170 RU before stabilising (Figure 5.10 A). This 
new value was then used as the base line, i.e. 0 RU, for examining ACIDap interactions 
with BASEap and the control peptide. 1 mg/mL of ACIDap peptide, in PBS pH 7.4, was 
injected across the two immobilised peptides (Figure 5.10 B). Although there was no 
change in response for the control peptide, an increase of -8.5 RU was observed on the 
flow cell containing immobilised BASEap. . 
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A I: first BASEap/control peptide injection 
200 
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140 
120 
Response (RU) 100 
B 
80 
60 
40 
20 
o 
30 
25 
20 
15 
Relative response (RU) 
10 
5 
o 
2: second BASEap/control peptide injection 
3: 10 mM NaOH injection 
4: Microfluidics changed so buffer ran through all 3 channels 
- Bare gold surface 
- Immobilised control peptide 
- Immobilised BASEap 
-90RU 
o 3000 6000 9000 12000 15000 
Time (seconds) 
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injection injection 
start stop 
, 
, 
V 
- Immobilised control peptide 
- Immobilised BASEap 
-5~~~~--~--~--~~--~ 
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Figure 5.10. SPR analysis of ACIDap:BASEap interactions. A) shows a raw 
sensogram of BASEap and a control peptide immobilised on two separate channels via 
their thiol group in a PBS pH 7.4 running buffer. B) shows a corrected sensogram, 
relative to the bare gold surface, of ACIDap washed over the channels to investigate its 
interactions with the two immobilised peptides. The start and end of sample injections 
are indicated by solid and hashed arrows, respectively. 
Page 201 
Chapter 5 
This result clearly indicates that the ACIDap peptide had a higher affinity for the 
BASEap peptide than the control peptide and was therefore forming a coiled-coil on the 
surface. The difference in the rate at which the coiled-coil formed in solution and on a 
surface is also interesting. When in solution, as measured with circular dichroism 
(Figure 5.6), the coiled-coils had formed within 30 seconds. However, when one of the 
coiled-coils was immobilised on a surface, coiled-coils were still forming after 5 
minutes. 
5.2.4.2 DPI analysis of BASEap:ACIDap coiled-coil formation 
To reinforce the results of the SPR, a similar experiment was performed using DPI. The 
DPI experiments were performed with the aid of Dr Steve Johnson. A DPI sensor chip 
consists of a silicon oxynitrile chip with two waveguides (Figure 5.11). The first 
waveguide, termed the sample waveguide, contains the two sample wells to which 
samples can be adsorbed to. The second waveguide acts as a reference and is buried 
within the sensor chip. A laser light is focused through the two waveguides to create an 
interference pattern on a charge coupled device (CCD). The interference pattern is 
formed by the light waves as they recombine after passing through the two waveguides 
(Cross, 2003). The adsorption of particles, e.g. proteins, to the sample wells within the 
sample waveguide alters the optical path length of the light wave as it passes through. 
By measuring the difference between the light wave passing through the sample 
waveguide with that of the reference waveguide, which will not interact with the 
sample, it is possible to obtain accurate measurements of the refractive index and 
thickness of the adsorbed layer (Cross, 2003). 
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Light wave 
Light wave 
CCD 
Figure 5.11. Dual Polarisation Interferometry (DPI). A schematic showing a DPI 
sensor chip. 
HPLC purified BASEap peptide (35 aa long) and the control peptide 
(SLDTLAEQLDPSANNVLSC: 19 aa long) were immobilised onto the two sample 
wells independently of one another (Figure 5.12, A and B). The immobilisation of the 
two peptides created a layer -0.6 nm thick on both channels (Figure 5.12 A, Tl), 
although a higher amount of the control peptide was immobilised (-3.4 ng/mm2 to -2.6 
ng/mm2: Figure 5.12 B, Ml). When the ACIDap peptide was washed over the two 
channels, there was a change in both thickness and mass on both channels. However, on 
the channel with immobilised BASEap there was a far larger increase in the thickness 
and mass (Figure 5.12, T2 and M2) compared to the control peptide (-0.2 nm and -0.08 
ng/mm2). 
Previous work has indicated that at high pH the ACID:BASE coiled-coil is unstable, 
leading to dissociation (O 'Shea, 1993). Therefore PBS pH 11.2 was washed over the 
two channels. Although there was minimal change in thickness and mass with regard to 
the control peptide,. the channel where BASEap was immobilised was observed to 
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decrease in thickness and mass to a level similar to that of the control peptide (Figure 
5.12, T3 and M3). One possible explanation for this observation is that the initial 
increase in thickness and mass on the control peptide channel is non-specifically bound 
ACIDap peptide whilst the higher increase seen within the BASEap channel is non-
specific and ACIDap:BASEap coiled-coil formation . When the channels are exposed to 
pH 11.2, it dissociates the ACIDap:BASEap coiled-coil leaving only the non-
specifically bound ACIDap and so the mass and thickness decrease to that of the control 
peptide channel. 
A Thickness - Baseap B Mass 
- Control 
,....., ,....., 
§ " Peptide 
'-' immobilisation (J) , 
~ I 
] 
U " ~ 
ACIJ?ap 
, 
PBS pH 11.2 
"'E; .., 
.§ Peptide 
OJ) I 5 immobil i~ation 
~ . , ~ ~ MI t 
::E 
PBS pH 11.2 
~., I---~--------
1000 1000 3000 .. 000 ~ooo 1000 2000 4000 jOOO 
Time (seconds) Time (seconds) 
Measurerrent II 1'2 1'3 MeasureJrenl M1 M2 M3 
BASE 0.596 1.155 1.034 BASE 0.258 0.563 0.437 
Thickness (run) Control 0.58 0.949 1.019 2 Mass (nwrrun ) Control 0.341 0.485 0.417 
Differeoce 0.016 0.206 O.DIS Diffureoce -0.083 0.D78 0.02 
Figure 5.12. DPI analysis of ACIDap:BASEap interactions. BASEap 
(AQLKKKLQANKKKLAQLKWKLQALKKKLAQGGGSC) and a control peptide 
(SLDTLAEQLDPSANNVLSC) were immobilised on two separate sample wells via 
their thiol group in a PBS pH 7.4 running buffer. ACIDap was washed over the sample 
wells to investigate its interactions with the two peptides. A pH 11 .2 PBS wash was 
used to investigate the effect of pH on the ACIDap:BASEap coiled-coil. The thickness 
(A) and mass (B) were measured and the difference between BASEap and the control 
peptide were noted at 2200, 4400 and 5610 seconds (TI-T3 and MI-M3). The start and 
end of sample injections are indicated by solid and hashed arrows, respectively. 
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5.2.5 SPR analysis of M13pIXHisACIDap phage interaction with 
surface immobilised BASEap 
The SPR and DPI experiments had indicated that ACIDap:BASEap coiled-coils were 
forming on a gold surface. The final experiment used SPR to investigate whether 
ACIDap, displayed on the M13 bacteriophage, could form coiled-coils with 
immobilised BASEap and in doing so anchor the phage to the surface. BASEap was 
injected over a single SPR channel, as in section 5.2.4.1, so that -90 RU of BASEap 
was immobilised. 100 f.lL (lOll virions/mL) of M13pIXHisACIDap, M13pIXHisFOS, 
M13 wild-type and M13pIIIACIDap phage were then injected across the immobilised 
BASEap peptide (Figure 5.13). M13pIIIACIDap produced the largest response (-450 
RU). This larger response was expected since the phage displayed -5 copies of the 
ACIDap peptide per phage particle and therefore should have had a greater affinity for 
BASEap compared to the other phage. M13pIXHisACIDap and M13pIXHisFOS 
produced similar responses to one another (-350 RU to -300 RU) although the phage 
particles displaying pIXHisACIDap did repeatedly, from three repeats of the experiment 
on separate sensor chips; produce a higher response of -50 RU. Compared to wild-type, 
which produced a response of -100 RU, these two phage showed much higher affinity 
forBASEap. 
The observation that the displayed HisFOS peptide also showed relatively high affinity, 
compared to wild-type, for the immobilised BASEap may suggest two possibilities. The 
first is that FOS does show some affinity for BASEap. Although coiled-coil pairs are 
known to be generally specific to their complementary partner (Newman, 2003), with 
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regard to the JUN:FOS and ACID:BASE leucine zipper pairs there have been no studies 
investigating their specificity. However, Sweeney, et al. (2006), who created the 
multimeric phage nanostructures using ACIDap:BASEap displaying phage (Figure 5.3 
D), also produced M13 phage particles displaying FOS on pill and BASEap on pIX. 
When these phage were mixed together, they failed to form the multimeric phage 
nanostructures observed with the ACIDap:BASEap displaying phage; although some 
multiple phage structures were seen. This suggests that FOS and BASEap have a low 
affinity for one another and do not form coiled-coils. 
Phage Phage 
600 injection injection 
start SlOP 
, 
PBS pH 11.2 PBS pH 11.2 , 
500 Y injection start injection stop 
,--., ~ , :::> , 
E5, 400 
Y 
Q) 
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0 300 - MI3plXHisACIDap 0.. 
r/:) - M 13plXHisFOS 
Q) 
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.~ 
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~ 
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Figure 5.13. SPR analysis of M13 phage and immobiIised BASEap. Shows a 
corrected sensorgram, relative to bare gold, where BASEap was immobilised onto a 
gold surface via its thiol group in a PBS pH 7.4 running buffer. Phage displaying 
ACIDap or FOS leucine zippers were washed over the immobilised peptide to 
investigate their interactions. The start and end of sample injections are indicated by 
solid and hashed arrows, respectively. 
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The second possibility is that the hexahis tag is interacting with the gold surface of the 
sensor chip. Histidine containing peptides have been shown to have a high affinity for 
gold surfaces (lori, 2008; Peele, 2005). There have also been studies using hexahistidine 
to attach peptides to an SPR gold surface (Wegner, 2003; Baek, 2004; Ro, 2005). 
However, none of these studies used a bare gold SPR sensor chip. They a11 utilised Ni-
NTA cross-linkers to immobilise the hexahistidine tags to the gold surface. Whether this 
was because the hexahistidine tags failed to directly bind the gold surface was not 
noted. 
Once again, a pH 11.2 wash was performed to dissociate the ACIDap:BASEap coiled-
coils (Figure 5.13). The increase in pH had no effect on the wild-type and plIIACIDap 
phage. This suggests that, as expected, the wild-type phage were bound non-specifically 
to the BASEap layer. The possibility of the M13pIIIACIDap phage forming 5 coiled-
coil interactions, and binding very tightly to the surface, may explain why the phage 
particles were not dissociated following the pH 11.2 wash. Both M 13pIXHisACIDap 
and M13plXHisFOS dissociated rapidly upon injection of the pH 11.2 buffer. This 
supports the notion thilt M13pIXHisACIDap was forming coiled-coils with the 
immobilised BASEap. However, it also suggests that the displayed FOS was forming 
coiled-coils with the BASEap peptide. A 
Table 5.1. Rate and equilibrium constants obtained from sensograms shown in 
Figures 5.10 Band 5.13. The standard deviation (±) is also provided. 
ka (M· ' s· ') kd (s· ') KA (11M) KD (M) Ch? 
AClDap only 177 ± 3.03 1.07 x 10.3 ± 5.07 x 10.5 1.65 x 105 6.06 X 10-6 0.109 
M 13pLXHisACIDap 9.85 x 105 + 4.95 X 103 1.9 X 10-4 ± 1.56 x 10-6 5.16 X 109 1.94 X 10-'0 4.24 
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Basic kinetic fits were done on the sensograms using the BIAevaluation software and a 
1: 1 binding model (Table 5.1 and Appendix C, section 5). A Chi2 value less than 10 
typically represents an acceptable fit for the sensogram (Biacore, 1997). The 
dissociation constant (Ko) of the parallel conformation of ACID:BASE has been found 
to be 3 x 10-8 M (0' Shea, 1993). However, this was calculated using circular dichroism 
measurements at different concentrations of urea. The SPR data within this study found 
the Ko of the anti-parallel ACID:BASE coiled-coil to be -6 x 10-6 M when using free 
ACIDap and -2 x 10-10 M when the ACIDap was displayed on the M13 particle. 
However, whereas the original study used free ACID and BASE (O'Shea, 1993), this 
study used an immobilised BASEap with the ACIDap peptide free in solution which 
would be expected to affect ACIDap:BASEap interactions. The higher Ko observed 
when the ACIDap was displayed on the M13 phage particle maya result of multiple 
ACIDap peptides being available for binding per phage particle, i.e. a phage may 
display two ACIDap peptides instead of one. It may also be that the M 13 coat proteins 
are interacting with the BASEap peptides, as the M13 wild-type result (Figure 5.13) 
suggests. 
5.3 Conclusions and Future Work 
The work described within this chapter provides proof of principle that leucine zippers 
can be displayed on the M 13 bacteriophage coat proteins, both pIlI and pIX, and used to 
attach the phage particle to a surface. Currently, nanodevices fabricated using the M13 
bacteriophage, e.g. metallic nanowires, are deposited .randomly on surfaces. In the 
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future the coiled-coils could be used as a generic phage anchoring method to attach 
multiple nanodevices to a pre-fabricated electronic circuit in a targeted manner. 
I have shown that the ACIDap leucine zipper could be displayed upon the M13 
bacteriophage and then used to anchor the phage particle to a gold surface via the 
ACIDap:BASEap coiled-coil interaction. To this end phage displaying ACIDap on pIlI 
and pIX were produced. A phage displaying the FOS leucine zipper, whose partner is 
JUN, was also produced. Since pIX phage display required the use of a phagemid 
display system an N-terminal hexahis (HHHHHH) tag was also incorporated. The use 
of this tag allowed for the purification of phage displaying the plXHisACIDap and 
plXHisFOS phage away from wild-type phage. 
To immobilise the BASEap peptide onto a gold surface a GGGSC linker sequence was 
added to the C-terminal. Using circular dichroism (CD) it was shown that the addition 
of this linker sequence had no detrimental effect on the ACIDap:BASEap coiled-coil 
formation within solution and the result repeated that of previous CD experiments using 
ACID:BASE pairs. Using Surface Plasmon Resonance and Dual Polarisation 
Interferometry it was shown that BASEap could be immobilised onto a gold or silicon 
oxynitrile surface and form coiled-coils with ACIDap. To my knowledge this is the first 
time that short leucine zippers have been shown to form coiled-coils on a surface when 
one of the pair was first immobilised on the surface. Further work with SPR showed 
that ACIDap, displayed on pIlI or pIX will form coiled-coils with an immobilised 
BASEap peptide and so anchor the phage to the surface. 
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These experiments need to be taken further in the future and moved onto gold electrodes 
on a silicon dioxide surface. BASEap would be immobilised on two gold surfaces 
separated by an Si02 layer where there would be no BASEap. Phage displaying pIX and 
pIlI ACIDap could then be washed across and immobilised between the two gold 
surfaces (Figure 5.4 A). Likewise the same could be done with the higher order 
structures fabricated in chapter 4 (Figure 5.4 B). With regard to the ACIDap:BASEap 
coiled-coil the SPR work could be taken further. The kinetic evaluation was basic 
within this study, e.g. only one concentration of ACIDap was used and the 
ACIDap:BASEap interaction was not allowed to reach equilibrium. Further work 
investigating the kinetics of the ACIDap:BASEap coiled-coil formation could be done. 
Likewise, SPR kinetic experiments could be performed using the JUN :FOS coiled-coil 
pair. The specificity of the coiled-coils for their partner, i.e. does FOS form a coiled-coil 
with immobilised BASEap, is an interesting area to explore since if they are specific 
then this would allow for the use of coiled-coil pairs to self-assemble phage onto 
different areas of a surface, e.g. one phage displaying ACIDap and another displaying 
FOS being directed to different areas by their specific partner. 
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Fabrication of Gold-Coated M13 
Bacteriophage 
This Chapter describes the work carried out attempting to fabricate gold nanowires 
using M 13 phage particles displaying tyrosine on p VIII as scaffolds. 
Chapter 6 
6.1 Introduction 
6.1.1 Bio-mineralisation of nanoparticIes 
The process by which biological molecules synthesise inorganic nanopartic1es, e.g. 
silica, metal, etc, is known as bio-mineralisation (Sarikaya, 2003). Nature exhibits a 
wide range of mechanisms and applications for bio-mineralisation. Most likely, 
organisms evolved the ability to produce inorganic nanopartic1es in response to metal 
ions taken up non-specifically from the environment via cationic membrane transport 
systems (Hu, 2007). Many metal ions are toxic to the cell, such as gold, cadmium, and 
silver ions (Crookes-Goodson, 2008), and are therefore commonly used as anti-bacterial 
agents. Algae, plants and bacteria have all evolved detoxification pathways that remove 
the metal ions from within the cell: either by actively pumping the ions out (Nies, 
2003), or by reducing the reactive ions to a relatively inert state, e.g. by the creation of 
metallic nanopartic1es (Silver, 1996). For instance, a silver resistant strain of 
Pseudomonas stutzeri, AG259, when incubated with silver nitrate produces silver 
nanopartic1es with a diameter of 35 to 46 nm, and silver sulphide at the cell surface 
(Slawson, 1992). In fact, some bacterial strains that are silver resistant are reported to 
have 25% of their dry weight as accumulated silver nanopartic1es at their cell walls 
(MandaI, 2006). The exact mechanism for the resistance found in P. stutzeri is still not 
fully understood. 
Another excellent example is that of the unicellular green alga, ChIarella vulgaris (Xie, 
2007). It was found that when the algae were incubated with chloroauric acid (HAuCI4), 
as a source of gold ions (Au3+), for two days that a variety of nanopartic1es were formed 
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exhibiting a wide range of triangular and hexagonal shapes (Xie, 2007). Further studies 
identified a 28 kDa protein, called the gold shape-direction protein (GSP), which was 
responsible for the creation of these nanoparticles (Xie, 2007). 
Other organisms have evolved far more exotic and fascinating bio-mineralisation 
methods. The magnetotactic bacteria, e.g. Magnetospirillium gryphiswaldense (Figure 
6.1 A), use either ferric (Fe3+) or ferrous (Fe2+) iron that has been taken up from the 
surrounding area to create magnetic iron nanoparticles (Komeili, 2007). Although the 
mechanism is not fully understood, it is thought that the iron-storage protein ferritin 
plays a lead role. Ferritin, which is associated with an intracellular membrane complex 
known as the magnetosome, quickly co-precipitates the ferric and ferrous irons to 
produce magnetite, or sometimes greigite (depending on the species), nanoparticles. 
These 30 - 50 nm nanoparticles are contained within the magneto some, which is itself 
linked to the cell via the cytoskeleton (Figure 6.1 B). 
The magnetotactic bacterium uses the nanoparticles to align the cell relative to a 
magnetic field. The field causes the magnetic nanoparticles to line up which in turn 
forces the magnetosome into alignment. The magneto some is linked to the cytoskeleton 
and so the cell can sense these changes and adjust its position appropriately. The theory 
behind the evolution of this system is complex and still disputed. These bacteria are 
typically aquatic micro-aerophiles, i.e. their metabolism functions best at low oxygen 
concentrations, and so they inhabit the oxic-anoxic transition zone which is found at the 
sediment/water interface (Stolz, 1993). It is thought that the bacteria use the 
magneto some to reach the oxic-anoxic transition zone. However, the mechanism by 
which the bacteria achieve this is still being researched. 
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A 
Magnetic 
O.5lJm Inner membrane Cytoskeletal filament 
Magnetosome 
Figure 6.1. The magnetotactic bacteria. (A) A transmission electron microscope 
image of the magneto tactic bacterium Magnetospiriluum gryphiswaldense. (B) A 
diagram showing the structure of the magnetosome within the bacterium. (C) Various 
morphologies and organisation of magnetosomes from different magneto tactic bacteria. 
(A) and (C) are taken from SchUler, (1999) and B adapted from Komeili, (2007). Scale 
bar in (C) equal to 100 nm. 
Perhaps the most fascinating aspect of the magneto tactic bacteria is that different 
species produce a plethora of diverse morphological crystalline nanoparticles and 
organise them differently within the magnetosome (Figure 6.1 C). The morphology of 
these nanoparticles is under genetic control and their fabrication occurs under ambient 
conditions (Schuler, 1999). This ability of organisms to reproducibly create 
nanoparticles under ambient conditions using genetically controlled proteins is what 
attracts engineers and scientists to bio-mineralisation and is a recurring theme through 
different studies. 
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6.1.2 Amino acid reduction of metal salts 
Gold nanoparticles are typically created by the reduction of gold salts (Au3+) in an 
organic solvent, e.g. toluene (Brust, 1994; Daniel, 2004). The reaction is typically done 
using a strong reducing agent, such as sodium borohydride (NaBH4) or citrate and is 
carried out in the presence of a so-called capping agent. Capping agents are typically a 
molecule such as citrate (Turkevich, 1951), various polymers, or bio-macromolecules 
(Mirkin, 1996), that act to stabilise the nanoparticles. Citrate is the most commonly used 
since it acts as both the reducing and capping agent. However, left over reagents, such 
as un-reacted citrate, need to be removed so that downstream applications of the 
nanoparticles are unaffected. All this must also be done at high temperature meaning 
that the creation of gold nanoparticles is very energy intensive. Nature works in ambient 
conditions and is less energy intensive. Therefore using Nature to fabricate 
nanoparticles has attracted a lot of attention in recent years. One area of attention has 
been in the ability of amino acids to act as nucleating and reducing agents (Sarikaya, 
2003; Tamerler, 2009). 
Many of these metal nucleating peptides have been identified using M13 phage display 
libraries and bio-panning (Flynn, 2003; Lee, 2002; Mao, 2003; Mao, 2004; Nam, 2010). 
In all of the studies the metal binding peptide is used to either bind to existing 
nanoparticles or bind to metal ions. The metal ions are then reduced with a strong 
reducing agent, e.g. sodium borohydride, onto the surface of the peptide. This, however, 
leads to a large amount of background material: either unbound nanoparticles or 
reduced metal un-associated with the peptides. None of the peptides actively reduce the 
metal ions, e.g. Au3+, to metal nanoparticles. 
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Relatively few groups have researched the metal salt reduction properties of single 
amino acids, repeats of these amino acids and peptides: with only a handful of papers 
being published. It has been shown that tyrosine (Zhou, 2001), tryptophan 
(Selvakannan, 2004) and aspartic acid (MandaI, 2002) all act as metal ion reducing 
agents. Tyrosine plays an important role as an electron transfer agent in photosystem II 
(the first protein complex in the light dependent reactions of photosynthesis; Barber, 
2008; Barry, 1990) as well as in various enzymes, such as galactose oxidase (Firbank, 
2004; Whittaker, 1990). More recently, it has been shown that this electron transfer 
mechanism can be used to reduce gold metal salts (Au3+) to metallic gold (Zhou, 2001; 
Selvakannan, 2004; Slocik, 2005 and Si, 2006). The proposed mechanism of tyrosine 
reduction of gold is depicted below in Figure 6.2. 
CH2 CH2 CH2 
pH 9-11 Mn+ 
• • Electron 
OH 0- donation o. 
Figure 6.2. Cartoon showing a proposed mechanism of metal reduction by 
tyrosine. Adapted from Si, 2006. 
It has been claimed that tyrosine (Y) is implicated in the reduction of gold salt by the 
spherical Cowpea Chlorotic Mottle Virus (CCMV; Slocik, 2005). Each CCMV coat 
protein, 180 make up the viral capsid (Liepold, 2005), has four endogenous tyrosine 
residues in close proximity to the C-terminus, which extends from the surface of the 
virus into solution (Speir, 1995). When CCMV was mixed with HAuCI4, metallic gold 
(Auo) was quickly formed. Measurement of the tyrosine fluorescence emission at 352 
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nm showed that it was quickly quenched. This was used as evidence that the tyrosine 
was donating its electron for the reduction of the gold ions and being oxidised and so 
losing its fluorescence. However, gold nanoparticles are able to quench fluorescent 
molecules (Schneider, 2006; Dulkeith, 2002). The possibility that this was occurring 
instead of the oxidation of the tyrosine was not discussed. However, studies using 
peptides have further indicated the metal ion reducing properties of tyrosine (Slocik, 
2004; Si, 2006). These studies took YYY peptides and mixed them with HAuCI4. As 
with CCMV, gold nanoparticles were rapidly formed, typically 20 nm in size (Si, 2006). 
As the work described in Chapter 5 has shown, it is possible to bind M 13 particles to a 
specific surface using leucine zipper interactions. This raises the possibility that phage 
bound to a quantum dot or gold nanoparticle (see Chapter 4) could be positioned 
between two gold electrodes. This could be achieved by displaying a leucine zipper at 
the end of the phage (Chapter 5) and depositing its complementary partner onto the gold 
electrode. When the higher order structure, with phage displaying leucine zippers, was 
washed over the gold surface, the leucine zippers would interact and therefore position 
the higher order structur~ between the two gold electrodes. The phage would then be 
used as scaffolds for metal deposition (Chapter 1, Figure 1.16). This self-assembled 
structure could then act as a simple molecular transistor. 
It is likely that if the phage were coated with a metal in solution that the leucine zipper's 
affinity for its complementary partner would be destroyed. Likewise, attachment of the 
phage to the surface first followed by metal deposition using a reducing agent, such as 
sodium borohydride, would result in large amounts of background. This background 
would negatively affect any electrical characteristics of the nano-device. Therefore a 
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preferable method would be to attach the phage to the surface first and then use the 
phage as the reducing agent to limit the deposition of metal to the phage only and 
minimize background. 
Therefore the rationale behind the work described within this chapter was that phage 
could be deposited onto a surface to replicate phage self-assembling onto a surface 
using leucine zippers. Then a tyrosine residue displayed on p VIII of the M 13 particle 
could be used as the reducing agent of gold ions to minimize background metal 
deposition. 
6.1.3 Aims of the work described within this Chapter 
The aims were as follows: 
1. To display tyrosine on the major coat protein p VIII of the M 13 bacteriophage. 
2. To deposit phage onto a silicon dioxide surface. 
3. To use the tyrosine displaying phage to examine its reduction of gold 
specifically onto the M 13 bacteriophage. 
4. To characterise the composition and electrical properties of the gold nanowires. 
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6.2 Results and Discussion 
6.2.1 Display of tyrosine on p VIII 
The wild-type M 13 P VIII coat protein contains two endogenous tyrosine (Y) residues at 
positions 21 and 24 (Chapter 1, Figure 1.10). They are located within the hydrophobic 
region, and are not thought to be solvent exposed (Vos, 2009; Overman, 1995; Matsuno, 
1998). The first six amino acids of the pVIII coat protein are, however, thought to be 
solvent exposed (Vos, 2009). Therefore to display a solvent exposed tyrosine residue on 
the pVIII coat protein, the aspartic acid (D) residue at position 4 of the mature pVIII 
coat protein was replaced with a tyrosine (Y) residue. This was achieved via a G to T 
substitution at position 1379 of the M13KE sequence (New England Biolabs, Ipswich, 
MA, U.S.A.) by site-directed mutagenesis with the D to YpVIIIfor and D to YpVIIIrev 
primers (Chapter 2, section 2.5.1) using M13KE RF DNA as the template. The site-
directed mutagenesis product was transformed into E.coli, and ten colonies picked and 
sent for sequencing whicl1 confirmed that they contained the correct mutation. 
One of these mutants (Appendix D, section 1.0) was carried forward for further 
experiments and termed MI3Y. Phage produced from this clone carry a tyrosine residue 
on all -2700 copies of pVIII. When grown in E.coli the M13Y phage produced an 
equivalent titer to wild-type M13 phage and had a similar morphology under TEM 
analysis to wild-type M13. 
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6.2.2 Fabrication of gold coated phage in solution 
The rationale for using tyrosine was to allow for in situ reduction of gold onto the M13 
phage particle after the phage had been deposited onto a surface. However, before 
starting surface experiments, the reduction capabilities of the M13Y phage in solution 
were investigated. M13Y was grown and purified using a caesium chloride gradient to 
remove possible reducing agents produced by the cell. Titrations were carried out using 
differing amounts of M13Y or wild-type M13 against 1 mM chi oro auric acid (HAuCI4): 
from hereon in chloroauric acid will be called gold salt. Likewise, titrations were carried 
out of differing concentrations of gold salt against 10 ilL of 1013 virions/mL of M13Y or 
wild-type M13. 5 ilL of each reaction was then taken and placed on a carbon coated 
TEM grid for 10 seconds before being washed in water. No stain was used. The result 
for both titrations with M13Y was the same (Figure 6.3 A) with large aggregates of 
filamentous structures present. There was no obvious difference between M13Y and 
wild-type M13 (Figure 6.3 B). The filamentous structures had an amorphous grey 
appearance to them with no obvious fine detail (Figure 6.3 A inset). As mentioned, the 
aggregates were present in all the reactions: no single phage particles were observed. 
Whenever large concentrations of phage, i.e. 50 and 100 ilL of M13Y phage, were 
mixed with gold salt then within 30 seconds of mixing there appeared a single grey 
dust-like particle within the solution. The diameter of the dust-like particle was between 
0.5-2 mm and increased in size the higher the concentration of M13Y phage. The dust-
like particle only appeared when M13Y phage was used, i.e. it did not appear when 
wild-type M13 phage or no phage were used. The dust-like particle stayed suspended 
within the solution but would settle at the bottom of the tube after leaving overnight. 
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However, it could easily be moved from the bottom of the tube with a single flick. 
Vigorous vortexing of the tube led to fragmentation of the dust-like particle into 
numerous smaller particles. Further vortexing made no difference. Examination of the 
dust-like particle in TEM showed the same aggregates as described previously (Figure 
6.3 A and B). 
A 
M13Y and gold salt 
Filamentous 
structure 
Uranyl acetate stained 
M13Y phage comparison 
C 
Wild-ty e M13 and gold salt 
B 
No phage with gold salt 
D 
Figure 6.3. A TEM image of M13 phage mixed with gold salt overnight in solution. 
Specifically, 100 ilL of M13Y (A) or wild-type M13 (B) phage (-1 x 1013 virions/mL) 
suspended in PBS pH 7.4 was added to 100 ilL of 1 mM chloroauric acid (HAuCI4) and 
mixed briefly and incubated overnight. D shows the same reaction with 100 ilL PBS 
instead of M13. C shows M13Y phage stained with uranyl acetate and no gold salt 
present. 5 ilL of each reaction was then taken and placed on a carbon coated TEM grid 
for 10 seconds before being washed in water. Scale bar equals 200 nm. 
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When the same experiment was carried out, but with no M13Y phage, none of the 
structures were observed (Figure 6.3 D). This suggests that the filamentous structures 
observed were M13Y phage. The fact that they can be seen using TEM indicates that 
the phage were coated with some electron dense material. The obvious candidate for 
this would be reduced gold. If gold was being deposited onto the M13Y phage it was 
concentration independent since the results were the same for titrations of M13Y to gold 
and gold to M13Y. Therefore the incubation time was investigated. 10 ilL of M13Y 
phage (and as controls 10 ilL of wild-type phage and 10 ilL of PBS pH 7.4), at a 
concentration of -1 x 1013 virions/ mL was added to 100 ilL of 6 mM gold salt and left 
for 1, 10, 30 and 60 minutes at room temperature. Samples were also left overnight and 
for 2 days at room temperature. 
Aggregates of filamentous structures were observed after 1 minute for both M13Y and 
wild-type phage (Figure 6.4 A and B). The structures did not alter in appearance for the 
10 minute, 30 minute (Figure 6.4 C and D), 60 minute and overnight incubation (Figure 
6.4 E and F). However, after 2 days incubation discrete nanoparticles were observed 
(Figure 6.4 G and H). The nanoparticles were ordered in a similar manner to the 
filamentous structures seen in earlier time points. This suggests that the nanoparticles 
were forming along the length of the phage particles. The only difference between 
M13Y and wild-type phage was that the nanoparticles on the M13Y phage were smaller 
(an average diameter of 4.2 nm ± 1.6 compared to 9.2 nm ± 7.7, n = 50). There also 
appeared a large number of background nanoparticles (highlighted with an arrow in 
Figure 6.4 G inset) . When no phage were present no nanoparticles were seen (result the 
same as Figure 6.3 D). This indicates either that the nanoparticles formed on the phage 
and proceeded to dissociate into the solution, 'or the. phage solution contained E. coli cell 
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Figure 6.4. Time course of M13Y and wild-type phage mixed with gold salt. TEM 
images of 10 [lL of M13Y or wild-type phage (-1 x 1013 virions/mL) added to 100 [lL 
of 6 mM chloroauric acid and left for 1 minute (A and B), 30 minutes (C and D), 
overnight (E and F) and two days (G and H). Scale bar equals 200 nm. 
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remnants that acted as nucleating sites. Further work needs to be carried out to ascertain 
which. 
Therefore within a solution-based reaction it appeared that the M13Y phage, as well as 
wild-type phage, could act as reducing agents to reduce gold ions, in the form of Au3+ 
from the chloroauric acid, to metallic gold. It is interesting that wild-type phage also 
produced nanoparticles; although they appeared far less ordered. This may be due to the 
presence of two endogenous tyrosine residues located within pVIII; although most 
studies predict that they are buried within the phage coat and not exposed to solution 
(Vos, 2009). Once again, the electron density of the nanoparticles strongly suggests 
that they contained metallic gold. 
The reaction was therefore observed to be concentration independent but time 
dependent. This result is not overly surprising since theoretically there were not enough 
tyrosine residues to reduce enough gold ions to form nanoparticles. Assuming that the 
two endogenous tyrosine residues within pVIII are solvent exposed, then along with the 
inserted tyrosine, it means that there are 3 tyrosine residues able to donate an electron to 
the Au3+ ions. Therefore each pVIII molecule can theoretically reduce one gold atom 
from Au3+ to metallic gold (Auo), with the 3 electrons being donated from the 3 tyrosine 
residues. Each M13 phage particle contains -2700 pVIII molecules, resulting in -2700 
metallic gold atoms. 
The following equation (Cseh, 2007) was used to calculate the number of gold atoms 
within the gold nanoparticles: 
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where NAu = number of gold atoms in a nanoparticle; R = radius of nanoparticle (A); 
03 
and V g = volume of gold atom (V g = 17 A ). 
The nanoparticles formed by M l3Y had an average diameter of 4.2 ± 1.6 nm and so a 
radius of 2.1 ± 0.8 nm. Therefore the number of gold atoms within an average Ml3Y 
nanoparticle was -2300. So it was impossible for the Ml3Y phage to reduce enough 
gold atoms to create the numerous nanoparticles observed. Therefore once the tyrosine 
residues had reduced the initial gold atoms, which has been measured to occur rapidly 
(Slocik, 2005, Slocik, 2004; Si, 2006), then the rest of the gold must reduce by a 
different mechanism independently of the Ml3Y phage concentration. 
The rapid aggregation seen when the phage were mixed with the chloroauric acid may 
be due to the presence of the Au3+ ions. It has been shown that Tobacco Mosaic Virus 
(TMV) mixed with copper chloride, producing Cu2+ ions, at a concentration above 0.5 
M leads to rapid aggregation of the TMV particles along with deposition of metallic 
copper on the TMV particles (Lee, 2006). Perhaps a similar mechanism occurs with 
Ml3 particles and Au3+ ions. A review of the literature shows many examples of M13 
phage particles mixed with positively charged atoms leading to aggregation (Nam, 
2006; Reiss, 2004 and Soo-Kwan, 2006). However, Lee et ai. (2006), found that when 
the concentration of CuClz was lower than 0.5 M that no copper deposition occurred 
upon the TMV particles. It therefore appears that solution reduction of metal salts is a 
"catch-22" situation. Metal reduction on phage particles may only occur at 
concentrations of metal ions that cause aggregation. 
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6.2.3 Deposition of M13Y onto carbon and patterning with gold 
For electronic measurements of any gold-coated phage, the ideal surface would be Si02 
due to its insulating properties. However, it was unknown whether phage would deposit 
onto an Si02 surface successfully. Additionally, phage deposited on Si02 could only be 
viewed using atomic force microscopy (AFM) which provides less detail than TEM. 
Therefore I decided to deposit M13Y phage onto a charged, carbon-coated TEM grid to 
initially carry out surface gold reduction experiments before moving onto Si02 surfaces. 
5 ~L of M13Y and wild-type (l x 1010 virions/mL) phage were placed onto an ultra-
violet charged, carbon-coated, copper TEM grid. The phage were left for 1 minute on 
the grid to allow for adsorption of the particles to the surface. Excess liquid was then 
removed using filter paper. 
A 10 ~L drop of 1 mM chloroauric acid (HAuCI4) was then placed onto the grid for 
different times (Figure 6.5 A-C) before being washed off with distilled water. After 1 
minute (Figure 6.5 A) nanoparticIes, -4 nm across, formed along the phage particle, and 
these increased in size in a time-dependent fashion (Figures 6.5 B and C). The shape 
and electron density strongly indicated that the nanoparticles consisted of gold. 
Occasionally after 1 hour of incubation with 1 mM HAuCl4 large background 
aggregates were observed. Once again, wild-type phage also produced similar structures 
to M13Y with similar incubation times (Figure 6.5 D). 
The main difference between the solution and surface based exposure of M13Y to 
chloroauric acid was the lack of aggregation when done on the surface. Since all the 
phage were deposited separately from one another, they could interact with the 
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chloroauric acid without aggregation. Therefore the initial rationale of phage deposition 
before gold reduction appeared to be correct. The other difference between solution and 
surface was the speed that nanoparticles were formed. With the solution based reaction 
it took 2 days for nanoparticles to form. This is contrasted with nanoparticle formation 
after 1 minute when the phage were present upon a surface. 
1 minute 10 minutes 1 hour 
Figure 6.5. Phage particles on a carbon surface exposed to gold salt. M13Y phage 
deposited on a carbon-coated, copper TEM grid incubated with 1 mM HAuCl4 for I 
minute (A), 10 minutes (B) and 1 hour (C) in a humid chamber. Wild-type was 
incubated for 10 minutes with 1 mM HAuCl4 (D) . A carbon-coated grid with no phage 
was incubated with 1 mM HAuCl4 for 1 hour (E). Scale bar equals 200 nm. 
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6.2.4 Attempts to deposit gold on M13 adsorbed to Si02 surface 
Since it appeared that the system was working on carbon surfaces, the experiments were 
moved onto a silicon dioxide surface. As explained above, the Si02 surface was 
necessary because any future electrical characterisation of the nanowires, or a 
nanodevice, would have to be done on a silicon surface. Therefore silicon surfaces 
(Compart Technology Ltd, Peterborough, U. K.) were prepared by cleaning 1 cm2 Si02 
chips with piranha solution. Piranha solution is a mixture of sulphuric acid and 
hydrogen peroxide (3: 1) which etches the silicon, removing any debris, and producing a 
clean surface for deposition. 
Initial experiments focused on depositing the phage onto the cleaned surface. It was 
found, using AFM (Chapter 2, section 2.5.5) that aging the surface overnight (whilst 
keeping it in a sealed humidity chamber to limit dust contamination) at room 
temperature before adding the phage resulted in a high concentration of phage 
deposition (Figure 6.6 A and B). 
IOnrn 
Height 
Onrn 
Figure 6.6. M13 bacteriophage particles adsorbed to. Si02 surface. M13Y phage on 
piranha cleaned Si02 (A, B). Surfaces viewed with .AFM. Scale bar equals 1 [A.m. 
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Phage failed to deposit on freshly cleaned silicon surfaces, perhaps due to the charge of 
the surface which changed from a net negative charge (which would be expected to 
repel the negatively charged phage particle) to a net neutral charge as it aged. 
M13Y Wild-type 
1 minute 
10 minutes 
IOnm 
1 hour Height 
Onm 
Figure 6.7. M13 phage particles adsorbed to Si02 and incubated with gold salt for 
different times. AFM image showing M13Y and wild-type phage exposed to a solution 
of 1 mM chloroauric acid (HAuCl4) for 1 minute, 10 minutes and 1 hour. Scale equals 1 
!lm. 
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Once it was found that virions could be deposited onto a bare Si02 surface, the next step 
was to investigate whether the tyrosine displayed on pVIII of M13Y, and the 
endogenous tyrosines of wild-type M13, could reduce gold from solution to coat the 
virus particle. When silicon surfaces covered in M13Y, or wild-type, phage were 
exposed to 1 mM chloroauric acid for either 1 or 10 minutes then only phage particles 
were observed (Figure 6.7 A-D), i.e. the phage particles had the same height and 
thickness as when no gold salt was used. When the phage were exposed for 1 hour then 
thicker structures were seen with a greater height than a single phage particle (Figure 
6.6 with arrows highlighting the structures). However, the structures appeared 
discontinuous with an inconsistent thickness. It was assumed that the reaction was 
occurring differently on the silicon surface than the carbon surface with a longer 
incubation period needed to result in gold deposition. Therefore the incubation time was 
increased. 
Following overnight incubation, it was observed that phage-like structures (Figure 6.8 C 
and D) were present which appeared thicker than phage only (Figure 6.8 A and B) and 
were of a greater height (Figure 6.9 A). It was also found that by increasing the 
chloroauric acid concentration to 6 mM (the chloroauric acid solution from Sigma was 
provided as a neat solution of 6 mM) that the height of the phage increased further 
(Figure 6.8 E and F; Figure 6.9 A). It is interesting that the width of the particles 
decreased when the phage were exposed to 1 mM chloroauric acid, compared to just 
phage on the surface, and then increased again when exposed to 6 mM (Figure 6.9 B). 
This is because AFM lacks the resolution to discern the width of objects smaller than its 
tip, which is typically 20 to 50 nm In SIze (Decossas, 2001). Therefore width 
measurements are often inaccurate. 
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Figure 6.8. M13 bacteriophage particles adsorbed to Si02 surface and incubated 
with varying amounts of gold salt. Phage on piranha cleaned Si02 (A, B) and 1 mM 
(C, D) or 6 mM (E, F) HAuCk Surfaces viewed with AFM. Scale bar equals 1 !-lm. 
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Method to determine height measurements of a phage particle 
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Figure 6.9. Height and width measurement of M13Y particles. Average phage 
particle heights and widths, after gold salt incubation, were measured from 100 phage 
particles using AFM (steps 1 to 3). Error bars show standard deviation. 
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Although the width measurements using AFM were dubious, the height measurements 
were more reliable since these measurements are largely independent of tip size (Figure 
6.9 A). When exposed to 1 mM chloroauric acid, the height of the phage particles 
increases substantially from 1 nm to 3 nm. However, these values are lower than the 
expected 6 nm diameter of the phage. This discrepancy can be explained by the particles 
perhaps being flattened by the tapping AFM tip. It was found that when the AFM used 
too much force then no phage were seen, i.e. they were completely flattened by the tip 
(result not shown). The height increased further when the phage were exposed to 6 mM 
chloroauric acid, although only by a small amount. Further incubation with 6 mM gold 
salt for 48 hours (Figure 6.8 G and H) did not lead to an increase in height (Figure 6.9 
A). 
Aside from the height differences it was found that the phage, after exposure to 
chI oro auric acid, exhibited a bead-like structure (Figure 6.8 D and F). This explains the 
wide variation in height (Figure 6.9 A) since the gaps between the beads decreases the 
average height. The bead-like structure may be linked to the helical structure of the M13 
phage particle (Chapter 1, section 1.5). 
A control was carried out to ascertain whether the morphological changes, i.e. the 
changes in height of the phage particles, associated with the gold salt were because of 
the gold ions being reduced or due to the low pH of the chloroauric acid solution: 
HAuCl4 solution is provided in dilute hydrochloric acid, pH -3 . M13Y phage (adsorbed 
to Si02 surface) were exposed to 1 mM hydrochloric acid pH 3 (Figure 6.10). After 
overnight incubation the phage particles appeared degraded (highlighted with arrows) 
Page 233 
Chapter 6 
with none of the bead-like structure or height changes seen when 1 mM chi oro auric acid 
was used. Therefore the morphological changes appear specific to chloroauric acid. 
Phage before exposure 
to hydrochloric acid 
Phage after exposure to 
hydrochloric acid 
IOnm 
Height 
Onm 
Figure 6.10. M13Y phage on Si02 surface exposed to dilute hydrochloric acid. 
M13Y phage were deposited on a silicon dioxide surface and exposed to 1 mM 
hydrochloric acid, pH 3, overnight. Surfaces viewed with AFM. Scale bar equals 1 !lm 
The morphological changes observed when M13Y was incubated with chi oro auric acid 
indicated that some material had coated the phage partiCles. Once again the results 
strongly indicated that the material was gold. To confirm that gold was coating the M13 
particles, scanning electron microscopy (SEM) was carried out. Gold is very electron 
dense and so it was expected that the gold coated phage particles would be very easily 
seen with an SEM (despite their small size). Therefore a silicon dioxide surface was 
prepared with M13Y phage and exposed to 6 mM chloroauric acid overnight (Figure 
6.11 A). This produced similar structures to those seen before (Figure 6.8 E). When the 
surface was viewed using the SEM, no phage shaped structures were seen (Figure 6.11 
B), indicating that no gold was present. This was further confirmed using energy-
dispersive X-ray spectroscopy (EDX), which is a technique that allows a user to 
determine the elemental composition of a sample within an SEM. EDX showed that no 
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Figure 6.11. Scanning electron microscopy of M13Y phage exposed to 6 mM gold 
salt on a Si02 surface. AFM scale bar equals 1 !-lm; SEM scale bar equals 100 !-lm. 
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Figure 6.12. Electronic characterisation of M13Y phage particles. M13Y phage 
particles were deposited on a Si02 surface and exposed to 6 rnM chloroauric acid (gold 
salt) overnight. Gold contacts were then drawn over the ends of the phage using ion 
beam lithography (A). Current measurements were then taken of the phage (B) and 
control measurements taken of the Si02 surface and the gold electrodes (C). Images 
were taken using AFM. Scale bar equals 1 !-tm. 
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gold was present within the sample (Figure 6.11 C). Some gold was observed as large 
aggregates (Figure 6.11 B, highlighted with an arrow). EDX of the aggregate (Figure 
6.11 E) showed that it was made of gold. 
Further to this work, the electrical conductivity of the gold coated phage was measured 
with the assistance of Dr Steve Johnson (School of Electronic and Electrical 
'Engineering, University of Leeds). This was achieved by using ion beam lithography to 
"draw" gold electrodes to the ends of the gold coated phage (Figure 6.13 A) using pre-
fabricated gold cross-hairs to orientate the ion beam. Dr Johnson carried out all the 
lithography involved in the creation of the gold electrodes. A potential was created 
across the gold coated phage (from -1.5 to 1.5 V). Instead of the expected linear 
relationship between applied potential and current (Figure 6.13 B, red line) no current 
was observed (Figure 6.13 B, blue line) . 5 coated phage particles were measured and 
none were conducting. 
It is very difficult to ~xplain what was happening to the phage when exposed to 
chloroauric acid. Clearly some morphological change was occurring, with the thickness 
of the phage increasing as the chi oro auric acid concentration was increased from 1 mM 
to 6 mM. The morphological change was not due to the low pH of the gold salt solution. 
It is possible that the gold ions (Au3+) were associating with the phage particles and 
producing the structures seen with AFM via some charge effect. However, that doesn't 
explain the structures seen with TEM on the carbon grids which are clearly metallic. It 
may be that the carbon-coated copper grid is somehow acting as a reducing agent. 
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Other alternatives may be that the gold layer was too small to be seen by SEM and 
EDX. Within SEM, the electron beam passes a certain distance into the surface, e.g. 
Si02• It may be that the electrons bouncing back from the Si02 surface are dwarfing 
those from the gold atoms coating the phage. However, this is unlikely. With regards to 
the conductivity measurements, the gold coating may consist of nanoparticles, as seen 
with the TEM results (Figure 6.4). These nanoparticles may be too far apart to allow for 
conductivity. Once again, this is unlikely since the TEM results indicate the 
nanoparticles are close enough together. 
6.3 Conclusions and Future Work 
The work described within this chapter has shown that tyrosine can be displayed on the 
major coat protein pVIII. Initial experiments in solution suggest that the M13Y and 
wild-type phage particles reduce gold ions from solution into metallic gold. However, 
the rapid appearance of a dust-like particle when using M13Y suggests that the extra 
displayed tyrosine does increase the gold reduction properties of the phage. Likewise, 
the appearance of the dust-like particle suggests that tyrosine is acting as the reducing 
agent of gold or plays a prevalent role. It is thought that the two endogenous pVIII 
tyrosines are not solvent exposed (Vos, 2009). However the gold reducing properties of 
wild-type M13 suggests that at pH 3, the pH at which the reduction was carried out at, 
that the endogenous tyrosine residues are solvent exposed. Further work with different 
pH gold salt solutions is needed to investigate this. 
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Work on a carbon surface showed that both M 13 Y and wild-type phage reduce the gold 
at a far quicker rate than in solution. TEM analysis showed that there was no real 
difference between the nanoparticles on M13Y and wild-type. This was further 
supported by work on a silicon dioxide surface, where M13Y and wild-type particles 
appeared at the same after gold salt incubation. Although the structures observed in 
solution and on the carbon surfaces appear to be gold based on their electron density, 
further EDX needs to be carried out to support this. However, the EDX and 
conductivity measurements on the structures fabricated on the Si02 surface showed that 
no gold was present, which contradicts the observations of TEM and AFM. 
Therefore the final conclusion must be that although phage can reduce gold in solution 
or on a carbon surface, that when adsorbed onto an Si02 surface that there is no gold 
reduction. 
Regardless of whether M 13 Y was reducing gold from solution, the rationale behind 
using tyrosine still stands. By using the phage particle to reduce gold it would allow for 
the M13 particle to be orjentated onto a surface and have gold specifically reduced onto 
the phage particles and so avoiding background gold deposition. Therefore a method 
using tyrosine (or something similar) still appears to be the best route. One such method 
could involve using lysine which has an amine side chain. There is a lysine at position 8 
of the mature p VIII coat protein which could be targeted with gold nanoparticles 
displaying an amine reactive crosslinker. 
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General Conclusions 
Chapter 7 
The overall aim of the work described within this thesis was to fabricate a self-
assembling molecular transistor using the M 13 bacteriophage. Although this was not 
achieved, there was significant progress towards the final objective. 
7.1 Conclusions from Chapter 3 
For practical bionanotechnology applications the M 13 bacteriophage is too long. At -1 
!-tm in length and highly flexible, it is difficult to envisage the phage particle predictably 
depositing onto a surface so that it can be incorporated into an existing circuit. 
Likewise, an M 13 bacteriophage fabricated transistor would be 2 microns in diameter. 
With a computer chip, the more transistors that can be packed into a given area, the 
faster the calculations of the computer chip. The size of the M 13 bacteriophage 
transistor would limit the number that could be deposited onto a surface. 
Therefore the work described within Chapter 3 used existing technologies to create, and 
purify, bespoke length phage particles. The microphage cassette, developed by 
Specthrie, et al. (1992), which produces a 50 nm long phage particle, was used as the 
starting point to create longer phage particles. A kanamycin gene (1165 bp) was inserted 
into the microphage cassette which in turn produced a phage particle -200 nm in length. 
The relationship between the length of inserted DNA and the length of the phage 
particle showed a linear relationship, which suggests that in the future, phage of a pre-
designed length can be produced. A relatively simple protocol was also established to 
purify these different length phage from wild-type length phage to produce a 
homologous population. This involved linear sucrose gradient purification followed by 
size exclusion chromatography. Using this purification technique regularly produced 
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yields of 2.5 x 1012 cfu from 1 L E.coli cultures, which is roughly analogous to wild-
type phage titers. 
7.2 Conclusions from Chapter 4 
The work described within Chapter 4 attempted to create the scaffold of the molecular 
transistor. The aim was to fabricate, and purify, 2 or 3 phage particles self-assembled 
around a nanoparticle. M 13 bacteriophage were created that displayed selenocysteine 
(Sel) on the minor coat protein pIli. Although the M13pIlISel phage were found to have 
a lower infectivity than wild-type M13 (-2 x 109 pfu/mL vs -4 x 1012 pfu/mL), they 
produced more virion particles (-20 x 1013 virions/mL vs -3 x 1013 virions/mL). The 
M 13pIIISei phage were mixed with either 10 nm gold nanoparticles or maleimide 
functionalised quantum dots. It was found that the phage self-assembled into a variety 
of higher order structures: from 2 to 4 phage bound to a single nanoparticle. 
However, purification of separate higher order structures, e.g. 3 phage per nanoparticle, 
was problematic. Using . linear sucrose density gradients it was possible to purify the 
higher order structures away from unbound phage and free nanoparticles. However it 
was not possible to purify the separate higher order structures. Finally, the 50 nm long 
microphage particles, displaying pIIISel were used to self-assemble higher order 
structures of two or three microphage per gold nanoparticle. Therefore although 
purification is still an issue, and needs to be resolved in the future, the work described 
within this Chapter has shown that the molecular transistor scaffold can be created from 
self-assembling phage. 
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7.3 Conclusions from Chapter 5 
Although a self-assembled molecular transistor could potentially be a useful 
nanodevice, with no way to place it specifically within a pre-fabricated circuit it would 
be of limited use. Therefore the work described within this Chapter addressed this issue 
by using the coiled-coil pair of leucine zippers ACID and BASE. ACID was displayed 
on pIX of the M 13 bacteriophage. SPR was then used to show that the displayed ACID 
peptide could be used to anchor the phage onto a gold surface via an immobilised BASE 
peptide. It is envisaged that with the self-assembled molecular transistor that 
selenocysteine would be displayed on pIlI, to direct the phage to the nanoparticles, and 
ACID displayed on pIX to target the transistor to a designated area on a surface. 
In the process of anchoring the phage to a surface the work within this Chapter showed, 
for the first time, that small coiled-coils can form on a surface when one of the pair is 
first immobilised. It also showed that other coiled-coils can be displayed on pIX. In this 
case it was FOS, which is part of the FOS:JUN coiled-coil pair. Although FOS showed 
some affinity for the immobilised BASE peptide, it was still lower than the affinity of 
ACID for BASE. This result raises the possibility of using phage displaying different 
coiled-coil pairs, i.e. one phage displaying FOS and the other displaying ACID, to 
simultaneously target those phage to different areas of a surface. Therefore different 
nanodevices could be fabricated and specifically deposited onto different areas of a 
surface. Further work could be carried out to investigate the kinetics of the 
ACIDap:BASEap coiled-coil formation on the gold surface of the SPR chip. Also, the 
immobilisation of the JUN coiled-coil could be investigated so that M 13 phage particles 
displaying its partner FOS could be anchored to the gold surface. 
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7.4 Conclusions from Chapter 6 
The aim of this Chapter was to use the M 13 bacteriophage to nucleate metallic gold 
from solution to create gold nanowires using a displayed tyrosine on p VIII. Within the 
self-assembled transistor, these gold nanowires would act as the source, drain, and gate 
electrode and so complete the nanodevice. A tyrosine residue was successfully inserted 
into position 4 of the p VIII coat protein with no effect on phage titer. Tyrosine was used 
as it has previously been shown to actively reduce gold salt (Au3+), from solution to 
metallic gold, when displayed on spherical virus particles and peptides. 
Within solution it was observed that the phage reduced the gold salt to metallic gold. 
However, both the tyrosine displaying phage and wild-type phage reduced gold. Wild-
type pVIII has two endogenous tyrosine residues which have been predicated to be 
inaccessible to solvent (Vos, 2009). This result suggests that in fact they are solvent 
exposed at pH 3. The addition of the extra tyrosine did have some effect. It was 
observed that the tyrosine displaying phage, in high concentrations, rapidly aggregated 
when exposed to gold salt creating grey dust-like particles. Wild-type phage did not 
produce similar particles. When the phage were deposited onto a carbon surface and 
then exposed to gold salt it was found that the reduction reaction was far more rapid 
(minutes instead of hours). Once again, wild-type also reduced gold. These results 
suggest that the display of an additional tyrosine appears to have had little effect on the 
gold reducing properties of the phage. 
The reactions were then moved to Si02 surfaces. It was found by AFM that exposure of 
the phage to gold salt resulted in the phage particles increasing in height (-3 nm vs 1 
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nm). This suggested that gold was being reduced onto the phage particles. However, 
SEM and EDX measurements of the particles showed that no gold was present. Gold 
electrodes were then "drawn" to the ends of the particles to carry out electrical 
measurements. However it was found that the particles were non-conducting. Therefore 
although within solution and on carbon surfaces the phage (both displaying tyrosine and 
wild-type) will reduce gold, that on an Si02 surface the chemistry does not work. 
Further work needs to be carried out to find a method to deposit gold onto the phage 
particles. 
7.5 Closing remarks 
Although the final aim of a self.·assembling transistor was not realised, a large bulk of 
the work towards that aim has been achieved within this study. Specifically, the scaffold 
of the transistor was self-assembled from 1 !lm and 50 nm long phage particles 
displaying selenocysteine. Also, a method was devised that would allow these scaffolds 
to be targeted to a surface. The only aspect that is lacking is the deposition of gold onto 
the scaffold to finish the self-assembling transistor and make it into a complete 
nanodevice. If this can be accomplished in the future then all the different features could 
be incorporated to fabricate the self-assembling transistor. 
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Appendix A 
1.0 DNA sequence of pM 1 
ACCGTCTATCAGGGCGATGGTCTAGAGCATATCTTTCTAGAAGATCTCCTAC 
AATATTCTCAGCT 
~ , , t 'I] " " ". ' " : < .' ' ! I j 1 .~ \ ... \' I', :, ., .. ; ) 1" ~ ; 'I' 
CGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCA~ 
~CTGGA~ACGTCTATCCACAGAATCAGGGATAACGCAGAAAGAAACATGT 
GGAGCCAAGCAGCAAGCCAGAACCGTAAAGGCGCGTTGTTGGCGTTTCCTA 
GGTCGCCCCTGGCGAGATTCAAATTCACGCTCAGTCAAAGTGCAACGCACG 
GCTAAGATACACGTCCATGGAGATACTCTGGGGT 
2.0 DNA sequence of pMicro plasmid 
GGGGGTGTGGAGATGCGCAGATTGCTCTAG 
CCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAA 
GTGGACTCTTGTTCCAAACTGG~AACGTCTGGATCCGCAATCTTTCTAGA 
AGATCTCCTACAATATTCTCAGCTGCCATGGAAAATCGATGTTCTTCTTTTAT 
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3.0 DNA sequence of pMicrokan 
TTGGAGATGCGCAGATTGCTCTAGA 
~~~~~~,~TTCAGGCGGTGCTACAG 
AGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTG 
- GTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTC 
TTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAG 
CAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTT 
TCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTG 
GTCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGT 
TATGAGCCATATTCAACGGGAAACGTCTTGCTCTAGGCCGCGATTAAATTCC 
AACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGG 
CAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAG 
TTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAG 
ATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGC 
ATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGG 
GAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATAT 
TGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTA 
ATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACG 
AATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGG 
CTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAACTTTTGCCATTCTCA 
CCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGA 
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CGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGA 
CCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCT 
TCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGA 
ATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAAGAATTAATTCAT 
GAGCGGATACATATGAATTCCGG CATCGCCCTGATAGACGGTTTTTCGCC 
GACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGG 
ACGTCTGGATCCGCAATCTTTCTAGAAGATCTCCTACAATATTCTCAGCT 
GCCATGGA 
4.0 DNA sequence of pM13CP 
Highlighted bases, e.g. A, C, T, G, show the 5 silent mutations. 
Position 1: 
TAATGCTACTACTATTAGTAGAATTGATGCCACCTTTTCAGCTCGCGCCCCA 
AATGAAAATATAGCTAAACAGGTTATTGACCATTTGCGAAATGTATCTAAT 
GGTCAAACTAAATCTACTCGTTCGCAGAATTGGGAATCAACTGTTATATGGA 
ATGAAACTTCCAGACACCGTACTTTAGTTGCATATTTAAAACATGTTGAGCT 
ACAGCATTATATTCAGCAATTAAGCTCTAAGCCATCCGCAAAAATGACCTCT 
TATCAAAAGGAGCAATTAAAGGTACTCTCTAATCCTGACCTGTTGGAGTTTG 
CTTCCGGTCTGGTTCGCTTTGAAGCTCGAATTAAAACGCGATATTTGAAGTC 
TTTCGGGCTTCCTCTTAATCTTTTTGATGCAATCCGCTTTGCTTCTGACTATA 
ATAGTCAGGGTAAAGACCTGATTTTTGATTTATGGTCATTCTCGTTTTCTGA 
ACTGTTTAAAGCATTTGAGGGGGATTCA 
Gene X: 
ATGAATATTTATGACGATTCCGCAGTATTGGACGCTATCCAGTCTAAACATT 
TTACTATTACCCCCTCTGGCAAAACTTCTTTTGCAAAAGCCTCTCGCTATTTT 
GGTTTTTATCGTCGTCTGGTAAACGAGGGTTATGATAGTGTTGCTCTTACTA 
TGCCTCGTAATTCCTTTTGGCGTTATGTATCTGCATTAGTTGAATGTGGTATT 
CCTAAATCTCAACTGATGAATCTTTCTACCTGTAATAATGTTGTTCCGTTAGT 
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TCGTTTTATTAACGTAGATTTTTCTTCCCAACGTCCTGACTGGTATAATGAGC 
CAGTTCTTAAAATCGCATAAGGTAATTCACA 
Gene V: 
ATGATTAAAGTTGAAATTAAACCATCTCAAGCCCAATTTACTACTCGTTCTG 
GTGTTTCTCGTCAGGGCAAGCCTTATTCACTGAATGAGCAGCTTTGTTACGT 
TGATTTGGGTAATGAATATCCGGTTCTTGTCAAGATTACTCTTGATGAAGGT 
CAGCCAGCCTATGCGCCTGGTCTGTACACCGTTCATCTGTCCTCTTTCAAAG 
TTGGTCAGTTCGGTTCCCTTATGATTGACCGTCTGCGCCTCGTTCCGGCTAA 
GTAAC 
- Gene VII: 
ATGGAGCAGGTCGCGGATTTCGACACAATTTATCAGGCGATGATACAAATC 
TCCGTTGTACTTTGTTTCGCGCTTGGTATAATCGCTGGGGGTCAAAG 
Gene IX: 
ATGAGTGTTTTAGTGTATTCTTTTGCCTCTTTCGTTTTAGGTTGGTGCCTTCG 
TAGTGGCATTACGTATTTTACCCGTTTAATGGAAACTTCCTC 
GeneVill: 
ATGAAAAAGTCTTTAGTCCTCAAAGCCTCTGTAGCCGTTGCTACCCTCGTTC 
CGATGCTGTCTTTCGCTGCAGTATCTGGTTCTTCTCCGGACTCGGATCCCGC 
AAAAGCGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTAT 
GCGTGGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGT 
TTAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGATACAATTAAAGGCT 
CCTTTTGGAGCCTTTTTTTTGGAGATTTTCAAC 
Gene III: 
GTGAAAAAATTATTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTC 
GGCCGAAACTGTTGAAAGTTGTTTAGCAAAATCCCATACAGAAAATTCATTT 
ACTAACGTCTGGAAAGACGACAAAACTTTAGATCGTTACGCTAACtATGAG 
GGCTGTCTGTGGAATGCTACAGGCGTTGTAGTTTGTACTGGTGACGAAACTC 
AGTGTTACGGTACATGGGTTCCTATTGGGCTTGCTATCCCTGAAAATGAGGG 
TGGTGGCTCTGAGGGTGGCGGTTCTGAGGGTGGCGGTTCTGAGGGTGGCGG 
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TACTAAACCTCCTGAGTACGGTGATACACCTATTCCGGGCTATACTTATATC 
AACCCTCTCGACGGCACTTATCCGCCTGGTACTGAGCAAAACCCCGCTAATC 
CTAATCCTTCTCTTGAGGAGTCTCAGCCTCTTAATACTTTCATGTTTCAA1AA 
TAATAGGTTCCGAAATAGGCAGGGGGCATTAACTGTTTATACGGGCACTGT 
TACTCAAGGCACTGACCCCGTTAAAACTTATTACCAGTACACTCCTGTATCA 
TCAAAAGCCATGTATGACGCTTACTGGAACGGTAAATTCAGAGACTGCGCT 
TTCCATTCTGGCTTTAATGAGGATTTATTTGTTTGTGAATATCAAGGCCAATC 
GTCTGACCTGCCTCAACCTCCTGTCAATGCTGGCGGCGGCTCTGGTGGTGGT 
TCTGGTGGCGGT2CCTGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGGGT 
GGCGGCTCTGAGGGAGGCGGTTCCGGTGGTGGCTCTGGTTCCGGTGATTTTG 
ATTATGAAAAGATGGCAAACGCTAATAAGGGGGCTATGACCGAAAATGCCG 
ATGAAAACGCGCTACAGTCTGACGCTAAAGGCAAACTTGATTCTGTCGCTA 
CTGATTACGGTGCTGCTATCGATGGTTTCATTGGTGACGTTTCCGGCCTTGCT 
AATGGTAATGGTGCTACTGGTGATTTTGCTGGCTCTAATTCCCAAATGGCTC 
AAGTCGGTGACGGTGATAATTCACCTTTAATGAATAATTTCCGTCAATATTT 
ACCTTCCCTCCCTCAATCGGTTGAATGTCGCCCTTTTGTCTTTGGCGCTGGTA 
AACCATATGAATTTTCTATTGATTGTGACAAAATAAACTTATTCCGTGGTGT 
CTTTGCGTTTCTTTTATATGTTGCCACCTTTATGTATGTATTTTCTACGTTTGC 
TAACATACTGCGTAATAAGGAGTCTTAATC 
Gene VI: 
ATGCCAGTTCTTTTGGGTATTCCGTTATTATTGCGTTTCCTCGGTTTCCTTCT 
GGTAACTTTGTTCGGCTATCTGCTTACTTTTCTTAAAAAGGGCTTCGGTAAG 
ATAGCTATTGCTATTTCATTGTTTCTTGCTCTTATTATTGGGCTTAACTCAAT 
TCTTGTGGGTTATCTCTCTGATATTAGCGCTCAATTACCCTCTGACTTTGTTC 
AGGGTGTTCAGTTAATTCTCCCGTCTAATGCGCTTCCCTGTTTTTATGTTATT 
CTCTCTGTAAAGGCTGCTATTTTT3ATTTTTGACGTTAAACAAAAAATCGTTT 
CTTATTTGGATTGGGATAAATAAT 
Gene I: 
ATGGCTGTTTATTTTGTAACTGGCAAATTAGGCTCTGGAAAGACGCTCGTTA 
GCGTTGGTAAGATTCAGGATAAAATTGTAGCTGGGTGCAAAATAGCAACTA 
ATCTTGATTTAAGGCTTCAAAACCTCCCGCAAGTCGGGAGGTTCGCTAAAAC 
GCCTCGCGTTCTTAGAATACCGGATAAGCCTTCTATATCTGATTTGCTTGCT 
ATTGGGCGCGGTAATGATTCCTACGATGAAAATAAAAACGGCTTGCTTGTTC 
TCGATGAGTGCGGTACTTGGTTTAATACCCGTTCTTGGAATGATAAGGAAAG 
ACAGCCGATTATTGATTGGTTTCTACATGCTCGTAAATTAGGATGGGATATT 
ATTTTTCTTGTTCAGGACTTATCTATTGTTGATAAACAGGCGCGTTCTGCATT 
AGCTGAACATGTTGTTTATTGTCGTCGTCTGGACAGAATTACTTTACCTTTTG 
TCGGTACTTTATATTCTCTTATTACTGGCTCGAAAATGCCTCTGCCTAAATTA 
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CATGTTGGCGTTGTTAAATATGGCGATTCTCAATTAAGCCCTACTGTTGAGC 
GTTGGCTTTATACTGGTAAGAATTTGTATAACGCATATGATCTAAACAGGCT 
TTTTCTAGTAATTATGATTCCGGTGTTTATTCTTATTTAACGCCTTATTTATC 
ACACGGTCGGTATTTCAAACCATTAAATTTAGGTCAGAAGATGAAATTAAC 
TAAAATATATTTGAAAAAGTTTTCTCGCGTTCTTTGTCTTGCGATTGGATTTG 
CATCAGCATTTACATATAGTTATATAACCCAACCTAAGCCGGAGGTTAAAA 
AGGTAGTCTCTCAGACCTATGATTTTGATAAATTCACTATTGACTCTTCTCA 
GCGTCTTAATCTAAGCTATCGCTATGTTTTCAAGGATTCTAAGGGAAAATTA 
ATTAATAGCGACGATTTACAGAAGCAAGGTTATTCACTCACATATATTGATT 
TATGTACTGTTTCCATTAAAAAAGGTAAT 
Gene XI 
ATGAAATTAACTAAAATATATTTGAAAAAGTTTTCTCGCGTTCTTTGTCTTG 
CGATTGGATTTGCATCAGCATTTACATATAGTTATATAACCCAACCTAAGCC 
GGAGGTTAAAAAGGTAGTCTCTCAGACCTATGATTTTGATAAATTCACTATT 
GACTCTTCTCAGCGTCTTAATCTAAGCTATCGCTATGTTTTCAAGGATTCTAA 
GGGAAAATTAATTAATAGCGACGATTTACAGAAGCAAGGTTATTCACTCAC 
ATATATTGATTTATGTACTGTTTCCATTAAAAAAGGTAATTCAA 
Gene IV: 
ATGAAG4TTGTTAAATGTAATTAATTTTGTTTTCTTGATGTTTGTTTCATCATC 
TTCTTTTGCTCAGGTAATTGAAATGAATAATTCGCCTCTGCGCGATTTTGTA 
ACTTGGTATTCAAAGCAATCAGGCGAATCCGTTATTGTTTCTCCCGATGTAA 
AAGGTACTGTTACTGTATATTCATCTGACGTTAAACCTGAAAATCTACGCAA 
TTTCTTTATTTCTGTTTTACGTGCAAATAATTTTGATATGGTAGGTTCTAACC 
CTTCCATTATTCAGAAGTATAATCCAAACAATCAGGATTATATTGATGAATT 
GCCATCATCTGATAATCAGGAATATGATGATAATTCCGCTCCTTCTGGTGGT 
TTCTTTGTTCCGCAAAATGATAATGTTACTCAAACTTTTAAAATTAATAACG 
TTCGGGCAAAGGATTTAATACGAGTTGTCGAATTGTTTGTAAAGTCTAATAC 
TTCTAAATCCTCAAATGTATTATCTATTGACGGCTCTAATCTATTAGTTGTTA 
GTGCTCCTAAAGATATTTTAGATAACCTTCCTCAATTCCTTTCAACTGTTGAT 
TTGCCAACTGACCAGATATTGATTGAGGGTTTGATATTTGAGGTTCAGCAAG 
GTGATGCTTTAGATTTTTCATTTGCTGCTGGCTCTCAGCGTGGCACTGTTGCA 
GGCGGTGTTAATACTGACCGCCTCACCTCTGTTTTATCTTCTGCTGGTGGTTC 
GTTCGGTATTTTTAATGGCGATGTTTTAGGGCTATCAGTTCGCGCATTAAAG 
ACTAATAGCCATTCAAAAATATTGTCTGTGCCACGTATTCTTACGCTTTCAG 
GTCAGAAGGGTTCTATCTCTGTTGGCCAGAATGTTCCTTTTATTACTGGTCGT 
GTGACTGGTGAATCTGCCAATGTAAATAATCCATTTCAGACGATTGAGCGTC 
AAAATGTAGGTATTTCCATGAGCGTTTTTCCTGTTGCAATGGCTGGCGGTAA 
TATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAG 
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GCAAGTGATGTTATTACTAATCAAAGAAGTATTGCTACAACGGTTAATTTGC 
GTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTC 
TCAGGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGT 
TTAGCTCCCGCTCTGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAA 
AGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCTGCAGAGAACA 
TGGCTTCATGTAGCAGGAGAAAAAAGGCTGCACCGGTGCGTCAGCAGAATA 
TGTGATACAGGATATATTCCGCTTCCTCGCTCACTGACTCGCTACGCTCGGT 
CGTTCGACTGCGGCGAGCGGAAACGGCTTACGAACGGGGCGGAGATTTCCT 
GGAAGATGCCAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAA 
GCCGTTTTTCCATAGGCTCCGCCCCCCTGACAAGCATCACGAAATCTGACGC 
TCGAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT 
CCCCCTGGCGGCTCCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGG 
TGTCATTCCGCTGTTATGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGT 
TCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACGAACCCCCCGTTC 
AGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGA 
AAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGAGG 
AGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTT 
TTGGTGACTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAAGAGTTGGTAGC 
TCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTCAGAG 
CAAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAAG 
GGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATG 
AACAATAAAACTGTCTGCTCTGCAG 
Chloramphenicol resistance gene: 
ACGCGTGTCCGAATTTCTGCATTCATCCGCTTATTATCACTTATTCAGGCGTA 
GCAACCAGGCGTTTAAGGGCACCAATAACTGCCTTAAAAAAATTACGCCCC 
GCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATTCTGCCGACA 
TGGAAGCCATCACAAACGGCATGATGAACCTGAATCGCCAGCGGCATCAGC 
ACCTTGTCGCCTTGCGTATAATATTTGCCCATGGTGAAAACGGGGGCGAAG 
AAGTTGTCCATATTGGCCACGTTTAAATCAAAACTGGTGAAACTCACCCAG 
GGATTGGCTGAGACGAAAAACATATTCTCAATAAACCCTTTAGGGAAATAG 
GCCAGGTTTTCACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAACT 
GCCGGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTG 
CTCATGGAAAACGGTGTAACAAGGGTGAACACTATCCCATATCACCAGCTC 
ACCGTCTTTCATTGCCATACGGAATTCCGGATGAGCATTCATCAGGCGGGCA 
AGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTATTTTTCTTTACGGTCT 
TTAAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAG 
CAACTGACTGAAATGCCTCAAAATGTTCTTTACGATGCCATTGGGATATATC 
AACGGTGGTATATCCAGTGATTTTTTTCTCCATTTTAGCTTCCTTAGCTCCTG 
AAAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTTCATTATG 
GTGAAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAAAAG 
TTGGCCCAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTCTG 
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CGAAGTGATCTTCCGTCACAGGTATTTATTCGACGCGTCCTATTGGTTAAAA 
AATGAGCTGATTTAACAAAAATTTAATGCGAATTTTAACAAAATATTAACGT 
TTACAATTTAAATATTTGCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGA 
TTATCAACCGGGGTACAT 
Gene II: 
ATGATTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTC5TGCT 
CCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGATCTCTCAAAAATAGC 
TACCCTCTCCGGCATTAATTTATCAGCTAGAACGGTTGAATATCATATTGAT 
GGTGATTTGACTGTCTCCGGCCTTTCTCACCCTTTTGAATCTTTACCTACACA 
TTACTCAGGCATTGCATTTAAAATATATGAGGGTTCTAAAAATTTTTATCCT 
TGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTT 
TTGGTACAACCGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCT 
AATTCTTTGCCTTGCCTGTATGATTTATTGGATGT 
4.1 DNA and protein sequence of M13CP 
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1891 TCT GAG GOT GGe GGT ACT AM CCT CCT GAG TAC GOT GAT ACA CCT A"IT CCG GGC TAT ACT TAT ATC Me CCT eTC GAC GGe ACT TAT CCG 
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, 1 N L. () l:' A K l' P N 1. 1" D K 1. D L 1. 
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4861 AAT CAG GM TAT GAT GAT AAT Tce GCT CCT Tet GGT GGT TTC TTT GTT CCG CM AAT GAT AAT GTT ACT eM ACT TTT A.AA ATI' MT MC 
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4951 GTT CGO GCA AAG GAT TTA ATA CGA GTT GTC GM TTG TI"I: GTA MG TCT MT ACT TCT AM TCC TCA AAT GTA TTA TCT ATT GAC GGC Tet 
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5491 TCC ATG AGe CTT 'IT!' ceT GTT eCA ATG GCT GGe GGT AAT AIT CTT CTG GAT ATT Ace AGe MG Gce GAT ACT TTG AGT TCT TCT ACT CAG 
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5581 eCA AGT GAT CTT AT'!' ACT AAT eM AGA ACT AT!' GCT ACA ACG GTT AAT TTG CGT GAT GGA CAG ACT CIT TTA CTC GGT GGe eTC ACT GAT 
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5941 GCT CGT TCG ACT GCG Gce AGe GGA Me GGe ITA eGA Ace GGG eGG AGA TI'T CCT GGA AGA TGC CAG GM GAT ACT TAA CAG GGA ACT GAG 
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6121 ACA GGA CTA TAA AGA TAC CAG GCG 'ITT CCC CCT GGe GGC TCC CTC GTG CGC TCT CCT GTT CCT GCC 'ITT CGG 'ITT Ace GGT GTC A'I"I' CCG 
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6481 GCC AGT TAC CTC GGT TCA AAG AGT TGG TAG erc AGA GM CCT TCG AM MC CGC CCT GCA AGG CGG TTT T'IT CGT TIT CAG AGe MG AGA 
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6571 TrA CGC GCA GAC CM MC GAT crc MG MG ATC ATC TTA 'ITA AGG GGT CTG ACG crc AGT GGA ACG AM ACT CAC GTT AAG GGA TIT TGG 
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6661 TCA TGA ACA ATA AM CTG TCT GCT CTG CAG ACG CGT GTC CGA A'IT TCT GCA TTC ATC CGC TTA ITA TCA CTl' AIT CAG GCG TAG eM CCA 
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7561 CGC CM AAG T'I'G GCC CAG GGC TTC CCG GTA TCA ACA GGG ACA CCA GGA TTT ATT TAT TCT GCG AAG TGA TC'l' TCC GTC ACA GGT ATT TAT 
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7831 TCG ATT CTC ITG TCiT GCT CCA GAC TCT CAG GCA ATG ACC TGA TAG CCT TTG TAG ATC TCT eM AAA TAG CTA CCC TCT CeG GCA TTA ATT 
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7921 TAT CAG CTA GM CGG ITG MT ATC 'ATA TTG ATG GTG AT'I' TGA CTG TCT CCG GCC TTT CTC ACC C'IT TTG MT C'IT TAC CTA CAC ATT ACT 
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8011 CAG GCA TTG CAT TTA AM TAT ATG AGG GTT CTA AM ATT 'ITT ATC CTl' GCG TTG AM TAA AGG CTl' CTC CCG eM AAG TAT TAC AGG GTC 
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8101 ATA ATG TTT TTG GTA CM CCG ATT TAG C'IT TAT GCT CTG AGG CTl' TAT TGC 'ITA ATT TTG CTA ATI CTT TGC CTT GCC TGT ATG A'IT TAT 
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1.0 DNA sequence of M13pIIISei phage 
pm start codon 
CTTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTCGCAATTCCTTTAG 
TGGTACCTTTCTATTCTCACTCTAGCGCTCGTGTCTGACACGGCCCATCGGTT 
GCAGGTCTGCACCAATCGGCCGAAACTGTTGAAAGTTGTTTAGCAAAATCC 
CATACAGAAAATTCATTTACTAACGTCTGGAAAGACGACAAAACTTTAGAT 
CGTTACGCTAACTATGAGGGCTGTCTGTGGAATGCTACAGGCGTTGTAGTTT 
GTACTGGTGACGAAACTCAGTGTTACGGTACATGGGTTCCTATTGGGCTTGC 
TATCCCTGAAAATGAGGGTGGTGGCTCTGAGGGTGGCTGTTCTGAGGGTGG 
CGGTTCTGAGGGTGGCGGTACTAAACCTCCTGAGTACGGTGATACACCTATT 
CCGGGCTATACTTATATCAACCCTCTCGACGGCACTTATCCGCCTGGTACTG 
AGCAAAACCCCGCTAATCCTAATCCTTCTCTTGAGGAGTCTCATCCCTCTTA 
TACTTTCATGTTTCCAAAAAATAAGTTCTCAAAAAAGGACAGGAGAAC 
Yellow = Selenocysteine peptide DNA sequence 
1.1 DNA and protein sequence of M13pIIISei phage 
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2~=~=~===~===~=_~~===~~===~~===~~ 
'lot ,. Y n '1' W "J PIG T. ,... I PEN EGG G SEC; G (' .9 EGG G S I:~ 
H3===~~==~~=~~=~==~~~~~==_=~~===~ 
1.('; ':; r~ 'J i K l' P E Y IJ 0 T P T P (J Y T Y T N l' T.· D G T Y !) P G T 
466 GAG eM Me eee GeT AAT ceT MT ceT TCT CTT GAG GAG -rCT CAT eee TeT TAT ACT TIC ATG 'ITT CCA AM AAT AAG ITC TCA AM MG GAC 
15/i 1', .J n '" A H P N ? ~; 1. I' E £ H If S Y 1. F ,<1 F P K N K F ~: K K D 
559 11.00 AGA AC 
le '} ~ " 
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2.0 DNA sequence of M13pIIIC phage 
pIlI start codon 
TTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTCGCAATTCCTTTAGT 
GGTACCTTTCTATTCTCACTCTAGCGCTCGTGTCTGCCACGGCCCATCGGTTG 
CAGGTCTGCACCAATCGGCCGAAACTGTTGAAAGTTGTTTAGCAAAATCCC 
ATACAGAAAATTCATTACTAACGTCTGAAAAGGACCGGACC 
Yellow = Cysteine peptide DNA sequence 
2.1 DNA and protein sequence of M13pIlIC phage 
===-~=~=~~~~=~~=~=-==~~~~~====~ 
relFNV K J~FA l'I,JVJ'FYSH~:f,Ak '~ H 
94 GGC eCA TeG GTT GeA GGT CTG CAe eM TeG Gee GM ACT OTT OM AGT TGT TTA OCA AM Tee CAT ACA GAA AAT TCA TTA CTA ACG TCT GAA 
.~) (; P 9 v {\ G L H 0 A E T 1::;'; (' r A l< f, H TN"; l.. L T S £:: 
1 a 7 MG GAe CGG Ace 
fi) D '1 
3.0 DNA and protein sequence of wild-type pIlI 
=~~~~=~~=~=-==~~~==~~~~~~~~~=~ 
VKKl,LF 1 1. !:-'r'i.3i13I\ETVE$rL1I.K~ H 
91 ACA GAA AAT TCA 'I"T'I' ACT Me GTe TGG AM GAC GAe MA ACT ITA GAT CGT TAe GCT Me TAT GAG GGe TGT CTG TGG AAT GCT ACA GGC 
31 l' F NSF T N V W K D K T L J) Y ANY E G (' L W N P. T 
181 GTI' GTA GTT TGT ACT GGT GAe GAA ACT CAG TOT TAe GGT ACA TGG GIT CeT AT!' GGG CTT GCT ATC CC'I' GAA AAT GAG GGT GGT GOe TCT 
(,1 V V V l' G !J E V '!' W V 11 r r, L AIr E.. N i-: '1 G $ 
271 GAG GGT GGe GGT TCT GAG GGT GGC GGT TCT GAG GGT GGe GGT ACT AM ceT ceT GAG TAe GGT GAT ACA eC'I' AT'I' eCG GGC TAT ACT TAT 
91 E G 11 $' E (j I; :; T K ? r F.' Y G D T P I F G Y T \' 
361 ATC MC CCT CTC GAC GGC ACT TAT CCG CCT GGT ACT GAG eM MC CCC GCT MT CCT MT CCT TCT err GAG GAG TCT CAG CCT CTl' MT 
121 I N P L 0 :; l' Y r '1' J:: Q N P ,.. N P N P ::> L F Po S 0 F' L N 
451 ACT TIC ATG TTl' CAG MT AAT AGG TIC CGA AAT AGG CAG GGG GCA TTA ACT GTT TAT ACG GGC ACT GTT ACT eM GGC ACT GAC CCC GTT 
1 <:'1. T F M F 0 n N r (,: G I, L 'r 'J Y T T V T (.. .G T .. i- '.t 
541 AM ACT TAT TAC CAG TAC ACT CCT GTA TCA TCA AM GCC ATG TAT GAC GCT TAC TGG MC GGT AM 'ITC AGA GAC TGC GCT TTC CAT TCT 
ttl1 K T Y Y Q Y " A M '{ [J A Y W N G K f R D r A r H f 
631 GGC 'ITT AAT GAG GAT TTA 'ITT GTT TGT GAA TAT eM GGC CAA TCG TCT GAC CTO CCT CAA CCT CCT GTC MT GCT GGC GGC GGC TCT GGT 
211 G r NED L r· v (' f Y () J iJ 5 S [) L P Q P P V NAG 1 S 
Hl==~= __ ~_==_~_=_=~_= __ ~ ___ ====_ 
£4' G t] S G G lj S r:: F !' l~ G Sf'; G G G S F. 'J G G S 11 G ,~ 
Sll TCT GGT TCC GGT GAT 'ITT GAT TAT GM MG ATO GCA AAC GCT MT MG GGG GCT ATO ACC GAA A.A.T GCC GAT GM MC GCG CTA CAG TCT 
'}'I 1 B G D FOE Y. MAN A N K GAM TEN " D f;: N r.. L ') S 
Rl_=~_~=~~==~~_===~~==~=_~=_==~= 
101 D A '3 K L [J.S 'J. D G II. AID FIG LI V f' G 1 Po N G 
991 MT GOT GCT ACT GGT GAT 'ITT GCT GGC TCT A.A.T TCC CAA ATG GCT CAA GTC GGT GAC GGT GAT MT TCA CCT 'ITA ATG MT AAT 'ITC CGT 
331 N:; T G fJ FAG NOM A (,.. V 0 G D N S ~. L .,-, N N F R 
10Bl CM TAT 'ITA CCT TCC CTC CCT CM TCG GTT GM TGT CGC CCT TTT GTC 'ITT GGC GCT GGT AM CCA TAT GM 'ITT TCT ATT GAT TGT GA'C 
H;J. 0 Y 1. ~; L 11 Q " P f' v F to; A G K P Y E If S D C D 
ll7l AM ATA MC 'ITA TTC CGT GGT GTC 'ITT GCG 'ITT CTT 'ITA TAT GTT Gee ACC 'ITT ATG TAT GTA 'ITT TCT ACG 'ITT GCT Me ATA CTG CGT 
J91 N L I f{ (j V f A f 1. TV'.. T f' ,., Y '.I F S T F 1<. J L 
1261 MT MG GAG TCT TM 
.J.21 N E S 
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1.0 Mass spectrometry data of ACIDap and BASEap peptides 
1.1 Fraction 1 of HPLC purified BASEap peptide 
100 
554 .82 
£7 
554 .77 55 .07 
554 .13 
847 .22 
O. 
6470b 
1141 .18 
47.40 
47 .57 
47 .73 
6 00 700 
778 .47 
CS 
176.27 
78 .&7 
71 .88 
800 900 
170 .35 
1170 .80 
B. 70 .82 
868 84 
1000 11 00 1 200 
1.2 Fraction 2 of HPLC purified BASEap peptide 
100 147 .22 C. 
84706 
ue.57 
58 .74 
841 .81 56 .10 
.. 11811 .08 
111 .2. 787.U 
554 .'1 
1132 .57 
07 17 .88 
554.77 55 .05 G' 
11 .40 787 .• 9 778 .47 
55 .20 751 ,88 
18 ,0' 
5U.34 
1283.4& 
1300 1400 
B, 
C , 
0' 
£ 
F, 
G , 
H, 
l' 
J 
K, 
L, 
3875 .00:1:0 .00 
3875.00:1:0.00 
3875.00.1;0,00 
3815.00 .. 0.00 
3875.00:1;0 .00 
3787 .00:1:0 . 
3875 .00:1:0 . 
3875.00:1:0 
3e75.00~O 
3131.00",0 . 
3 1131 .0hO . 
3988.00z0. 
39U.OO:l:O 
3111,QO:l:O 
398i .50:l:0 . 
3787 .00sO . 
M ' 3931.00:1:0 . 
N, 3S131.0hO 
0 3175 OOzO 
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1.3 HPLC purified ACIDap peptide 
100 
481 .1 1 
A. 
88 1.70 
6 1 .115 
12 .2 1 
" ' .48 
82 .4& 
82 .7 1 
8 1.71 
1 3 ." 
.3 
1175.28 
175.61 
175.14 
117 4.(15 
176.211 
1176 .&4 
178.17 
2.0 DNA sequence of pCGMTpIXHisACIDap 
A: 3522.00.0 .00 
B: 3522.00",0 .00 
GTGGAATTGTGAGCGGATAACAATTGAATTCAGGAGGAATTTAAAATGAAA 
AAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTGGCCC 
AGGCGGCCAAGCTTCACCACCACCACCACCACGCGCAGCTGGAAAAAGAAC 
TTCAGGCGCTGGAAAAAGAACTGGCGCAGCTGGAATGGGAAAACCAGGCG 
CTGGAAAAAGAACTGGCGCAGCTGCAGTCTGGTGGTGGTTCTGGCATGAGT 
GTTTTAGTGTATTCTTTCGCCTCTTTCGTTTTAGGTTGGTGCCTTCGTAGTGG 
CATTACGTATTTTACCCGTTTAATGGAAACTTCCTCATAATAAGCTAGAT 
Yellow = pIXHisACID DNA sequence 
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2.1 DNA and protein sequence of pCGMTpIXHisACIDap 
l=~=_=~~~_~=~~~~~~~~~~=~====~==~ 
.l'JEY. ADtJN IQEEfYMKKT!,lAl1,VALA0PA 
~======~~~~~~~~===~~~====~ ~~==== 
3? TV!, (J AllY !J Ii H H H H H A. Q J.I t: K E L CJ A. T. g 1< F. r, A Q 1, 
ln~=~~===~~~===========~~~~=~==== 
I) J t Ii E N C. A t. E X E LAC' t. Q S 0 G 'j S G H ~: v TJ 'J Y SPA ~: 
280 TTC GTT TTA GGT TGG TGC C'IT CGT AGT GGC ATT ACG TAT 'ITI' Ace CGT TTA ATG GAA ACT Tee TeA TAA TAA GCT AGA 
14 F V 1. 0 W ... I, j'{ ;; r; 1 T '{ P 1: !'< \... M f; T S :; M A k 
3.0 DNA sequence of pCGMTpIXHisFOS 
GGCTTCCTGACAGGAGGCCGtTTTGTTTTGCAGCCCACCTCTGGCACGACAG 
GTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTA 
GCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG 
TTGTGTGGAATTGTGAGCGGATAACAATTGAATTCAGGAGGAATTTAAAAT 
GAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGT 
GGCCCAGGCGGCCAAGCTTCACCACCACCACCACCACCTGAACGATACCCT 
GCAAGCGGAAACCGATCAGCTGGAAGATGAAAAAAGCGCGCTGCAAACCG 
AAATTGCGAACCTGCTGAACGAAAAAGAAAAACTGGAATTTATTCTGGCGG 
CGCATCTGCAGTCTGGTGGTGGTTCTGGCATGAGTGTTTTAGTGTATTCTTTC 
GCCTCTTTCGTTTTAGGTTGGTGCCTTCGTAGTGGCATTACGTATTTTACCCG 
TTTAATGGAAACTTCCTCATAATAAGCTAGATAATTAATTAGGAGGAATTTA 
AAATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCTGC 
CCAACCAGCCATGGCCAGGATTCCGGGTGTTGCGGCGGGGGATCATTGGGC 
GCGGGGGGTGTGTTCTGGCGGCGGCTCCATGGAGCAGGTCGCGGATTTCGA 
CACAATTTATCAGGCGATGATACAAATCTCCGTTGTACTTTGTTTCGCGCTT 
GGTGTAATCGCTGGGGGTCAAAGATAATAAGOCCTCGCGGGCCAGATCTGC 
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TCTCTGAGGAGGATCTGGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCG 
CGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCG 
Yellow = pIXHisFOS DNA sequence 
3.1 DNA and protein sequence of pCGMTpIXHisFOS 
=~=~-==~==~=~===~=~=~-~===~==~~ 
f.i F L l' r; G T< F V \, c.' P T S fJ l' T G F P T G K R A V S: A T Q t, 
"~==~~=~-~=-~~~~~~===~~=~====~~= 
nM Vf:Sl,lRHpnJ.,Y·rL~FRl.v('rVE1. J..rJNt~M 
IH~~_~~~~~~~=~=~======~=~==~==~~~ 
(;3 1 () E ~~ F K M K K T A JAr A v A LAG F fi T V A (J A /I, f. I H 
2~~~~~~=~=~=~=~~=~=~=~~~==~~~~=~= 
:Ill H Ii H H H L N 1) 'r 1, (; A E. T D Q L F. P f:: K SAL t, T EtA N L 
373 eTC Me GM AAA GM AAA CTG GM TTT ATT eTC GCG GeG CAT CTG CAG TCT GGT GGT GGT TCT Goe ATG AGT GTT 'ITA GTG TAT TCT TTC Gee 
u:, 1. N EKE; K L E f r L A A H L l' '3 G G G '? (; M f • 1- " Y SF>' 
466 TCT TIC G'IT TTA GGT TGG TGe CTI' CGT AGT GGe ATT ACG TAT TT'I' Ace CGT TTA ATG GM ACT Tee TCA TAA TAA GCT AGA TAA ITA AT'I' AGG 
lr:.£i S F V L r: w r:: L R :) fJ 1 T Y I.l T i<; I, 1-1 E T S S - f.. R 1, 1 r-. 
559 AGG AAT ITA AAA TGA AAT Ace TAT TGC CTA eGG CAG eeG CTG GAT TGT TAT TAC TeG CTG eec Me CAG CCA TGG eCA GGA TIC eGG Gro TTG 
11\1 H N L K M N T Y C J~ H (' P 1.. D (' Y Y ::; 1, P NO!' tV I' C, f:' }i V L 
6n===~~====~=====~-~-==~=~~~~_==~ :n a R ~ oJ JIG R G'-; .~ L P. A P. f' W' ~ P ~; R r S T (l r 1 R R Y 
~5~===~~=====~====~=~~====~==== __ 
;,..,') K .S f.' L Y F' V S R L V ~ ~; 1, r; V K 0 N K A r~ R 'A R .. 0; A L ::; ~1 
nB==~=_=~~~~_~==-~~=~~=~~~~~-= 
?~ S " K LA!. 1 F N ,q Fe: r f v K ~ ]I.. H f L T N R f' 
4.0 DNA sequence of M13pIIIACIDap 
pIlI start codon 
TTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTCGCAATTCCTTTAGT 
GGTACCTTTCTATTCTCACTCTGCGCAGCTGGAAAAAGAACTTCAGGCGCTG 
GAAAAAGAACTGGCGCAGCTGGAATGGGAAAACCAGGCGCTGGAAAAAGA 
ACTGGCGCAGCTGCAGTCTGGTGGTGGTTCTGCCGAAACTGTTGAAAGTTGT 
TTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCTGGAAAGACGAC 
AAAACTTTAGATCGTTACGCTAACTATGAGGGCTGTCTGTGGAATGCTACAG 
GCGTTGTAGTTTGTACTGGTGACGAAACTCAGTGTTACGGTACATGGGTTCC 
TATTGGGCTTGCTATCCCTGAAAATGAGGGTGGTGGCTCTGAGGGTGGCTGT 
TCTGAGGGTGGCGGTTCTGAGGGTGGCGGTACTAAACCTCCTGAGTACGGT 
GATACACCTATTCCGGGCTATACTTATATCAACCCTCTCGACGGCACTTATC 
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CGCCTGGTACTGAGCAAAACCCCGCTAATCCTAATCCTTCTCTTGAGGAGTC 
TCATCCCTCTTATACTTTCATGTTTCCAAAAAATAAGTTCTCAAAAAAGGAC 
AGGAGA 
Yellow = ACID peptide DNA sequence 
4.1 DNA and protein sequence of M13pIIIACIDap 
1 'ITT 'ITT Tl'G GAG 11.'17 TTC Me GTG AAA AAA ITA ITA TIC GCA ATT CCT ITA GTG GTA CCT 'ITC TAT TCT CAe TCT GCG CAG CTG GM AAA GM 
FFl. FN A L VftF'Y H AQ EKE 
~~~==~~~==~=~=~~~==~~~==~=~~===~ 
"2 Q L Q E ~ f; N I, i< F. L Q L Q G G S 
lH=~~~~~~~_~~~~~~~~~~==~~~~~~~=~= 
~', TV£. K T r, f N V W Y, D 0 }( l' T.. IJ I? Y 11. 
2~~=_=~==~=~=~_~~~=~~~~~~=~=~=~_~ 
'HN'{ WN 'rG V CT I;'.'l'QCYGT v IGI. 
H3=~=~~_===~_===~_===~_===~~==_~= 
1 , .. , 1!> NEG r C 'J G '3' E (; G T K ~ P E Y C; 
466 GAT 11.(11. CCT ATT CCG GGC TAT ACT TAT ATe Me ccr eTC GAe GGC ACT TAT eeG ceT GGT ACT GAG eM Me eee GCT AAT CCT AAT CCT TCT 
5,:' 'r p i' ~ Y I' L L T Y f' fJ T E Q N f· N 
~~--~~=~=~=~~~~~~=~~~~--
B7 1. E f' 1 (I )( F Y, l( r.J R 
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5.0 SPR kinetic fits for ACIDap and M13pIXHisACID interacting with 
immobilised BASEap peptide 
5.1 SPR kinetic fit for ACIDap interacting with immobilised BASEap 
(Chapter 5, Figure 5.10 B) 
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5.2 SPR kinetic fit for M13pIXHisACIDap interacting with 
immobilised BASEap (Chapter 5, Figure 5.13 B) 
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1.0 DNA sequence of M13Y 
AATTCCGGTTAATGGAACTTCCCTCATGAAAAAGTCTTTAGTCCTCAAAGCC 
TCTGTAGCCGTTGCTACCCTCGTTCCGATGCTGTCTTTCGCTGCTGAGGGTIA 
CGATCCCGCAAAAGCGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAATA 
TATCGGTTATGCGTGGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGT 
ATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGATACA 
ATTAAAGGCTCCTTTTGGAGCCTTTTTTTTGGAGATTTTCAACGTGAAAAAA 
TTATTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCTAGCGCTCG 
TGTCTGACACGGCCCATCGGTTGCAGGTCTGCACCAATCGGCCGAAACTGTT 
Yellow = p VIII coat protein DNA sequence 
Underline = G to T substitution for D to Y replacement 
1.1 DNA and protein sequence of M13Y 
~=~~-~==~~-~~==~=~~=~=~=~=~=~~= 
1 P 'J N G T ~. i. 1<1 K K ~j T. V IJ K 11, So 'I I.. V A T L V 11 ,<1 1. S P 11 
~=-==~==~-=~~==~==-~~=~==---~~~= 
31. A J; :; X. D l' A K A A F N S L Q h S A 'r E Y I I,'; YAW A tot V V V 
ln~===~~=~_=~_~~~=~===~~~~~~==~_= 
63 I V r; A T 1 {i 1. K !,. f' Y, K F' 'r S K A ~; T r.. T I K G S II W :; 
280 eTl' TIT T'I'T GG.I\ GAT 'ITT eM CGT GAA AM AIT ATI' 11..1"1' CGe AAT Tee TTT AGT GGT Ace TTT CTA TI'C TeA eTC TAG eGC Teo TGT CTG ACA 
;-1 L [. F r. 0 .i~ Q R E K III R N ~; F S G T T' L F f3 L R Fj C J.. T 
373 CGG eee ATC GGT TGC AGG TCT GCA eCA ATC GGC eGA Me TGT T 
12'J Po P I :J C J? SAP I rJ n N (: 
2.0 DNA and protein sequence of wild-type M13 p VIII 
~~-~~==~=~~=~=~=~=~=~~==-==~==~ 
M Y. K !l L II L K 1\ S V A V Ii T 1, V I' M 1. ~; F A A E G l) D P A K 
~-=~~==~==-~~=~==---~~~=~===~~=~ ?~ A A f N 3 I 0 J, 5 " T f' Y I G YAW A M II V II I II C; A TIn I 
187 MG CTG TIT AAG AM TTC Ace TCG AM GCA AGe TGA 
(.3 f( L P Y. Y. r 'T' S K A S 
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